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CH EM OTH ERAPY CLINICAL TRIAL  
FOR CATS 
W ITH SARCOM AS
The incidence o f soft tissue sarcomas in cats has risen significantly during the last decade.
There is epidemiological evidence that vaccines are associated with this increase. The 
combination o f surgery and radiation therapy provides the best control for these tumors in 
cats. However, many cats still fail to be cured. Chemotherapy is indicated for cats with 
soft tissue sarcomas when surgery or radiation therapy is not possible or has not been 
successful. The combination o f chemotherapy and radiation therapy may also help to 
control sarcomas in cats.
Ifosfam ide is one o f three chemotherapeutic agents that have proven significant activity 
against soft tissue sarcomas in people. Response rates have been superior to those seen 
with doxorubicin. We recently evaluated ifosfamide in tumor bearing dogs and 
measurable responses were observed. The purpose o f  the present study is to document 
evidence o f  antitumor activity when ifosfamide is used to treat cats with vaccine- 
associated sarcomas. If ifosfamide proves effective, we anticipate incorporating its use 
in combination with radiation therapy and surgery.
Eligibility criteria :
• Biopsy-proven soft tissue sarcoma
• M easurable disease must be present
• No prior chemotherapy, radiation therapy or surgery
• No cardiac, renal or hepatic disease
Cats will be seen by an oncologist for an initial appointment and evaluation and then 
treatment with ifosfamide will be scheduled. Ifosfamide is given with saline diuresis over
6 hours. Bloodwork will need to be obtained days 7, 14 and 21 after treatment. If  cats
respond to ifosfamide, treatments will be continued every 21 days. If  there is no 
response, the owners may explore other treatment options.
*Funding is available fo r this chem otherapy  tria l. If you have questions about the 
ifosfamide study or have a client interested in participating, please contact the oncologists 
at Cornell at (607) 253-3060.
* Funding provided by the V accine A ssociated Feline Sarcoma Task Force and Winn Feline Foundation
Fungal and Viral Skin Disorders of the Cat
William H. Miller,Jr., VMD, DACVD 
Professor o f Dermatology 
Medical Director - Companion Animal Hospital 
Cornell University
Viral Disorders
FeLV/FTV
The feline leukemia and immunodeficiency viruses usually affect the skin via their 
immunosuppressive actions, e.g., recurrent abscesses, general unthriftiness, etc. Because these 
viruses persists in the cat’s body, the cat may develop an immune complex disorder which can 
present as skin disease, polyarthropathy, o r a lupus-like condition. Some “specific” disorders 
associated with these viruses are:
FeLV Cutaneous Horns: Multiple cutaneous horns that develop in a mature cat need 
investigation since something is triggering the focal epidermal proliferation. In addition to  FeLV, 
squamous cell carcinoma (spontaneous or viral induced) or other epithelial tum or types must be 
considered.
FeLV Exfoliative Dermatitis: A pruritic, crusting dermatitis involving the head/neck and 
elsewhere o f  the mature cat Response o f  the condition to  steroids, antibiotics, etc is poor and the 
cat feels poorly. On skin biopsy, there are syncytial-type giant cells in the epidermis and outer 
root sheath o f  the hair follicle. A poptotic cells are common, especially around the giant cells.
FTV Demodicosis: Demodicosis caused by D em odex cati is rare in the cat and all(?) cases
o f recurrent/recalcitrant disease have some underlying immunosuppressive disorder. Demodicosis 
caused by D em odex gatoi is not associated with immunosuppression.
FTV Exfoliative Dermatitis: A rare dermatitis characterized by a generalized, nonpruritic 
papulocrustus eruption most pronounced on the head and limbs. The basal cells o f  the epidermis 
show a pallor not seen in other feline disorders.
Feline Cowpox Virus Infection
A European condition primarily but an occasional case has been recognized in the US. 
Cats become infected while hunting infected rodents. Peak incidence in the fall. Viremia with or 
without pyrexia, anorexia, etc follows the bite and then 10 to  14 days later more classical pox 
lesions appear. Self-cure is the rule. Zoonotic for cats, dogs, and humans.
Feline Infectious Peritonitis
Skin disease beyond that due to  decreased grooming is extraordinarily rare in this disease. 
Because the virus persists, and immune complex/vasculitis presentation can be seen.
Feline Rhinotracheitis Infection
The true incidence o f  skin lesions associated w ith this a-herpesvirus is unknown but 
probably is very low. A pre-existing immunosuppression may be needed for significant lesions to 
occur.
An ulcerative and necrotizing facial dermatitis and stomatitis has been associates with 
herpes infection in adult cats with or without the history o f  more classical respiratory signs. An 
occasional kitten may also develop the dermatitis. Affected cats develop an ulcerative, crusted 
dermatitis o f  their face primarily. Skin biopsies are necessary to  separate this condition from 
drug reaction, pemphigus, or other ulcerative conditions. Here, the surface and follicular 
epithelium contains multinucleated keratinocytes which may contain inclusion bodies. Treatment 
with lysine (250 mg q24h) and/or a-interferon (60-120 IU/cat/day) may have some benefit.
Feline Papillomavirus Infection
Papillomavirus infection in the cat is relative new. Although there are reports o f  cats with 
singular lesions, most focus on multicentic disease with a sharply-demarcated dysplastic skin 
condition. These lesions are typical o f  those seen in humans with Bow en’s disease. The original 
dysplastic lesion gradually become frankly neoplastic (squamous cell carcinoma in-situ). In 
humans, tum or cells which breach the epidermis tend to  metastasize quickly. That does not 
appear to  be the case in cats. Lesional treatment with laser surgery (viable viral particles in 
vapor!!), pliseotherapy, etc does not prevent the development o f  new lesions.
Fungal Disorders
Dermatophytosis
Ringworm is alive and well in the cat population and, until an effective vaccine is available, 
it will be the bane o f  every cattery owner. The only real changes in this disease are the advances 
made in treatment.
Although clipping will result in more clinical lesions, the removal o f  infected hairs is very 
important for long term control. Cats should be treated with local agents and wholebody agents 
since they often has unrecognized areas o f  active disease.
Cattery Recommendations:
1. Suspend all travel in and out and culture all cats
2. Separate infected, non-infected, and uncertain status (culture pending) cats.
3. Topical and systemic treatment o f  all nonpregnant adults and kittens over 12 weeks o f 
age.
a. Griseofulvin:
Microsized: 25-60 mg/kg q l2 h  Ultramicrosized: 2.5-15m g/kg q l2 h
b. Ketoconazole: 5-10 mg/kg q24h
c. Itraconazole: 5 -1 0  mg/kg q24h
d. Fluconazole: 50 mg/cat q24h
e. Terbinafine: 20 mg/kg q48h
4. Culture “cured” individuals 3 times at weekly intervals. Remove to  uncertain room 
while results are pending.
5. Bum  down the cattery!
Malassezia Dermatitis
M alassezia pachyderm atis is a lipophilic, non-lipid-dependent, nonmycelial saprophytic 
yeast that is a normal inhabitant o f  normal dogs and cats. Six other lipid-dependent species (M  
furfur, M . globus, M. obtuse, M . restricta, M . slooffiae, cm dM . sym podialis) can also be found. 
Normally, very small numbers o f  these organisms are found in the ear canals, middle ear, oral 
cavity, skin (especially intertrigenous regions), anal sacs, and vaginal, prepucial, and anal mucosa. 
Moisture encourages replication and increases the normal population o f  yeast on the body.
Malassezia dermatitis is common in dogs and rare (or rarely recognized?) in the cat.
Yeast proliferate in response to  some insult, e.g., hypersensitivity, swimming, etc. Once the yeast 
reach some critical mass, the underlying disorder can be removed but the yeast and the symptoms 
they produce will persist until specifically treated. Beyond allergy, be it atopy or food 
hypersensitivity, the trigger event in cats is uncertain.
Clinical Signs
In the nonpruritic animal there is the surface accumulation o f  scale (cat), scale-cmst (dog, 
cat), or wax (dog). In the dog, significant numbers o f  yeast produce a characteristic smell. In the 
ear canals, toe webs, face folds, axillary areas, and other intertrigenous zones, inflammation and 
pruritus are usually present. As can be seen, the trouble spots for M alassezia  are the classic areas 
o f  pruritus in allergy. In well over 50% o f the chronic allergic dogs examined by the author, the 
atopy or food hypersensitivity is complicated by a secondary M alassezia  dermatitis. The same 
phenomenon occurs in the allergic cat but the frequency is much lower.
Diagnosis
Although Malassezia dermatitis or otitis can be suspected by the smell o f  the animal’s skin 
or ears or by the nature o f  the surface changes, the diagnosis needs to  be confirmed by cytologic 
demonstration o f  “excessive” numbers o f  organisms or by histopathology. Cytology is least 
expensive and most rapid and is the preferred method o f diagnosis. For truncal lesions, surface 
debris is collected by pressing a clean glass slide, clear cellophane tape, or specially manufactured 
gel-coated slide to the involved area. The area can also be scraped with a scalpel blade. Around 
the face and toes, material is best collected with a dull scoop or a Q-tip. The author uses the 
blade and Q-tip techniques. Sample material is transferred to  a slide and stained with either Diff- 
Quik or New  Methylene Blue. Diff-Quik is difficult to use with cellophane tape or gel-coated
slides. Since the first fixative o f  Diff-Quik is alcohol based, the slide should be briefly heat fixed 
before staining.
Various authors have defined the number o f  yeast they consider normal, e.g., ^1/HPF, 
and figures vary with collection technique and magnification used (40X, 100X). Humidity and 
sample site enter the picture as well. For example, more organisms will be found in the inguinal 
region during the moist summer months and folded areas, e.g., claw fold, always have more 
organisms then the surrounding skin on the digit. Another often forgotten variable is w hether the 
animal is licking or scratching the area. Mechanical traum a removes surface debris and yeast. 
Traumatized areas should be avoided during sample collection. With all these variables, the 
author believes it is very difficult to  define what a normal number o f  yeast is and slide 
interpretation must always be considered in light o f  the patient before you. In most cases, the 
diagnosis o f  yeast or not will be straight forward - yeast will abound or none will be seen. With 
practice, yeast can be seen with the 10X objective. At 40X, they jump out at you and the author 
believes that oil emersion never is needed. I f  the animal looks and smells like yeast should be 
present but none are seen make sure the specimen is examined carefully (40X) for Staphylococcal 
overgrowth. In some cases (Staphylococcal hypersensitivity?), what appears to  be due to  yeast is 
due to bacteria.
In the odd case, the cytologic finds don’t fit the clinical picture and more samples should 
be evaluated to  resolve the dilemma. Skin biopsy can be useful in these troublesome cases. When 
biopsy is to  be used, the hair in the area should not be clipped closely (leave at least Ve inch long) 
and no surface cleaning can be done. Areas where the animal is known to  lick or scratch should 
be avoided if possible. I f  these areas can not be avoided, biopsy the areas at edge where the 
surface epithelium stands the most chance o f  being intact.
Treatment
The first rule o f  treatm ent is to  determine why the M alassezia  dermatitis is present. Is the 
animal allergic? Does it have a primary or secondary seborrheic condition? Is its cutaneous 
ecology being affected by antibiotics or steroids? The list goes on. I f  the yeast are addressed but 
the underlying cause is ignored, the infection will recur or will not respond as rapidly or 
completely. Conversely, resolution o f  the underlying disease may result in the spontaneous 
disappearance o f  the yeast.
Since M alassezia  in a noninvasive organism, topical treatm ents can be sufficient to  resolve 
the dermatitis provided that the animal isn’t  hypersensitive to  the yeast. With hypersensitivity, the 
hidden organisms (anal sacs, middle ear, vagina, etc) may liberate enough antigen that the allergic 
reaction will continue despite the diligent use o f  appropriate topicals. Is that residual foot licking 
because the cat is atopic and needs allergy testing or is it a sign o f  a M alassezia  hypersensitivity? 
Since M alassezia  antigen is not available commercially for skin testing, clinical impression is 
critical in these cases. Is the pruritus steroid non-responsive? Is the itching intense but the 
number o f  yeast low? Has the cat had repeated bouts o f M alassezia  dermatitis? I f  the 
hypersensitivity is proven or strongly suspected, systemic treatments will be needed.
Systemic treatments to  be used include ketoconazole (10 mg/kg q24h), itraconazole (5 
mg/kg q24h), o r fluconazole (10-20 mg/kg ql2-24h). Itraconazole and fluconazole are safer then 
ketoconazole but much more expensive. Ketoconazole is now available in generic formulation 
which has significantly reduced its cost ($1.30/200 mg tab @CUHA). Typically, a 30 to  45 days 
course o f  treatment is needed if  topical treatments aren’t  used. Topicals can shorten the course o f 
systemic treatment but no set figure on how much shorter can be given. The rule o f thumb used 
to  determine when to  stop treatment in bacterial disease (7 to  14 days beyond clinical cure) is 
appropriate for M alassezia  as well.
I f  the cat doesn’t  turn into a killer with topical treatments, shampoos can be valuable as 
either an adjunctive or the sole treatment o f  M alassezia  dermatitis since the bathing mechanically 
removes the yeast, the active ingredients in the shampoo can actually kill some o f  the organisms, 
and the surface ecology o f  the skin is significantly altered, disfavoring yeast growth. The 
shortcoming o f bathing is that not all areas are cleaned as well as others and the active ingredient 
is removed when the suds are rinsed. With no residual product on the skin, the cat can reinocuate 
the skin from its oral or anal population. Residual products are very limited in the United States 
and include Resichlor Rinse with Spherulites (Virbac), LymDyp (DVM), or a 50:50 solution o f 
vinegar and w ater (Wegmans). The efficacy o f  the Resichlor rinse is unproven at this time. In 
Canada, enilconazole (Imaverol) is available as a dip and is very effective. Clients can have this 
product mailed to  them by a Canadian veterinarian provided that they have a valid client 
relationship with the veterinarian.
For local disease, e.g., face folds, or ears, topicals with antifungals (Panalog, Otomax, 
Baytril Otic, Tresaderm, etc) all work well. Remember that wax can protect the yeast from the 
active ingredient and regular cleaning is needed.
Candidal Dermatitis
C andida spp. yeasts are normal inhabitants o f  the alimentary, upper respiratory, ear canal, 
and genital mucosa o f probably all mammals. Candidiasis is a very rare disease in domestic 
animals. Proliferation requires alteration in the cutaneous or mucosal ecology or 
immunosuppression. In women, vaginal candidiasis is a common sequella to  antibiotic treatment. 
In dogs and cats, antibiotic use in the immunologically normal animal does not predispose to 
candidiasis. In most cases, the candidiasis is associated with local alteration o f  the cutaneous 
environment in an immunosuppressed patient. Immunosuppression or altered ecology by itself 
appears to  be insufficient to  cause infection.
Since Candida spp. yeasts form hyphae they invade the epithelium, resulting in an 
ulcerative dermatitis. Unlike Malassezia which produces a fairly classical odor and clinical 
picture, C andida  does not. The only way to  determine whether the ulcerative lesions seen are due 
to  Candida, toxic epidermal necrolysis, pemphigus, or any o f  the other differential diagnoses is to 
demonstrate the yeast by cytology or histology. In contrast to  Malassezia, Candida show narrow- 
based and multilateral budding and pseudo hyphae or true hyphae can be present.
In candidiasis, both systemic (ketoconazole o r itraconazole) and topical treatments are 
needed M oisture needs to  avoided and topicals containing steroids are contraindicated in most 
cases.
Disorders Causing Exfoliation and Hair Loss
William H. Miller, Jr., VMD, DACVD 
Professor o f  Dermatology 
Medical Director - Companion Animal Hospital 
Cornell University
Exfoliative Disorders
Exfoliative disorders are those where the stratum comeum is shed in large sheets rather 
then as individual and therefore invisible cells. Disorders o f  keratinization, although not strictly 
an exfoliative disorder, are considered here.
I. Primary Keratinization Disorders
Unlike the dog where primary seborrhea is fairly common, it is rare in the cat.
Generalized Disease: Recognized most commonly in Persians. Signs at or near birth. Variable 
expression so some kittens are worse then others. Greasy, unmanageable 
coat with ceruminous otitis and multiple comedones. Diagnosis by history 
and biopsy. Treatment by bathing? Retinoids unproven.
Localized Disease:
Feline Acne: Common problem. Can be a one-time disorder, a chronically relapsing 
condition, or a permanent problem. Comedones around the limps and on the chin. 
Simple cases require no treatment or respond nicely to  topical treatment. Resistant cases 
should be examined carefully for secondary bacterial ox M alassezia  infection. Fatty acid 
supplement (DermCaps) can be o f  some benefit in chronic cases. Retinoids have worked 
but very few cases reported.
Stud Tail: An uncommon problem seen most commonly in intact males but can be
seen in neutered males and altered and unaltered females. Accumulation o f 
keratosebaceous debris along the entire dorsal surface o f  the tail. Castration does not 
resolve the problem but may slow its progression. Frequent cleaning with a degreasing 
shampoo (e.g., SulfOxyDex) keeps condition under control.
Idiopathic Facial Dermatitis o f Persian and Himalayan Cats: Seen primarily in young 
cats (<12 month o f  age). Nonpruritic initially but pruritus develops w ith time. Often 
secondarily infected with bacteria or M alassezia. N o uniformly effective treatment 
reported.
H. Secondary Keratinization Disorders
a.Endocrine Causes
Hypothyroidism
Diabetes mellitus
<r
Cushing's Disease (see hyperfragility syndrome)
b.Infectious Causes
Dermatophytosis: Generalized disease is uncommon except in longhaired kittens.
When generalized disease is recognized, especially in an adult cat, 
a search for some underlying disease should be undertaken.
M alassezia  infection: Rare?
c.Parasitic Causes
Demodicosis: Seborrheic demodicosis can be caused by D em odex fe lis  or D em odex 
gatoi. Demodicosis caused by D. fe lis  indicates that the cat has some 
serious underlying disease, e.g., FIV  infection. The “virulence” o f  the 
triggering disease will influence the success o f  treatm ent. In mildly 
immunosuppressed patients, topicals (Mitaban, LymDyp, Frontline Spray) 
can resolve the skin lesions. D ata on relapse rates are unavailable. In 
seriously immunosuppressed cats, topicals tend to  w ork poorly. Daily 
ivermectin (0.3 mg/kg) by mouth or injection rapidly reduces the mite 
count. Data on duration o f  therapy and relapse rates are unavailable.
Demodicosis caused by D em odex gatoi, a.k.a. D em odex shortstubby, is 
far more common in the southern parts o f  this country. This mite is 
contagious from rodent (the point source o f  infection?) to  cat and from 
cat to  cat. Symptoms vary from none to  seborrhea to  intense pruritus. 
Since the mite is very small (use you lOx objective on  your microscope!!) 
and only invades the surface keratin layer, the cat removes it easily while 
licking. Never scrape an area the cat is licking as this will be artificially 
negative. In cats who are furmowing their entire body, positive scrapings 
may be impossible to  obtain. An ivermectin-response test does not 
exclude this diagnosis. Failure to  respond to  topicals (Mitaban, LymDyp, 
Frontline spray?) Excludes the diagnosis. All contact cats need to  be 
treated.
Cheyletiella: As fleas increased in incidence, Cheyletiella infestation decreased since the 
classical flea control products usually kill this mite. W ith the popularity 
o f  Program and Advantage, the incidence is increase again. The mite 
typical is found in highest numbers over the dorsum  with variable pruritus. 
Diagnosis is difficult especially when the cat is itchy. Best way to 
demonstrate the mite is with the flea comb or vacuum cleaner. The mass 
o f  hair and scale that is collected is best evaluated by means o f  floatation 
techniques. These techniques are at best diagnostic 65% o f  the time. 
Ultimate test is response to  treatment. Ivermectin (.3 mg/kg q l4 d  for 2 
to  4 treatments) receives widest use. U se o f  a topical agent at the first 
treatment can accelerate response in the very itchy cat.
Misc: Lice and fur mites cause scaly lesions but their size (lice) or numbers (fur
mites) make diagnosis straight forward. Ectopic ear mites can cause 
disease on the body and are difficult to  find in this location. However, 
these cats always have bad ears. Ectopic infestation best treated with
topicals or ivermectin.
d. Metabolic causes
Cats with liver or pancreatic disease usually with develop a generalized greasy coat. Since 
the greasiness tends to  occur late in the course o f  the disease, the prognosis for these cats is 
guarded.
e. Environmental Causes
Low humidity will dry a cat's coat. This is especially true when the cat is a heavy 
groomer. W ith grooming, w ater is put on the hair and skin and will evaporate rapidly when the 
relative humidity is below 40%. I f  one cat in a multiple cat household is dryer then the others, 
it would be appropriate to  determine if  the cat has some underlying skin condition which has 
increased its grooming. I f  the flakiness is strictly due to  low humidity, moisturizers will work but 
most cats fail to see the sense o f  humor in their prolonged use.
HI. Exfoliative Dermatoses
True exfoliative dermatoses are very serious disorders and are indicative o f  serious 
internal disease.
a. FeLV/FIV Disease
b. Drug Eruption
At Cornell, approximately 2% o f the cats we see in dermatology have a drug eruption. 
If  blood dyscrasias etc are counted, the number o f  cats with drug reactions increases sharply. The 
reaction can be an irritant one where the skin in areas o f  contact becomes inflammed. The most 
important area where this occurs is in and around the ears. Cats’ ears are much more sensitive 
then dogs’ ears and yet w e tend to  treat them in a very similar fashion. When an otitis externa 
in the cat that was responding nicely to  treatm ent starts to  worse, drug eruption should be 
seriously considered.
After an initial period o f  sensitization, typically 7 to 14 days, a drug reaction can anytime 
during administration. The reaction can occur during the 1st, 3rd, o r 15th administration. Once the 
reaction occurs however, it will reappear at every subsequent administration. W hen a drug 
reaction occurs in a  cat taking multiple drugs, the last drug added is the most likely culprit.
There is no specific pattern o f  reaction seen with a particular drug and the reaction pattern 
can change every time the drug is administer to  the same cat. Nonlesional pruritus as seen in 
atopy and food hypersensitivity is a very rare manifestation o f  drug hypersensitivity - everything 
else is fair game! A lthough the diagnosis o f  drug eruption can be supported by some specific 
histopathologic changes, there are many cases where the pathology o f  the drug em ption mimics 
that o f  a naturally occurring disease, e.g., pemphigus foliaceous. I f  the animal is suspected to 
have a drug reaction, the drug should be stopped and the eruption should stops its progression 
with in 14 days. Depending on the nature o f  the lesions, e.g., superficial pustular vs ulcerative, 
the skin may heal completely during this withdrawal period.
c. Thymoma
The exfoliative dermatitis seen with thymoma is a rare disease o f the middle-aged to  old 
cat. The exfoliation usually starts around the head and neck and pruritus is typically absent. Hair 
loss, especially o f  the feet, can accompany the exfoliation. With time, the whole body can be 
affected. Some cats, especially orange ones, lose hairshaft pigment and turn white. Beyond the 
skin lesions, the cats usually are heathy. Skin biopsies show a cell-poor hydropic interface
dermatitis. Although not unique to  this disorder, this reaction pattern is rare in other conditions 
o f  the cat and should prompt the appropriate thoracic evaluation. Only surgery is curative.
d. Parapsoriasis
An extraordinarily rare exfoliative condition. Separated from other conditions by skin 
biopsy where lymphocytes lineup with the basal layer o f  the epidermis and hair follicle. 
Immunosuppressive steroid therapy is necessary to resolve lesions and keep them in remission.
e. Cutaneous lymphoma.
Far less commonly recognized in the cat then the dog. Typically very slowly progressive. 
Limited to  no data on the “best” treatment.
Nontraumatic Hair Loss Disorders
The most common cause o f  regionalized or widespread nontraumatic hair loss is 
unrecognized excessive grooming. The cat is a furmower but only does so when the owner is out 
o f  sight. In order o f  decreasing frequency, the real causes o f  feline nontraumatic hair loss are:
a. Defluxion disorders
Stress, e.g., fever, parturition, drug administration, etc, interrupts hair growth. With 
“mild” stress, the hairs start to  grow  again in a day o r so but are left w ith a “dimple” in the hair 
shaft. This weakens the hair shaft and in 7 to  10 days, the hair breaks o ff at or near the skin’s 
surface giving the coat a disheveled look. This process is called anagen defluxion. With more 
pronounced stress, the hair cycle is interrupted and all the hairs are put into the resting (telogen) 
phase. When the animal’s skin returns to  normal, usually 30 to  45 days later, all the follicles 
switch to  anagen and the telogen hairs are pushed out. The affected cat undergoes an excessive 
shed and may go bald. This process is called telogen defluxion. Both o f  these conditions are self- 
limiting and are diagnosed by trichography.
b. Hair Shaft defects.
Congenital or acquired hair shaft defects weaken the hair shaft so that it breaks more 
easily during grooming o r other normal activities. The most com mon acquired hair shaft defect 
in the cat is dermatophytosis. Others include Trichorrhexis nodosa, trichoptilosis and color 
dilution alopecia. Diagnosis by trichography.
c. Acquired skin hyperfragility syndrome.
A very serious metabolic condition o f  the aged cat where the skin becomes very thin and 
fragile but not hyperextensible. The most common cause is hyperadrenocorticism but it can occur 
with primary or secondary hyperprogesteronemia, various liver disorders, or pancreatic 
adenocarcinoma. Because o f  the severe catabolic nature o f  these conditions, hair growth stops 
and hair loss can be recognized in frictional areas. In some cats, the coat is dull and dry but no 
hair loss is obvious.
d. M ural folliculitis
Mural folliculitis is a recently coined histologic term  used to  describe the presence o f  cells 
within the hair follicle wall. The type o f  cell seen dictates the types o f  clinical conditions to  be 
considered. For example, a neutrophilic mural folliculitis is most indicative o f  bacterial disease
but can be seen with various autoimmune disorders. Lymphocytes can suggest dermatophytosis, 
drug reaction, early lymphoma, or an idiopathic condition.
e. Endocrine disorders
Unlike the dog who develops hair loss early in the course o f  its endocrine disease, the cat 
rarely does so.
The Itchy Cat
William H. Miller, Jr., VMD, DACVD 
Professor of Dermatology 
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Pruritus, the sensation which evokes the need to itch, is a complex process which can be mediated 
centrally, peripherally, or peripherally with significant central modification. Foryears, psychogenic pruritus 
was thought to be important in the cat. Today we know that the vast majority o f itchy cats are perfectly 
sane- their skin tingles, tickles, bums, or whatever and they respond in the expected fashion by itching. The 
premature diagnosis of psychogenic pruritus does the cat and its owner a great disjustice.
For some unknown reason, cat skin appears to be programmed to itch. The cat has a much more 
rapid and profound eosinophilic response then does the dog. The major basic protein found in these cell 
can damp an allergic reaction by breaking down histamine but can also accelerate the reaction by damaging 
collagen and by causing mast cell degranulation. In normal cats, the number of mast cells around the 
superficial dermal blood vessels can be nearly double that found in the dog (20/hpf vs 12/hpf). The 
number in allergic cats usually is even greater. These findings can lead to allergic amplification where the 
pruritus is well out of proportion to the allergic stimulus. At the initial allergic event, some mast cells 
degranulate and attract eosinophils into the area. When the cat itches, some additional mast cells can 
degranulate via the pressure caused during licking or scratching and a vicious cycle starts. Because of this 
amplification system, itchy cats usually require a longer course o f steroids then do dogs. Cats have fewer 
steroid receptors then do dogs so they require higher doses o f drug to control the same level of pruritus. 
The attack dose o f prednisolone for the cat is 2.2 mg/kg/day and most itchy cats will require 10 to 14 days 
o f treatment before the fire is taken out o f the skin.
ALLERGIC DISORDERS
Allergic disease are the most common reason for the cat to itch and they appear to be increasing 
in frequency. As in the dog, some cats have more then one allergic disorder, e.g., flea bite hypersensitivity 
and atopy, so the diagnostic evaluation must continue until the cat is itch free.
Unlike the dog, the allergic cat has no predictable pattern for its pruritus. The atopic cat can have 
miliary dermatitis, facial pruritus, anterior body pruritus, whole body pruritus, traumatic alopecia 
anywhere, eosinophilic plaques, or eosinophilic granulomas.
Flea Bite Hypersensitivity:
Worldwide, the most common allergic skin disease o f the cat. Fairly easy to diagnose but more 
difficult to control. Products like Program and Advantage have made life easier but by no means have 
solved the problem. Purified flea saliva is in the pipeline so we may be able to address the hypersensitivity 
in a specific manner in the next few years.
Atopy:
By definition, atopy is a genetically influenced disorder where the animal becomes allergic to 
normally innocuous environmental antigens. Was uncommon in cats but appears to be increasing in 
frequency. Except in purebred cats where signs occur early in life, the standard DSH starts to itch typically 
between age 3 and 5. Over 85% of atopic cats itch during the warm weather. Unlike the atopic dog where 
progression to nonseasonal pruritus is commonplace, most atopic cats stay seasonal for long periods o f
Clinical signs are very variable and their severity influences when the cat is presented for treatment. 
With intense scratching, the cat is presented shortly after the itching starts. Cats who just groom 
excessively many not get bad enough for weeks to months on end. With the variability o f signs and timing 
to presentation, it can be difficult to offer the tentative diagnosis o f atopy when the cat first starts to itch. 
Good records are necessary to document the seasonally recurrent nature of the cat's problem.
Diagnosis:
History: Variable specificity
Physical: Minimal specificity
Steroid response test: Very helpful in ruling out atopy. The uncomplicated atopic cat 
must stop itching when the appropriate dose (2.2 mg/kg/day) of 
prednisolone is given. A poor response indicates that die cat is 
not atopic. However, a positive response does not mean that the 
cat is atopic.
Differential exclusion: The best method to support the diagnosis of atopy.
Allergy testing: The most specific method to document atopy. The testing not only 
confirms the diagnosis but defines the allergens so immunotherapy can be 
formulated.
Serologic Tests: At this point, the currently available serologic tests have
such poor sensitivity and specificity that they are o f very 
questionable value.
Intradermal Testing: The gold standard
Treatment:
Cats are resistent to steroid side effects so these drugs are used with regularity in 
the atopic cat. For cats with a short allergy season, DepoMedrol injections (4-5 mg/kg) are used 
frequently. As long as the young healthy cat does not require more then 3 or 4 injections per year, 
the margin of safety of this treatment is wide. When more frequent injections are required or the 
cats is old, oral steroids are safer. The drug is given daily to heal the rash and then on an alternate 
day basis to keep things under control. Prednisone (2.2 mg/kg/day) and methylprednisone (1.8 
mg/kg/day) are safest but some cats do not respond to these drugs. Dexamethasone (0.2 
mg/kg/day) or triamcinolone (0.2 mg/kg/day) usually work in these prednisone resistent cats but 
are not as safe because of their longer duration of action. These latter two drugs should be used 
every 3rd day if possible.
When steroids are not an option, nonsteroidal drugs or immunotherapy vaccines 
may be beneficial.
ANTIHISTAMINES
Antihistamines can minimize the impact of histamine on the animal's pruritus. Since 
histamine is only one of many mediators of pruritus, these agents are not uniformly effective. However, 
in some patients, the results with antihistamines are as good as they are with corticosteroids. 
Antihistamines should be avoided or used with caution in pregnant animals or animals with glaucoma, 
seizure disorders, retentive disorders, heart disease, or know allergy to antihistamines. Antihistamine
overdose can kill animals. Since ketoconazole is known to alter the liver metabolism of antihistamines in 
humans, it would be prudent to avoid the use of ketoconazole and antihistamines in dogs and cats. If both 
agents need to be used simultaneously, the patient should be monitored carefully. Of the hundreds of 
antihistamines available, the following have proved to be effective in dogs or cats.
Drug Dog Dosage Cat Dosage
Diphenhydramine 2.2 mg/kg q8h ------------
Chlorpheniramine 0.22 mg/kg q8h 2-4 mg/cat q l2h
Hydroxyzine 2.2 mg/kg q8h ------------
Clemastine 0.05-0.10 mg/kg q l2h  0.68 mg/cat ql2h
Amitriptyline 1 -2 mg/kg q 12h 5 mg/cat q24h
Cyproheptadine -------------  2 mg/cat ql2h
FATTY ACID SUPPLEMENTS
The first report on the antipruritic effects o f specially-formulated fatty acid supplements 
appeared in the veterinary literature in 1988. That report and others prompted intense study with these 
agents. We know that these special supplements can control pruritus in some animals but what is not know 
is what is the best formulation and the optimum dosage of said. Several studies have shown that dogs are 
very individualistic in their response to these supplements, suggesting that there is no one best supplement. 
If one supplement does not work, another with a different formulation should be tried. If a supplement is 
to be effective, results will be seen before 21 days of treatment.
Supplement Dog Dosage Cat Dosage
DermCaps Per label Per label
EfaVet Per label Per label
Eicosapentaenoic acid 40 mg/kg q24h ??
Gamma linolenic acid >40 mg/kg q24h >8 mg/kg q24h
DRUG COMBINATIONS
Because of the vast number of mediators o f pruritus and the narrow focus of nonsteroidal 
agents, many drugs reduce but do not eliminate pruritus. Simultaneous administration of two or more 
drugs, each with a different target mediator, can improve the efficacy o f each drug. The steroid-sparing 
effects of antihistamines and DermCaps have been proven as has been the additive benefit of administering 
DermCaps with an antihistamine. The author routinely dispenses DermCaps with antihistamines. If the 
combination proves to be effective, the antihistamine is discontinued to determine if the DermCaps, the 
antihistamine, or both are responsible for the patient's improvement.
IMMUNOSUPPRESSIVE TREATMENTS
Simplistically, allergy is an overactive immune response to an allergen. If the allergen can 
not be eliminated and the pruritus can not be controlled with immunotherapy, corticosteroids, or 
nonsteroidal agents, the patient is destroyed. For the extra-special patient and client, immunosuppressive 
treatment may be beneficial. Agents which can be effective are:
Dogs: Azathioprine: 2 mg/kg q24h, Cyclosporin 5 mg/kg q24h
Cats: Chlorambucil: 2-6 mg/m2 BSA q24h
IMMUNOTHERAPY
Immunotherapy is the most specific form of treatment for atopy. Response is allergen
specific so an allergy test must be performed to formulate a specific vaccine. Response rate in cats is 
approximately 75%.
Food Hypersensitivity:
Food allergy can occur in any cat and can occur at any age. The kitten or geriatric patient appears 
to be equally susceptible. Signs are variable and are nonseasonal provided the cat eats the offending "food" 
year-round. Foods include foods, water, snacks, rodents, and anything else that enters the cat's mouth. 
Accordingly, simply changing the cat's cat food is o f limited value in the diagnosis and treatment of food 
allergy. The cat's (and owner's!!) whole lifestyle needs to be modified to prevent accidental ingestion of 
the "food".
Young cats with a sudden onset o f a steroid nonresponsive, intensely pruritic disease are prime 
candidates for a food allergy. However, a steroid responsive fur mower might have a food allergy. The 
only way to say yes or no to food allergy is to investigate it. Unfortunately, serologic and intradermal 
allergy tests are of little or no use in the diagnosis o f food allergy. Dietary change is the only reliable test. 
Although there are various "hypoallergenic" cat foods which appear to be very good in a large number of 
cats, there are no 100% effective commercial foods and homecooking is still advised. If a response is to 
be seen, it will be noticeable in the first 30 days o f the diet. Complete response may take 10 or more 
weeks.
Treatment involves avoiding the offending food. The author asks the owners to challenge their cat 
with individual "pure" foods so that the specific allergen can be identified. Once the allergen, occasionally 
the allergens, are identified, the owner will be able to find a commercial food which agrees with the cat. 
Rarely, homecooking must be continued and the diet must be balanced with fatty acids, taurine, and 
vitamins and minerals.
Insect and Arachnid Hypersensitivity:
House dust mites and fleas are well know problems for allergic cats. In dogs, skin test reactions 
to insects (ant, black fly, moth, etc) are commonplace and may be o f significance to some "atopic" dogs. 
Information of the significance of most of these insects in cats is lacking but they can play an important role 
in allergic pruritus.
MOSQUITO BITE HYPERSENSITIVITY
A uncommon (?) lesionally pruritic disorder. Signs during warm weather. Reactions significantly 
worse at each subsequent exposure. Diagnosis by documenting a seasonal eosinophilic dermatitis 
which resolves spontaneously with mosquito control. Corticosteroids accelerate healing. Skin 
testing and immunotherapy may be beneficial.
PARASITIC HYPERSENSITIVITY
IgE is both the antiparasitic and antiallergen antibody and some animals become clinically allergic 
to their parasites. If  serologic allergy tests for cats become useful, antiparasitic IgE probably will 
interfere with the kinetics of the routine allergy test. All atopic cats should be parasite free for 30 
or more days before serologic tests are performed.
Intestinal Parasite Hypersensitivity:Rare. Pruritic skin disease associated with 
roundworm or hookworm infection. Worming history o f all pruritic cats should be 
reviewed.
Mite Hypersensitivity:Common. The cat itches well out o f proportion to the 
number of mites present. Hypersensitivity makes diagnosis more difficult as some/many
mites are killed. Pruritus can persist for several weeks after all the mites are killed.
(r
Heartworm Hypersensitivity: Rare. As heartworm disease becomes more
common in cats, this disorder will be seen.
Miscellaneous Hypersensitivities:
Contact Hypersensitivity:
Drug Hypersensitivity: 
Bacterial Hypersensitivity: 
Malassezia Hypersensitivity: 
Hormonal Hypersensitivity:
LUMPS, BUMPS, AND LEFTOVERS
William H. Miller, Jr., VMD, DACVD 
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EO SINO PH ILIC GRANULOM A C O M PLE X
This complex still continues to plague us. The three components (eosinophilic ulcer, eosinophilic 
plaque, eosinophilic granuloma with collagen degeneration) have well established clinical features but looks 
and exudative cytology can be deceiving. If treatment difficulties are occurring, a skin biopsy should be 
performed before radical and expensive treatments are undertaken.
Ulcer: The name is a misnomer as there are no eosinophils in the lesions. Most cases are 
idiopathic. Cases which respond poorly to treatment may be secondarily infected and antibiotics should 
be considered.
Plaque: The most common presentation. Lesion full of mast cells and eosinophils. Lesion
probably develops after mast cell degranulation (immunologic or
nonimmunologic). Recurrent cases should be evaluated for allergies.
Granuloma: Occur in the mouth, on the chin, or on the legs. Most cases are nonpruritic and
may reflect some transient or permanent primary collagen damage. In pruritic 
cases, eosinophils probably enter the area first and recurrent cases should be 
evaluated for allergies.
All forms and cases need to be treated until the lesion disappears entirely. Most lesions heal on 
the surface well before the dermal inflammation is gone and cessation of therapy at surface healing usually 
guarantees a relapse. Steroids are the first line of defense but antihistamines, DermCaps, and other agents 
used in allergic cats have some use. Lesions of the complex that were steroid responsive but have become 
steroid resistant are infected or have undergone metaplasia to a squamous cell carcinoma.
PANNICULITIS
Panniculitis is inflammation of the subcutaneous fat. In most cases, the fat becomes necrotic and 
the material discharges through the skin. The diagnosis of panniculitis is easy. The determination of its 
underlying cause is difficult and successful treatment requires that the cause be determined.
Post-vaccinai: Solitary lesions of panniculitis are more common then the generalized
form. In the past, most solitary lesions in the cat where thought to be 
idiopathic. Today, we know that they can be a sign of a vaccine or drug 
reaction which might "go" to fibrosarcoma. Diagnosis of panniculitis is 
easily made by cytology but the true diagnosis requires surgical removal 
with wide margins.
Idiopathic Sterile: Although rare cases of dietary steatitis still are reported, this cause of
panniculitis are rare. True cases of primary, generalized panniculitis are 
very rare in the cat.
Infectious: Recurrent "idiopathic panniculitis" lesions on the ventrum or at the site of
previous wound or surgery should be evaluated carefully for atypical
mycobacterial, Nocardial, or other bacterial infections. Aspiration 
'■ cytology for culture is reported to be more effective then biopsy 
techniques. Regardless of die organism isolated, treatment is long and 
problematic, especially in atypical mycobacteroisis. In that disorder 
Baytril® (11-22 mg/kg q24h - CAREFUL OF BLINDNESS) can be 
effective but not all cases will respond. If an initial response is seen, 
treatment must be continued until all lesions disappear (eyes and fingers) 
and then for at least two more months. Premature cessation of treatment 
predisposes to relapse. For resistant cases, clofazimine (8-12 
mg/kg/q24h) has been successful in some cases. Detailed reading on the 
drug (CVT12) should be done before treatment is undertaken.
PERFO RA TIN G  D ERM ATITIS
Some cats appear to develop abnormal areas of collagen in their superficial dermis. Instead of 
developing an eosinophilic granuloma at the site, these cats eliminate the damaged collagen through their 
epidermis. The clinical lesions are very well circumscribed crusty lesions. Diagnosis by biopsy. Vitamin 
C (100 mg/ql2h) may be of some benefit.
ACTINIC DERM ATITIS
Lightly pigmented cats will develop an actinic dermatitis if they are allowed to bask in the sun. In 
cloudy climates (Ithaca!!), it takes years for the dermatitis to develop. Even if the sun bathing is abruptly 
stopped at the first sign of change, the dysplastic cells will persist and may continue their transformation 
to full-fledged tumor cells (squamous cell carcinoma). In most cases, the solar exposure can’t be stopped 
completely and tumor will develop. The pliseotherapy, strontium 90 p irradiation, used in Bowen’s disease 
works very nicely to eradicate the dysplastic cells.
FE L IN E  SARCOID
A recently describe tumor of predominantly young cats with a rural background. One or more 
lesions especially on the nose, face, ear, feet, and tip of the tail. Slow growing but incomplete excision 
accelerates growth rate. Resembles equine sarcoid in its histology and biological behavior but no viral 
etiology show here (yet). Wide surgical excision is curative.
PLASM A C E L L  PODODERMATTTTS
Still a disorder with an unknown pathomechamsm. The majority of cats have no systemic 
involvement and experience one episode in their lives. When the cat is ill, myeloma must be considered. 
Cat with recurrent or recalcitrant disease should be checked for FIV.
Since some (many?) cases undergo spontaneous resolution, the determination of a successful 
treatment is difficult. If the cat can be housed indoors on a soft carpet, no treatment is needed. When the 
pads ulcerate, infection is present (cause or result of the ulceration?) and needs to be treated for typically 
30 days. Cats crippled by their disease or subject to recurrent infection will respond to high levels of 
prednisolone (4.4 mg/kg q24h) or other immune modulators. Healed pads may remain somewhat soft due 
to scarring deep in the pad.
FE L IN E  C LA W  DISORDERS
Beyond traumatic avulsion of an individual claw, claw disorders, especially those involving 
multiple claws on multiple paws, are rare in the cat Unlike the dog where disorders of the claw itself are 
fairly common, cats tend to present with paronychial involvement. In the author’s practice, the paronychia 
usually is sterile and secondary to pemphigus, systemic lupus, or drug eruption. Bacterial disease, when
present, usually is superimposed on some sterile disease but primary bacterial paronychia does occur in 
immunosuppressed cats.
Destructive paronychia, a condition when the paronychial skin is ulcerated, is more common in 
the cat then dog. Thrombi lodge in the vessels of the digital skin blocking blood flow with subsequent 
tissue necrosis. The most commonly recognized condition involves thrombosis from an asymptomatic 
bronchogenic carcinoma.
U LC ER A TIV E D ERM ATITIS W ITH  LIN EA R  SU BEPID ER M A L FIBR O SIS
This condition was reported in the early 90's as an idiopathic condition of the cat. It remains so 
today. Affected individuals develop spontaneous erupting crusted ulcers over the dorsal neck and shoulder 
area. The lesion usually is not pruritic but will not heal. Surgery is curative.
Once removed, this lesion has no significance. Since the site of involvement is in a vaccine zone, 
the tissue should be sent for histologic evaluation where it can be differentiated from a vaccine-induced
panniculitis.
M ILIA R Y DERM ATITIS
The most common crusting skin disorder o f the cat is miliary dermatitis. In the early era of 
feline dermatology, miliary dermatitis was thought to be a specific disease entity. Today, we know 
that miliary dermatitis is a reaction pattern in the cat and not a specific disease. Diseases seen within 
this reaction pattern include:
Bacterial folliculitis 
Cheyletiella infestation 
Demodicosis 
Nutritional deficiency 
Food allergy 
Lupus
Mast cell disease
Dermatophytosis 
Feline scabies 
Trombiculosis 
Flea allergy 
Insect allergy 
Drug reaction 
FIV infection
Otodectes
Pediculosis
Fur mite infestation
Atopy
Pemphigus
EM/TEN
Idiopathic

Diabetic Ketoacidosis
Nishi Dhupa, BVM, DACVECC, DACVIM 
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Diabetes Mellitus was first reported in a cat in 1927 and is now recognized as a 
fairly common endocrine disorder. Diabetes mellitus results when insulin secretion by 
pancreatic beta cells is impaired, or when tissue cells are resistant to the action of insulin. 
In both situations the body’s ability to regulate glucose metabolism is impaired. Insulin 
deficiency accounts for the fasting hyperglycemia seen in this disorder. Severe deficiency 
also results in marked glucose overproduction and excessive mobilization of the body’s 
protein and fat stores.
Diabetic ketoacidosis (DKA) results from an absolute or relative insulin 
deficiency in conjunction with glucagon and stress hormone excess. It is crucial to 
identify underlying disease factors contributing to stress in these patients. Stress factors 
include changes in environment, dehydration and concomitant disease. Commonly 
associated diseases include feline hepatic lipidosis, renal disease, urinary tract and other 
infection, and pancreatitis. DKA is characterized by hyperglycemia, dehydration, 
ketonemia, metabolic acidosis and multiple electrolyte abnormalities. Treatment must be 
intensive and directed towards the correction of fluid, electrolyte and acid-base 
abnormalities as well as the correction of abnormal carbohydrate metabolism. Without 
treatment DKA is fatal and it should be considered a medical emergency. The mortality 
rate for DKA is 25-30 %, even with aggressive treatment.
Clinical Signs
Clinical signs seen in cats with ketoacidosis include polyuria, polydipsia, weight 
loss, anorexia, vomiting, diarrhea, lethargy, weakness, dehydration, obtundation and 
hyper- or hypoventilation. These clinical signs may develop in various combinations and 
are usually severe in the ketoacidotic cat.
Diagnostic Work-up
A. Laboratory tests
a. Immediate PCV, TS, BUN and blood glucose
b. CBC, Chemistry panel
c. Venous or arterial blood gas analysis
d. Serum electrolytes
e. Serum osmolality
B. Imaging tests
a. Chest radiographs
b. Abdominal radiographs
c. +/- Abdominal Ultrasound
C. Urinalysis, including culture and sensitivity
Fluid, Acid-base and Electrolyte abnormalities
Hyperglycemia causes an osmotic diuresis, predisposing to dehydration. 
Excessive fluid loss can lead to severe hypovolemia, with associated hypotension, 
compromised tissue perfusion, and lactic acidosis. Ketonemia further compounds the 
metabolic acidosis. DKA patients also suffer total body depletion of potassium and 
phosphorous due to anorexia and osmotic diuresis. Magnesium is also lost into the urine 
and severe hypomagnesemia may be associated with a refractory hypokalemia.
Treatment
A. Fluid Therapy
The fluid of choice is an isotonic solution such as 0.9% sodium chloride, lactated 
Ringer’s solution or Plasmalyte-A. ‘Shock’ doses (20-40 ml/kg) of fluids may be 
required in cases of severe hypovolemic shock or acidosis. In more stable patients, 
fluid requirements should be calculated to restore hydration over 1 0 - 1 2  hours.
B. Correction of Metabolic Acidosis
Metabolic acidosis may correct following intravenous fluid and insulin therapy via 
oxidation of ketone bodies and excretion of hydrogen ions in the urine. In cases of 
severe acidosis (pH <7.1; TC 02 < 10 mEq/1) judicious administration of sodium 
bicarbonate is recommended in order to improve cardiac contractility and peripheral 
vascular tone. The estimated dose of NaHCC>3 = 0.3 x BW^g x (18-serum HCO3). One 
quarter of the deficit is administered intravenously over 2 0  minutes; the remainder is 
administered in intravenous fluids over 4-6 hours. Side effects of sodium bicarbonate 
therapy include decreased serum potassium concentrations and hyperosmolality.
C. Correction of Electrolyte Abnormalities
a. Potassium: Serum potassium levels may decline precipitously following 
fluid and insulin therapy. Clinical signs include marked skeletal muscle 
weakness (as evidenced by poor neck muscle tone), paralytic ileus, 
respiratory paralysis and cardiac arrhythmias. Supplementation of 
intravenous fluids with Potassium Chloride (KC1) is essential.
Potassium replacem ent*:
Serum K (mEq/1) KC1 /L fluids (mEq) Max. rate (ml/lb/hr)
3.6-5.0 20 12
3.1-3.5 30 8
2.6-3.0 40 5.5
2.1-2.5 60 4
< 2.0 80 3
* Rate of supplementation should not exceed 0.5 mEq/kg/hr
b. Phosphorus: Hypophosphatemia may develop following insulin therapy 
due to intracellular shifting of phosphorus. Hypophosphatemia causes 
skeletal muscle weakness, hemolytic anemia and respiratory failure, due to 
decreased 2,3DPG and ATP levels in active tissue and red blood cells. If 
phosphorus levels decrease below 1.8 mg/dl or CPK levels are high (> 
1500), phosphate replacement is indicated. Potassium phosphate may be 
dosed as an intravenous constant rate infusion of 0.01-0.03 mmol/kg/hr, 
for 12-24 hours. Serum phosphorus concentration must be monitored 
closely during therapy. Over supplementation may cause hypocalcemia.
c. Magnesium: Hypomagnesemia has been associated with the development 
of refractory hypokalemia. In these cases, magnesium supplementation 
can be provided intravenously, using magnesium sulfate at a dose of 1 
mEq/kg/day.
D. Insulin therapy
Regular, crystalline insulin is the insulin of choice in DKA. It may be
administered intravenously or intramuscularly.
a. Intravenous insulin
If given intravenously, insulin is diluted in isotonic saline solution and 
administered as a constant rate infusion at a dose of 1.1 U/kg/24 hr. If the 
total daily dose of insulin is placed in 240 mis of saline, is can be infused 
at a rate of 10 ml/hr. When provided intravenously, insulin acts rapidly to 
lower the blood glucose level and frequent monitoring is recommended.
b. Intramuscular insulin
Alternatively, regular insulin may be administered by the intramuscular 
route. It is used hourly at a dose of 0.1-0.2 U/kg until blood glucose 
concentration decreases to less than 300 mg/dl. At that point, insulin 
frequency can be reduced to every 6  hours and it may be administered 
intramuscularly or subcutaneously (if the patient is well hydrated). Blood 
glucose monitoring should be hourly initially, but may be measured every 
2-4 hours once the frequency of insulin administration decreases.
c. Supplementation with dextrose
It is important to note that the metabolism of ketones requires insulin. If 
the blood glucose level drops into the normal range, but ketonemia 
persists, insulin therapy must be continued. This necessitates the 
supplementation of intravenous fluids with dextrose, in order to prevent 
the onset of hypoglycemia. The continued supplementation of dextrose
provides a carbohydrate substrate that enhances the metabolism of 
ketones, v
d. Long term insulin therapy
Once the patient is well-hydrated and no longer ketoacidotic, 
subcutaneous insulin injections can be initiated. Regular insulin may be 
used at a dose of 0.5-1 U/kg; Long acting insulin (NPH, Lente or 
Ultralente) may be dosed at 0.5 U/kg.
Insulin CRI - Therapy Adjustments
If glucose is:
> 250 mg/dl 
150-250 mg/dl 
100-150 mg/dl 
< 1 0 0  mg/dl
Fluids +/- dextrose
Isotonic fluid 
IV fluid + 2.5 % dextrose 
IV fluid + 5% dextrose 
IV fluid + 5% dextrose
Insulin (1.1 U/kg/day) 
1 0  ml/hr 
1 0  ml/hr 
5 ml/hr
Stop insulin infusion
E. Antibiotic therapy is indicated in the presence of systemic infection or fever.
References
Available upon request.
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Blood transfusions play a critical role in the management of cats with anemia, 
bleeding disorders and hypoalbuminemia. The transfusable components of blood are 
erythrocytes, leukocytes, platelets, coagulation factors and albumin. Historically 
veterinarians have relied on in-house donor cats as a source of blood for transfusion 
purposes. Blood was collected for immediate use and sophisticated collection and storage 
techniques were not well developed. The growing need for transfusions has led to 
advances in collection and storage techniques as well as to the development of large 
blood donor programs in veterinary institutions. More recently, commercial animal blood 
banks have been successful in the marketing of blood products to veterinary practitioners.
Blood typing and Cross matching
Blood types are genetic markers on erythrocyte surfaces that are antigenic and 
species specific. Two or more blood types make up a blood group system.
The only blood group system recognized in cats is the AB blood group system. 
This consists of three blood types: type A, type B and type AB. Type A is the most 
common blood type; type B is more common in certain breeds such as Persian, 
Himalayan, Abyssinian, Birman, Scottish fold, Somali, British shorthair and Devon Rex 
cats; type AB occurs extremely rarely. A simple blood typing card is available to classify 
cats as type A, B or AB.
Blood cross matching tests discover the serologic compatibility or incompatibility 
between donor and recipient; they test for the presence or absence of naturally occurring 
and induced alloantibodies in serum or plasma. A major cross match tests for 
alloantibodies in the recipient’s plasma against donor cells, whereas a minor cross match 
test looks for alloantibodies in the donor’s plasma against the recipient’s red blood cells. 
A major cross match incompatibility predicts that the transfused donor cells will be 
attacked by the patient’s plasma, causing a potentially life-threatening transfusion 
reaction.
In contrast to dogs, cats have naturally occurring alloantibodies against the blood 
type antigen they lack. Type A cats have weak anti-B alloantibodies, which cause a 
shortened survival of transfused B cells in type A cats. Type B cats possess strong anti-A 
antibodies and a mismatched transfusion will result in fatal acute hemolytic transfusion 
reaction. If blood typing is not available, a cross match should be carried out prior to any 
transfusion in a cat.
Blood component therapy
Indications for the use of fresh whole blood include anemia, excessive 
hemorrhage and bleeding disorders (related to platelet or clotting factor deficiencies). 
Stored whole blood has the same indications but is less useful in the treatment of 
coagulation abnormalities. Whole blood transfusions are still the most common form of 
blood transfusion therapy in feline medicine.
Separation of blood into its cellular and plasma components allows for more efficient 
replacement of the patient’s needs. Component therapy also reduces the likelihood of 
transfusion reactions resulting from unnecessary cellular or plasma protein 
administration. Selection of appropriate components also reduces the likelihood of 
volume overload following transfusion therapy in an anemic, but euvolemic, patient.
Whole blood can be separated into the following components: packed red blood 
cells (PRBC) and whole plasma. Plasma may be further classified as fresh, stored, frozen, 
or fresh-frozen plasma (FFP). Further plasma derivatives can include cryoprecipitate and 
platelet-rich plasma, although these are not used in feline medicine at this stage.
Packed red blood cells are prepared by removing plasma from a unit of whole 
blood. They are suspended in anticoagulant and preservative additive solutions and stored 
at 1-6°C. The shelf life varies from 21 to 35 days. Packed red cells are used in anemic 
patients, to increase oxygen carrying capacity, where there is no need for platelets or 
clotting factors. After separation of red cells from the unit of blood, the remaining plasma 
is frozen. This fresh frozen plasma contains coagulation factors and may be used to treat 
patients with acquired or congenital coagulation disorders. It may also be used in severely 
hypoproteinemic patients in order to raise recipient serum albumin concentrations.
While component therapy is ideal for meeting specific patient requirements, in 
feline medicine it has proven difficult to achieve due to the difficulty with the creation of 
closed and sterile blood collection systems. However, academic institutions and 
commercial blood banks are beginning to use and supply packed red cells and plasma.
Rate of administration
1) Whole blood or Packed Red Blood Cells: 10 ml/kg, over 1-4 hours; may give
more rapidly in hemorrhagic shock
2) Plasma: 10 ml/kg, over 1-2 hours
Whole blood and packed red blood cells should be administered after slow warming to 
37°C. Blood administration sets containing filters are commonly used; these filters 
remove blood clots and other particles.
Transfusion Reactions
Blood transfusions can produce various adverse reactions, ranging from allergic 
urticaria to life-threatening hemolytic reactions. The severity of most transfusion 
reactions is dose dependant; early recognition of a problem can avert disaster. Patients 
should be carefully observed, particularly during the first 30 minutes of the transfusion.
Cats with type B erythrocytes have strong, naturally occurring anti-A antibody. 
These cats will have strong, acute and often fatal transfusion reactions if given type A 
blood. Fewer than 30% of type A cats have anti-B antibodies, and type AB cats have no 
preformed antibodies to blood types. If type A cats receive type B blood, a slow 
transfusion reaction may result in an abbreviated donor red cell life span, thereby 
reducing the effectiveness of the transfusion.
Monitoring parameters include measurements of temperature, heart rate, pulse 
strength and synchronicity, and respiratory rate. These parameters should be monitored 
15, 30 and 60 minutes into the transfusion. If a reaction is suspected, the transfusion must 
be stopped immediately. Clinical signs associated with transfusion reactions include 
fever, vomiting, facial edema, hemolysis, tachypnea, urinary and fecal incontinence, 
tremors and shock. Severe reactions are rare when patients have been correctly typed and 
cross-matched.
The benefit of the prophylactic use of antihistamines and glucocorticoids has been 
debated. Pre-treatment with 0.5 mg/kg of diphenhydramine administered intramuscularly 
or subcutaneously, may reduce the risk of acute hypersensitivity reactions. However, 
there is no published literature supporting this at this time. Glucocorticoids do not acutely 
suppress the production of IgG or IgM antibodies and therefore are not considered to be 
useful in prevention of transfusion reactions.
Blood donor programs
Incentive Plan
a. Free vaccinations (Rabies, FVRCP, FeLV) (yearly)
b. CBC, Biochemistry Profile, Feline Leukemia, FIV, and hemobartonella 
screening (yearly)
c. Blood typing
d. Free blood transfusion if ever becomes necessary
e. 8 - 1 0  pound bag of cat food with each donation
Annual health screen
a. Laboratory screening (CBC, Profile, FeLV, FIV, hemobartonella)
b. Physical examination.
Cats with abnormal lab work, heart murmurs or abnormal heart rhythms 
are excluded from the donation program.
Caution: In some cases “sub-clinical” heart disease can be missed, 
particularly in cats.
c. Minimum weight requirement ( 8  pounds)
d. Age range of 1 to 10 years 
Donation Procedure
Unlike dogs, cats require sedation/anesthesia to donate. As with dogs, owners 
will leave their cat at the hospital for the day. Each cat receives a complete 
physical exam prior to donation. Cats are sedated with a ketamine/diazepam 
mixture or anesthetized using an inhalant anesthesia (isoflurane). Blood is 
obtained from the jugular vein and the entire donation process takes about 10-15 
minutes. Cats are offered a high calorie meal following donation and are 
observed for any problems. Most cats are discharged within 2 hours of donation.
Alternatives to Blood Transfusion: The use of Oxyglobin
Despite the growth of commercial animal blood banks and blood donor programs 
at large veterinary centers, blood products remain a limited resource. Additionally, 
despite the advances in species-specific blood typing and cross matching techniques, 
transfusion reactions still occur.
Corporate research has focused on the development of hemoglobin solutions, as 
alternatives to blood transfusion. Because hemoglobin solutions lack red blood cell 
antigens, there is no need for cross matching and blood typing. In January 1998 the FDA 
approved a hemoglobin-based oxygen-carrying solution (Oxyglobin, Biopure, Boston, 
MA) for use in dogs. This solution consists of hemoglobin polymers, has low viscosity 
and is isosmotic. The product can be stored at room temperature for up to two years. 
When administered to a patient, it increases plasma and total hemoglobin concentration 
and thus increases arterial oxygen content. Its oxygen affinity is lower than that of canine 
and feline blood, thereby enhancing oxygen delivery to tissues. The enhanced oxygen 
content and delivery permits efficient tissue oxygenation without increased cardiac work.
Oxyglobin has a variety of clinical indications for the emergency veterinary 
patient. It has been used in cases of hemolytic anemia, thromboembolic disease and 
vascular obstruction, postoperative hemorrhage, with variable success. Side effects 
include the potential for volume overload, mild vomiting and diarrhea. The mucous 
membranes, sclera and urine become discolored after treatment. Discoloration of serum 
will also interfere with the results of certain laboratory tests such as serum creatinine, 
serum bilirubin and coagulation parameters.
The use of hemoglobin based oxygen carriers such as Oxyglobin is worth 
considering in anemic patients. The dose range for dogs is 15-30 ml/kg; however the high
end of the range should be avoided in euvolemic patients. The rate of administration 
should not exceed 10ml/kg/hr in dogs. Although the solution has not been approved for 
use in cats, a lower dosage of 3-5ml/kg has been proposed. Cats receiving Oxyglobin 
should be very closely monitored for signs of volume overload.
There have been questions raised about serious side effects such as volume 
overload, pulmonary edema and hypertension, particularly in the feline species. Further 
clinical evaluation is necessary before the complete picture is evident. In the meantime, 
Oxyglobin is a useful addition to our arsenal of emergency treatments in anemic and 
hemorrhaging patients.
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FE L IN E  H YPERTH YRO ID ISM : 6000 CATS AND COUNTING
Jane M. Turrel, DVM, DACVR, DACVIM (Oncology), DACVR (Radiation Oncology) 
Veterinary Oncology Specialties, Pacifica CA 94044
In 1979, my favorite cat, Boo, lost weight, developed a ravenous appetite, had an 
unkempt coat and had daily episodes o f vomiting. She had had a cholecystoduodenostomy 
performed 2  years before and developed subsequent mild liver enzyme elevation and frequent 
biliary calculi. A complete work-up failed to identify her problem. She was hospitalized while I 
went to visit my parents for Christmas. A veterinary student suggested that a serum T 4  be done. 
Her T4  was “off-the-scale” . As soon as I returned home, a thyroid scan confirmed bilateral 
thyroid tumors. Boo had a hemithyroidectomy done and barely survived the surgery. At that 
time she weighed 4 pounds. Thus began my goal to use radioiodine to destroy the remaining 
thyroid tumor tissue and Boo became the first cat treated with radioiodine for hyperthyroidism 
at UC Davis.
Hyperthyroidism, originally described in 1979 by Jean Holzworth, is currently the most 
common endocrine disease o f the cat and is caused by multinodular adenomatous hyperplasia, 
functional adenomas or functional carcinomas of thyroid tissue. Histologically, it is difficult to 
differentiate these 3 forms. Thyroid adenomas involve both lobes, 70% of the time and one lobe, 
30% of the time. Malignant thyroid tumors (usually involving one lobe) have a prevalence of 3 to 
5%. The age range o f affected cats is 4 to 22 years with an average age o f 14 years. Diagnosis of 
hyperthyroidism is usually straightforward. A history of weight loss and increased appetite, 
physical examination findings of an enlarged thyroid gland, rapid heart rate and weight loss, and a 
high serum thyroxine concentration are features we all would like to see to make the diagnosis of 
this condition. In reality, there is a broad spectrum of historical findings and clinical signs that 
many cats are presented with and diagnosis is more difficult. We have suspected from the first 
descriptions o f this disease that its etiology was dietary induced and a recent publication has 
confirmed this.
Historical and Clinical Findings
Weight loss is the most common and predominant finding; sometimes only a few ounces 
are lost and in other cats, over 50% of body weight can be lost in a relatively short period of 
time. Weight loss of more than a few ounces in older cats is important and should be investigated. 
Obese cats with hyperthyroidism placed on reducing diets are often undetected because weight 
loss is encouraged and only until the cat overshoots the weight reduction goal will the cat be 
presented. Many cats are not presented until weight loss is marked because owners think the cat 
is "just getting old". Typically, a brisk to ravenous appetite is observed with cats changing from 
finicky eaters into vocal scavengers for food.
Increased incidence of vomiting is commonly seen and is usually related to a higher 
presence of hairballs, increased intestinal motility, or voracious appetite causing gastric 
distension. Stools may have a fetid odor, change to a pale gray color, and become voluminous. 
The frequency of defection is increased. Occasionally, stools will progress to diarrhea.
Polydipsia and polyuria are frequently noted clinical signs. Many cats will double water 
consumption and seek unusual sources of water (jumping into the bathtub or sink to drink from
the faucet or swimming pool). Some owners notice the need to change the litter pan more 
frequently because of the increased urine present.
Behavior and personality changes are seen in 20 to 30% of affected cats. Hyperactivity 
and restlessness characterize classical signs o f hyperthyroidism. Most owners reject the concept 
of hyperactivity until it is pointed out to them that it is unusual for an older cat to be awake for 
more than a few hours a day. On presentation, hyperthyroid cats are difficult to control because 
of increased activity. Some cats develop an aggressive attitude, often attacking and biting. Other 
cats will become more affectionate and seek more attention. Inappropriate defecation and/or 
urination have been reported. The owner may report that the cat is frequently hiding in unusual 
locations within the house or become withdrawn. Some cats will change sleeping locations from 
sunny or warm areas to cool bare floors or shady areas because o f the increased peripheral 
circulation. One striking sign associated with this disease is increased vocalization, oftentimes 
when the cat is alone in a room (owners describe these cats as "senile"). Sometimes cats with 
other diseases will destabilize, such as those inflammatory bowel disease, diabetes mellitus or 
heart disease.
The apathetic form of hyperthyroidism is seen in approximately 10% - 15% of 
hyperthyroid cats and is marked by signs o f poor to no appetite, dehydration and emaciation, 
and marked lethargy and weakness. These may or may not be preceded by the classic signs of 
hyperthyroidism.
Physical Exam ination Findings
Palpation of the thyroid gland is an essential part o f the physical examination and should 
be performed on all cats regardless of age. The normal thyroid gland is a bilobed structure located 
on either side of the trachea just caudal to the larynx with no connecting isthmus. These 2 lobes 
are not palpable in normal cats. Most cats with hyperthyroidism have at least one palpable 
thyroid lobe. Frequently one lobe is larger than the other is; the larger lobe usually gravitates 
caudally into the ventral cervical region. Markedly enlarged thyroid lobes may be located within 
the thoracic inlet or even in the cranial mediastinum. The disease is not always bilateral so both 
sides of the trachea should be carefully palpated. To properly palpate the thyroid gland, place 
the cat in a standing position with the head and neck extended vertically. The thumb and index 
finger should be placed on either side o f the trachea at the thoracic inlet and gently slid toward the 
larynx. Enlarged thyroid lobes will slip under the finger/thumb as the hand is advanced cranially.
Thyroid tumors may elude palpation because o f their location dorsolateral to the trachea, 
gravitation of tumors through the thoracic inlet into the cranial mediastinum, or inexperience of 
the veterinarian. Therefore, hyperthyroidism cannot be ruled out based on palpation. 
Conversely, palpation o f one or two thyroid lobes is abnormal and should be investigated further.
Integumentary changes include an unkempt, greasy, easily matted hair coat. The owners 
often note excessive shedding. Occasionally cats will pull hair out in clumps while grooming. 
Excessive shedding and grooming are more common and a change in hair coat color to reddish or 
brownish tinged hair can be seen. Longhair cats previously easily groomed are commonly 
presented with heavily matted coats. Ears and feet feel warm because o f peripheral 
vasodilatation. Excessively long toenails are common.
A variety o f cardiac abnormalities including tachycardia, premature beats, gallop rhythm, 
and systolic murmurs are seen in cats with hyperthyroidism. In one study only 30% of
hyperthyroid cats had normal cardiac function. Other signs include a pronounced pounding 
heartbeat, dyspnea and panting. Approximately 50% of cats with hyperthyroidism will have 
radiographic evidence of cardiomegaly. Echocardiographs will show hyperdynamic function of 
the myocardium rather than cardiomyopathy. Those cats with concurrent cardiomyopathy and 
hyperthyroidism may show signs of heart failure including pleural or pericardial effusion and 
pulmonary edema.
Other clinical signs are moderate to severe gingivitis and dental disease (reflecting the 
degree o f debilitation) and difficulty in being handled due to hyperactivity and aggressiveness. 
Abdominal palpation will often show small kidneys due to concurrent kidney disease. Cats that 
urinate during examination should be evaluated for urinary tract infections. And finally, some cats 
will show few clinical signs and are remarkably healthy.
Recent studies have shown that a majority of hyperthyroid cats are also hypertensive (> 
160 mm Hg). Clinically, signs of hypertension include pounding heart, venous distention, 
polyuria/polydipsia, tachycardia, and small kidneys. Hypertension usually occurs when cats 
have both hyperthyroidism and kidney disease. Blood pressure should be measured when the cat 
is well hydrated.
Serum Thyroxine Concentration (T 4) Testing
The most reliable and widely used test for diagnosing feline hyperthyroidism is total 
serum T4  concentration determination. Total T4  is a combination o f free and protein-bound 
thyroxine concentrations. Each laboratory has established normal ranges for their particular assay 
and therefore normal values are not interchangeable between laboratories. Hyperthyroid cats may 
have total T4  concentrations 30 times higher than normal or they may have total T4  
concentrations in the high normal reference range. Typically, older euthyroid cats have normal T 4  
concentrations near the lower half of the normal reference range. Total thyroxine concentrations 
in the middle or high end of the reference range are abnormal for older cats. When found in 
conjunction with one or two palpable thyroid nodules, a free T4  should be done to confirm the 
diagnosis.
Serum T4  concentrations fluctuate from day to day and hour to hour with variations 
found to be greater over a 15-day period than over a 10-hour period. The degree o f fluctuation 
can result in a normal serum T 4  concentration once and a high serum T4  concentration the next 
time. Routine testing of T3 is not helpful or warranted.
Some cats have clinical signs of hyperthyroidism before serum T4  concentrations are 
above the normal reference range. Systemic non-thyroidal diseases of several days’ duration can 
also lower serum T4  concentrations. Some medications such as cortisone, NSAIDS, 
trimethoprim-sulfa, and anticonvulsants will lower total T 4 . In these cases; a free T 4  by 
equilibrium dialysis is the more reliable test. The T 3  suppression test and TSH or TRH 
stimulating tests are not used much at this time. No assay for determining TSH concentrations of 
cats exists at this time.
Technetium -99m  Pertechnetate Thyroid Scanning
The most reliable procedure for establishing the diagnosis of hyperthyroidism in cats is 
the technetium-99m (9 9 mTc) pertechnetate thyroid scan. The test is simple and easily performed.
Approximately 3 to 5 mCi of 99mTc is injected subcutaneously. This radioisotope is trapped in 
the iodine-seeking tissues o f the body (thyroid gland, salivary glands, and gastric mucosa). 
Enough trapping of this radioisotope is completed after 20 to 60 minutes to image the body using 
a gamma camera. Normal thyroid lobes and the salivary glands should accumulate approximately 
the same amount o f 99mTc and so should be approximately the same size and intensity on the 
scan image. Findings typical of hyperthyroidism are increased uptake in the thyroid gland relative 
to the salivary tissue and increased thyroid lobe size. Failure to visualize thyroid tissue occurs 
when cats are fed dietary supplements, diets or supplements high in iodine (kelp), or have been 
given organic iodide preparations to control signs of hyperthyroidism. Antithyroid drugs do not 
interfere with performing a thyroid scan.
From the scan images, one can determine whether one or both thyroid lobes are involved, 
the relative size o f the affected thyroid lobes, presence of functional ectopic thyroid tissue, and 
whether the tumors are benign or malignant. In the presence o f unilateral thyroid lobe 
involvement (30%), the only thyroidal uptake will be by the affected side. The normal 
contralateral lobe will be atrophied and so will not trap 99mTc (not visible). The vast majority of 
cats will have bilateral thyroid adenomas (70%); some have both lobes affected to the same extent 
(symmetric) and some will have one lobe much larger than the other (asymmetric). Ectopic 
thyroid tissue is rarely seen in hyperthyroid cats because its tissue will be atrophied unless a 
functional tumor is also present in that ectopic tissue.
The incidence of thyroid carcinomas is approximately 5%. These carcinomas appear as 
multiple nodules distributed throughout the neck and cranial mediastinum. Other sites of 
metastases (lung, liver, and bone) from functional malignant thyroid tumors are usually functional 
and so can easily be found on the scan. Malignant non-functional thyroid tumors are rare and will 
not trap radioisotope. In some of these cats, the opposite thyroid lobe may have functional 
benign tumors. Cats that have had thyroidectomy with recurrence o f clinical signs will often have 
multiple “hot spots” reflecting fragmentation of the residual thyroid tumors adherent to the 
thyroid capsule. These scans are impossible to differentiate from cats with thyroid carcinoma.
Many facilites treating cats with radioiodine do not perform thyroid scans. I believe that 
it is an invaluable source of information. Approximately 50 to 75 cats each year are sent home 
untreated because the thyroid scan was negative. In those cases repeat total and free T4’s confirm 
that the cats are not hyperthyroid and that the original tests were in error. Secondly, cats with 
thyroid carcinomas can be identified and the correct dose of radioiodine can be given. Finally, the 
thyroid scan is used to help individualize the best estimated radioiodine dose for each cat.
Laboratory Abnormalities
Although several changes have been noted on serum chemistry profiles o f hyperthyroid 
cats, the only consistent ones are mild to moderate elevations of liver enzymes (serum alkaline 
phosphatase, serum alanine aminotransferase, and serum aspartate aminotransferase). Liver 
enzyme elevations are related to the high metabolic rate of the cat and usually are not caused by 
pathologic changes in the liver. Typically, the only hematological changes are a mild leucopenia 
and mild hemoconcentration. The urinalysis should be normal with a specific gravity of > 1.035.
Renal disease often occurs simultaneously in cats with hyperthyroidism and may or may 
not be caused by the hyperthyroidism. Since most cats with hyperthyroidism are older, pre­
existing renal disease may be exacerbated by the metabolic changes of hyperthyroidism. Some
cats will develop renal failure, possibly due to hypertension. Biochemical changes o f these cats 
are low urine specific gravity, high normal to high blood urea nitrogen, high normal to high 
creatinine, and high serum phosphorus levels. The presence of compensated kidney disease does 
not preclude radioiodine treatment.
Differential Diagnosis and C oncurrent Diseases
Many other diseases can occur which either mimic the signs o f hyperthyroidism or can 
occur simultaneously and be obscured because of the similarity o f signs. Diabetes mellitus, 
chronic renal disease, inflammatory bowel disease, pancreatic insufficiency, cardiomyopathy, and 
hypertension are the most common diseases producing at least some signs similar to feline 
hyperthyroidism. Most of the signs o f these diseases will be exacerbated by even mildly elevated 
serum T4  concentrations. Elimination of hyperthyroidism will often result in easier control of 
these concurrent diseases or allow them to go into remission. Cats with previously diagnosed 
cardiomyopathy should be re-evaluated 3 months after treatment for hyperthyroidism to re­
assess the diagnosis and the need for medication.
Other diseases with a less optimistic outlook need to be discovered before the cat is given 
definitive treatment for hyperthyroidism. These include lymphoma of the abdominal viscera, 
other neoplasms of the viscera, oral tumors, lung disease (cats don’t cough), severe renal disease, 
and congestive cardiomyopathy. Unfortunately, a search for unknown neoplasms can be cost 
prohibitive as well as delaying treatment for hyperthyroidism. In those cases, underlying diseases 
may only surface after effective treatment for hyperthyroidism has been done. Oral medication to 
control the hyperthyroidism is worthwhile so that the work-up for the more occult disease can 
be continued.
The best strategy for detection o f concurrent diseases is a complete physical examination 
including examination of the oral cavity for infection, dental disease, and neoplasia, careful 
auscultation o f the heart and lungs and thorough palpation of the abdominal cavity. A complete 
blood count, serum biochemistry profile and urinalysis are the minimum database. Abdominal 
and thoracic radiographs may be indicated based on the physical examination findings. Further 
testing may include examination of the abdomen by ultrasound and the heart by ultrasound or 
electrocardiogram.
One o f the most important rules o f hyperthyroidism and concurrent disease is that there 
must be a direct relationship between the degree o f illness in the cat and the level of thyroid 
hormone concentrations. Emaciated cats with an only slightly elevated T 4  should tell you that 
something else is seriously wrong.
Initial Treatm ent
After the diagnosis o f hyperthyroidism has been made, the owner should be advised 
regarding the appropriate treatment. I f  the cat is seriously ill with either hyperthyroidism alone 
or with concurrent disease, I prefer to treat both diseases, the one with radiodioine and the other 
appropriately. There are others who prefer that the cat be stabilized before definitive treatment is 
undertaken. In most cases when the cat is asymptomatic or is in stable condition, definitive 
treatment should be scheduled as soon as possible.
Antithyroid drugs are indicated for cats seriously ill with hyperthyroidism but caution 
must used when making that decision. Approximately 25% of cats will develop side effects to 
these drugs. Propylthiouracil and methimazole are most commonly used to counteract thyroid 
production. Methimazole is used more frequently because it produces fewer side effects. Both 
drugs act by preventing thyroid hormone synthesis and can result in a return to euthyroidism in 1 
to 2 weeks. The initial dose o f methimazole is 2.5 -5  mg orally bid to tid but is dependent on the 
T 4  concentration. The T4  concentration should fall into the normal range within 2 weeks. If it 
does not, the dose should be regulated appropriately. Similarly, the cat's medical condition should 
also stabilize. If  it does not, another reason for the cat’s illness should be searched for. Cats that 
are stable at this time should be referred for radioiodine treatment or thyroidectomy.
It should be noted that, regardless o f treatment modality selected, if tachycardia or other 
cardiac arrhythmias are present, beta-blockers should be prescribed. Antihypertensive drugs, 
antibiotics, and kidney disease management may have to be instituted as well.
Radioiodine Treatm ent
Radioiodine treatment is acknowledged as the safest, most effective treatment and is the 
treatment of choice for feline hyperthyroidism. Radioiodine ( 1 3 1 I) has a half-life o f 8  days and 
emits a spectrum of beta and gamma radiations. Iodine is actively trapped and incorporated into 
the functional thyroid tumors but does not accumulate in atrophied normal thyroid tissue. 
Therefore, normal thyroid tissue as well as the parathyroid glands and other surrounding tissues 
are spared the effects o f irradiation.
The dose of ,31I activity administered is based on the serum T4  concentration, the size of 
the thyroid tumor on palpation and thyroid scan, and whether the tumor appeared benign or 
malignant on the thyroid scan. Other considerations are the cat’s other medical problems and 
inherent body metabolism. Activities of 131I administered for benign tumors range from 1 to 8  
millicuries and are given subcutaneously; the dose o f 13 *1 for malignant tumors is much higher and 
ranges from 15 to 25 millicuries. Cats on antithyroid drugs must have the drug stopped for 4 to 5 
days before treatment. Otherwise 131I uptake is lowered and excretion is accelerated increasing 
the likelihood for a second treatment. Some cats are so fragile that they cannot be removed from 
antithyroid drugs before treatment; in those cases, ,31I is given at a higher dose to counteract the 
effects o f these drugs.
As rules for radioiodine usage have become less rigid in some states, radioisotope licenses 
have been granted to numerous veterinary hospitals. Hyperthyroid cats can be readily 
transported to these referral centers. The procedure for scanning and treatment takes only a few 
hours. Some referral centers have gamma cameras but most treat cats based on Palpation and T4 
levels. Doses of radioiodine are either determined as a fixed dose ranging from 4 to 10 mCi 
depending on the facility. In other facilities, doses are individualized but without the benefit o f a 
scan. The risk for cats becoming hyperthyroid by either method is high.
Within one to two days after treatment, cats improve clinically and feel much better. By 
the time the cats are discharged, thyroid hormone levels are usually in the normal range. Cats 
treated with radioiodine are usually hospitalized for 4 to 14 days (depending on the radiation 
safety rules o f the state they are treated in) so those radioactive excreta can be collected. This 
hospitalization period is in sharp contrast to humans treated with radioiodine who can go home 
the same day.
The major disadvantage of 13  *1 treatment is the hospitalization time required. No side 
effects from the treatment are present. Normal thyroid tissue and parathyroid glands are spared 
and normal thyroid function returns within 1 month after treatment. During this recuperative 
period, some cats will be sluggish, have a decreased appetite, and appear to sleep more than 
usual. These signs gradually lessen as thyroid hormone concentrations return to normal.
Cats with thyroid carcinoma given therapeutic doses of radioiodine will have complete 
ablation o f all thyroid tissue and will require thyroid supplementation and frequent monitoring to 
ensure tumor control. Long-term tumor control and good quality-of-life are the usual results after 
radioiodine treatment o f thyroid carcinoma. Only rarely will cats succumb to recurrent or 
persistent malignancy. In some cases, the residual thyroid mass remains and may need to be 
excised if it persists longer than 6  months.
Approximately 5% of cats given an individualized dose (dose selected for the tumor and 
the cat) require a second treatment to eliminate the tumor. Another 5 % of cats will develop 
hypothyroidism after radioiodine treatment; this can easily be treated with thyroxine 
supplementation. Recurrence o f hyperthyroidism after successful treatment is rare, occurs 2 to 8  
years after initial treatment, and is usually associated with a malignant thyroid tumor.
Thyroidectomy
If radioiodine treatment is not selected for one reason or another, the other treatment 
alternative is thyroidectomy that can be done by practitioners with reasonable surgical skills. 
Ideally, a thyroid scan should be performed before surgery to identify which thyroid lobes are 
involved and the location of that tissue. Only then can an informed decision be made on which 
thyroid tissue needs to be removed. In reality, few cats are scanned before thyroidectomy and the 
decision to remove 1 or 2  lobes is based on thyroid lobe appearance at the time of surgery.
Unilateral thyroidectomy, usually done by the extracapsular method, is performed in 
those cats which have unilateral thyroid tumors as identified on 99m'pc thyroid scan or by 
inspection of the thyroid lobes at surgery. Since only 1 lobe is removed, the likelihood of the cat 
becoming hypothyroid or hypocalcemic is low. The major disadvantage o f this technique is that 
the probability of the opposite lobe having or developing adenomatous tissue is high, 
approaching 80%.
Bilateral thyroidectomy, usually now performed using the modified 
intracapsular/extracapsular technique, is done when both lobes are affected. The intracapsular 
technique involves peeling the thyroid tissue from the capsule to leave intact the blood supply to 
the parathyroid glands. The modification is that the parathyroid glands located at the cranial 
poles are undisturbed by leaving the capsule around that tissue (extracapsular). Regardless o f the 
surgical procedure used, all tissue should be submitted for histopathology. Examination o f the 
tissue will determine if thyroid tissue was removed (occasionally lymph nodes are removed 
instead of thyroid tissue), whether parathyroid glands are present in the sample, and if thyroid 
tissue is benign or malignant. If a diagnosis of malignancy is given, a thyroid scan should be 
performed soon after surgery to identify if the tumor has metastasized to lymph nodes and lungs. 
If metastases are found, high-dose radioiodine treatment is indicated.
Intraoperative complications include damage to the vagosympathetic trunk causing 
Homer's syndrome, damage to the laryngeal nerve causing laryngeal paralysis, damage to the
esophageal nerves causing megaesophagus, and uncontrolled hemorrhage. Occasionally both 
thyroid lobes cannot be found despite lengthy dissection usually due to gravitation o f the larger 
lobe into the thoracic inlet. A few cats will have neoplastic ectopic thyroid tissue in the cranial 
mediastinum which is also difficult to retrieve. In both situations, these cats will remain 
hyperthyroid after surgery.
The most serious post-operative complication is disruption o f the blood supply to the 
parathyroid glands resulting in hypocalcemia. This situation is life-threatening and occasionally 
despite intensive treatment for hypocalcemia can be fatal. Serum calcium levels should be 
monitored daily for 4 to 7 days after bilateral thyroidectomy. If the serum calcium concentration 
falls below 7.0 mg/dl, the cat may show signs of hypocalcemia including restlessness, facial 
pruritis, ear twitching, abnormal behavior, muscle tremors, tetany, and convulsions.
The other serious complication of thyroidectomy is loss o f normal thyroid hormone 
production. I f  a unilateral thyroidectomy is done and the remaining thyroid lobe is normal, serum 
T4  concentrations will return to the normal range over the ensuing month due to stimulation of 
the atrophied thyroid tissue's response to TRH and TSH. When bilateral thyroidectomy is done, 
serum T4  concentration will be low and the cat should be supplemented with thyroxine at a 
dosage o f 0.1 mg/cat once daily. In the vast majority o f cats having bilateral thyroidectomy, 
clinical signs o f hypothyroidism will not develop. This is either due to stimulation of ectopic 
thyroid tissue to produce T 4  or, perhaps more commonly, production o f thyroid hormones by 
residual thyroid tumor cells adhering to the thyroid gland capsule. Over a long enough time, these 
cells will once again produce excessive levels o f thyroid hormones. Serum T4  concentrations 
should be routinely monitored every 6  months on cats having any thyroidectomy procedure. If  a 
cat becomes hyperthyroid after having a total thyroidectomy, radioiodine treatment should be 
done because the likelihood of hypocalcemia increases greatly with subsequent surgeries.
Long-term  Medical M anagement
A few hyperthyroid cats are not good candidates for either radioiodine treatment or 
surgery because of either concurrent disease or advanced age (> 20 years). Some clients refuse 
definitive treatment for a wide variety of reasons citing that these procedures are either too 
stressful, too risky, too expensive, etc. Regardless of the reason, the only other treatment 
alternative is continuous medical management with antithyroid drugs. Generally, methimazole is 
given at a dosage o f 5 mg/cat bid to tid. As the tumor enlarges, the dose o f methimazole must be 
increased. Frequent monitoring of T4 's and CBC's should be done to ensure proper dosage and to 
detect hematologic abnormalities. Cats should not be kept on antithyroid drugs for longer than 6  
months. Beyond that time, owner compliance is diminished, the risk o f side-effects is increased, 
the need to increase the dose and frequency of administration is increased, and the cost 
effectiveness begins to equal the cost of either radioiodine treatment or thyroidectomy.
Several disadvantages of these drugs are readily apparent. Antithyroid drugs do not affect 
the growth of the thyroid tumor and so as the tumors grow, more drug must be given. 
Antithyroid drugs must be given at least once to three times daily for the remainder o f the cat's 
life in order to control clinical signs. Periodic T 4  concentration determinations and a complete 
blood count (every 2 weeks for 3 months) should be done to insure that the correct dosage of 
drug is given and that toxic bone marrow effects or autoimmune disorders are not developing. 
25% of cats on antithyroid drugs will suffer from mild to fatal side-effects. Methimazole is less 
toxic than propylthiouracil but both drugs can cause similar side-effects. Thyroid carcinomas are
seen in cats on long-term methimazole due to malignant transformation of the previously benign 
adenomas.
Side-effects associated with antithyroid drugs include anorexia, vomiting, dehydration, 
lethargy, and skin rashes/excoriations or alopecia. More severe side-effects are the hematologic 
complications that can be life-threatening. They include the presence of antinuclear antibodies, 
Coombs' positive hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia. Side- 
effects are more likely to occur in the first 3 months of treatment but can develop at any time. If 
side-effects occur, then withdrawal from the drug should be done immediately and supportive 
care for the side-effects should be done. The decision to perform definitive treatment must be 
reconsidered at this time.
Treatm ent Sequel
Cats receiving definitive treatment for hyperthyroidism generally have dramatic 
improvement in health and will regain normal behavior, appetite, and physical appearance within 
1 to 2 months after treatment. In the first few weeks after treatment several important 
physiologic changes are occurring which need to be identified and monitored. Cardiac changes are 
dramatic with return to normal heart rate and rhythm. An important sequel to these cardiac 
changes is a lowering of blood pressure (80% of cats have high blood pressure before treatment). 
Lowered blood pressure results in a reduction of the glomerular filtration rate by approximately 
25%. This drop can be significant in cats with early renal disease and precipitate decompensated 
renal failure. These cats need to be managed with either oral or subcutaneous fluid 
supplementation, low-quantity, high-quality protein diet, calcium supplementation to increase 
available calcium in the gastrointestinal tract, and other supportive therapy. Intensive and 
aggressive treatment and careful monitoring of these cats must be done until the kidneys have 
readjusted to the physiologic changes.
Heart failure can result after hyperthyroidism is corrected, mostly due to loss of stimulus 
to the heart and residual hypertension from the concurrent renal disease. Hypertension and/or 
cardiac drugs must be given until these problems resolve.
Another important finding is that some cats will not return to their weight and predicted 
good health. Monthly rechecks for the first 3 months should be done to assess physical status 
and to monitor T4  concentrations. If the cat does not gain weight, then an aggressive search for an 
underlying disease must be done. The most common problems are decompensated renal disease, 
cardiomyopathy, or a second neoplasm.

3It is the balance of "compensatory" increases in single nephron GFR with the development of 
glomerulosclerosis that w ill determine total kidney GFR (and to what magnitude the BUN and 
serum creatinine will increase with advancing renal lesions). It often seems inevitable that 
once chronic renal failure is diagnosed that it invariably gets worse (more renal lesions 
accumulate or further renal functions are lost). It is not possible to predict the rate of th is  
progression in experimental or clinical animals. Figure 4. displays several possible scenarios 
that may be observed during the course of chronic renal failure.
Figure 4 -A. Linear Decline in Excre tory Figure 4-C. Prolonged Periods of Stable
Renal Function Excretory Renal Function After In it ia l
Decline
Figure 4-B. 
Renal Function
Weeks or Months 
Episodic Decline in Excretory Figure 4-D.
After Initial Decline
Weeks or Months 
Increased Excretory Function
Weeks or Months Weeks or Months
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Figure 5-A. Increased Concentrations of 
Serum Creatinine Due to Acute P re-R enal 
Factors (No Further Lesions or permanent 
hemodynamic changes have occurred w ith in  
the kidneys)
Figure 5-B. Increased Concentrations of 
Serum Creatinine Did Not Return to the 
Original Baseline Due to Acquisition of Acute 
Renal Failure Lesions (Acute Tubu la r 
Necrosis).
Though the lesions of CRF are permanent, reversible factors that reduce renal function o r 
contribute to further development of renal lesions can exist on top of CRF. These include 
dehydration, hypoadrenocorticism, anesthesia and surgery, heart failure, urinary tra c t 
obstruction, urinary tract infections, leptospirosis, hypercalcemia, hypokalemia, pyometra, 
heartworms, systemic lupus erythematosus, endocarditis, ehrlich iosis, Rocky Mountain 
Spotted Fever, and borreliosis (?).
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CATS W ITH CHRONIC RENAL FA ILU R E (CRF) - 
HOW D IFFER EN T THAN C R F IN DOGS ?
Dennis J. Chew, DVM , Dip ACVIM
The Ohio State University College of Veterinary Medicine, Columbus, Ohio
Frequency of Chronic Renal Failure in Cats
Chronic renal failure is common in cats and its prevalence is apparently increasing. As 
many as 15 to 30 % of cats over the age o f 15 have CRF. This increase in the detection of CRF 
in cats could be due to an actual increase in the frequency of this disorder or possibly due to 
increased veterinary attention to aging cats. Cats less than 3 years of age uncommonly have 
CRF; increased risk for CRF has been seen in cats greater than 7 years old.
Differential Diagnoses
Tubulo-interstitial nephritis of unknown cause accounts for the number one diagnosis of 
CRF in the cat, as in the dog. Cats have several renal diseases that deserve extra consideration 
compared to that in dogs.
Glomerulonephritis and Renal Amyloidosis
Primary glomerular disease appears to be less common in cats than in dogs as a cause for 
endstage renal disease. Chronic antigenemia from FeLV or FIV should be considered as a possible 
underlying cause in cats with glomerulonephritis. In Abyssinian cats amyloidosis appears to be 
familial, probably a dominant trait with variable penetrance (DiBartola). Renal amyloid occurs 
sporadically in non-Abyssinian cats. There is extreme variability in the age of onset and the 
severity of renal involvement. Amyloid is preferentially deposited in the renal medulla and to 
some degree in glomemli in 75% of affected cats. Proteinuria is a less reliable indicator o f renal 
amyloidosis in cats than in dogs (non-Shar Pei) due to variable glomerular involvement in cats. 
Since biopsies sample tissue from the cortex, medullary amyloid deposits will be missed and 
glomemli may not contain amyloid obscuring the diagnosis. Biopsy may reveal changes of 
chronic interstitial nephritis and fibrosis associated with amyloid deposits.
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Polycystic Kidney Disease and Renal Lym phom a
Polycystic kidney disease (PKD) is an important consideration in Persian and other 
longhair cats, whereas this is extremely uncommon in dogs. A variable number o f cortical and 
medullary cysts continue to increase in number and size with age in affected cats leading to 
progressive loss o f functional renal mass occupied by the cysts. Chronic tubulointerstitial 
nephritis is also associated with the renal cysts. All cats with PKD have at least one parent also 
affected with PKD (autosomal dominance inheritance). Renal ultrasonography is the imaging 
method o f choice to confirm PKD. Renal biopsy is not necessary. Renal cysts may be seen with 
ultrasound in some affected cats as early as 7 weeks o f age; the absence o f detectable cysts by 6  
months o f age usually indicates that the cat is not affected with PKD. Enlarged non-painful 
kidneys are often detected on abdominal palpation. Irregular protrusions are palpable from the 
kidneys o f some PKD affected cats, while other cyst enlargements appear smooth and 
symmetrical.
Bilateral renal lymphoma resulting in CRF is much more likely in cats than dogs. Renal 
LSA is a major differential for enlarged kidneys in the cat, both smooth and irregular on 
palpation or with renal imaging. The kidneys may be the only organ documented with LSA 
infiltration. Feline leukemia virus status is often negative when the kidney is the only organ 
affected with lymphoma. Fine needle aspiration of renal tissue and cytology is usually adequate 
to diagnose renal LSA. Chemotherapy may be effective in lessening the degree of renal failure 
when neoplastic lymphocyte infiltration is diminished.
Urinary T ract Infection (UTI)
UTI in cats with chronic renal failure appears much more commonly than in cats with 
lower urinary tract disorders. UTI in cats with chronic renal failure appears to be more common 
than that encountered in dogs with chronic renal failure. The reasons for this remain to be 
determined but could be related to loss o f a protective effect conferred by maximal urinary 
concentrating capacity during advancing renal disease. Alternatively, diseased renal tissue may 
be more readily colonized by bacteria(acquired pyelonephritis). A third possibility is that upper 
urinary tract infections may be the initial cause for loss o f renal function.
Hyperthyroidism
The effects of hyperthyroidism on renal function and renal disease in cats have not been 
fully characterized. Since cats with CRF and hyperthyroidism tend to be older, it is difficult to 
assess a possible interaction between these two disorders. It is likely that hyperthyroidism is 
underdiagnosed in cats with chronic renal failure since nearly half o f cats with CRF and 
hyperthyroidism will have a normal T4 level on a single measurement. It has been noted by us 
and others that a population of hyperthyroid cats develop azotemia or display a worsening of 
azotemia following therapy to induce euthyroidism. It is known that thyroid hormones have a 
supportive role for GFR through its effects to increase renal blood flow. It is possible that 
lessening the degree o f hyperthyroidism results in decreased RBF and GFR which unmasks 
azotemia in cats with marginal renal function prior to therapy. GFR decreased while BUN and 
serum creatinine increased in a group of cats which underwent bilateral thyroidectomy as
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treatment for hyperthyroidism (Graves). Some cats in this study developed overt renal 
azotemia. Some increase in serum creatinine concentration are expected following the 
development of euthyroidism due to increased muscle mass (origin o f creatinine). Similar 
findings have been observed in some cats in which euthyroidism was achieved following 
methimazole or 1-131 radiation treatments (DiBartola).
Hyperthyroidism is known to result in dilute urine and polyuria with polydipsia. This 
effect is likely due to increased RBF and medullary solute washout, though a direct effect on the 
collecting tubules and ADH receptor interaction cannot be excluded. Psychogenic mechanisms 
also cannot be excluded. Hyperthyroidism is known to result in hypercalciuria in other species 
due to enhanced bone calcium mobilization; this effect may have some role in the development of 
polyuria as well as a possible role in creating chronic renal damage by excessive exposure of renal 
tissue to calcium. Most cats with hyperthyroidism also have increased systemic blood pressure 
which could injure renal tissue.
Should cats with overt azotemia and hyperthyroidism be treated for hyperthyroidism ? It 
is likely that many o f these cats will increase their level o f azotemia following treatments that 
result in euthyroidism. In some cats this increase in creatinine will be mild, while other cats will 
experience large increases in serum creatinine. If clinical signs related to hyperthyroidism are 
severe, at attempt at treatment is warranted. We recommend screening cats with obvious 
azotemia and those suspected of renal disease with a methimazole challenge. Methimazole 
treatment provides a reversible means of inducing euthyroidism and observing what happens to 
the level o f renal function. An initial dose o f 2.5 mg BID is given for 2 weeks and then serum 
biochemistry is repeated to evaluate renal function and T4 levels. If renal function is stable, the 
dose is gradually increased every two weeks as needed until T4 levels have entered the normal 
range if renal function remains stable. The dose can be increased to 2.5 mg TID, then 5 mg BID, 
and 5 mg TID if needed. Methimazole is discontinued if renal function deteriorates during the 
methimazole challenge. If renal function remains stable, then long term methimazole can be 
considered for therapy or more-definitive treatment of hyperthyroidism provided by 1-131 
treatment or surgery. The definition of "stable" renal function is arbitrary and in our hospital 
means that the creatinine increased less than 2 . 0  mg/dl in those without initial azotemia and less 
than 1.0 mg/dl in those with obvious azotemia. Supplementation with thyroxine should be 
considered for those cats with renal disease that become hypothyroid following definitive 
treatment.
Potassium Depletion Nephropathy
A syndrome of chronic renal failure and severe muscle weakness has been observed in 
clinical and research cats fed acidifying diets that were marginally replete with potassium, 
decreased in magnesium, and high in protein content. This syndrome has been referred to as 
potassium depletion nephropathy or kaliopenic nephropathy, though it occurs in a setting with 
other complex nutrient modifications. Chronic hypokalemia can cause functional renal lesions 
(e.g. defective urinary concentrating ability, decreased GFR), structural renal lesions, and 
chronic renal failure, but the exact mechanisms remain unknown. Chronic renal failure appears to 
be the most common condition associated with hypokalemia in general populations of sick cats.
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The question remains o f whether potassium depletion and hypokalemia occur prior to the 
development of CRF as a possible cause or as an effect after CRF develops. Truncal ataxia with 
a "hanging head" is an effect o f severe potassium depletion and hypokalemia. This type of severe 
manifestation is now much less common as pet food manufacturers have increased potassium 
supplementation of their diets. It is possible that subclinical potassium depletion may be 
important in cats with CRF that develop weight loss, lethargy, anorexia, poor quality of hair 
coat and anemia ; usually these problems are blamed on advancing renal failure. Potassium 
supplementation to cats with hypokalemia and CRF has been described to have many beneficial 
effects on general well-being as well as on improved renal function. A beneficial effect of 
potassium supplementation to cats with CRF and normal serum potassium concentration 
remains to be shown, but anecdotes do support this use. A recent study at OSU (Theisen) 
failed to show a beneficial effect on renal function of potassium gluconate vs sodium gluconate 
supplementation to cats with chronic renal failure and normokalemia.
History
Lethargy, anorexia, and weight loss are the most common signs in cats with CRF. 
Polyuria and polydipsia are detected by owners in less than half the cases, in contrast to most 
dogs. Vomiting is reported in about 30-50% of cats with CRF. Inappropriate location for 
urinations are uncommon in cats with just CRF.
Physical Exam
Dehydration and emaciation are the most common findings detectable on physical 
examination. Oral ulcers occur occasionally, but less so than in dogs. Tongue-tip necrosis, as 
seen in uremic dogs, is very rare in cats with CRF . Small and irregular kidneys are palpable in 
about 25 % of cats with CRF. About 25 % of cats with CRF will have palpably enlarged 
kidneys, higher than that encountered in dogs. Nearly two-thirds o f cats with CRF display 
systemic arterial systolic hypertension when assessed by Doppler and occlusive cuff methods. 
Retinal lesions are occasionally encountered especially during severe hypertension (retinal 
detachments, hemorrhages), observed in as many as 4 to 5 % of cats with CRF.
Table 1). Differential Considerations for Renomegaly in Cats
1. Lymphoma (LSA)
2 . Granulomatous Nephritis -FIP/Toxoplasmosis
3. Hydronephrosis
4. Polycystic Kidney Disease (PKD)
5. Perinephric Pseudocyst
6 . Acute Primary Renal Disease 
Pyelonephritis 
Acute Tubular Necrosis
7. Intact Male Kidneys
8 . Compensatory Hypertrophy -Unilateral
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Chronic primary (in trin s ic ) renal failure (CRF) is not a specific diagnosis, but rather the 
endpoint of a variety of generalized vascular, glomerular, interstitial, and /or tubular disease 
processes (see Figure 1). Accurate diagnosis is essential in order to construct a therapeutic 
plan likely to be of any benefit.
Chronic Renal Failure (CRF) : Renal Lesions and Nature of Progression
Figure 1. Potential Causes for Chronic Azotemia, including Chronic Pre-Renal, Chronic Post- 
Renal, and Chronic Primary-Renal
Progression of Chronic Renal Failure
CRF is clin ica lly characterized in dogs and cats by the development of variably progressive 
irreversib le intrarenal lesions and loss of renal functions ( sometimes referred to as " the 
inexorable progression of chronic renal failure"). It is not known for certain why progressive 
loss of renal function and development of renal lesions occur in CRF. The original cause of the 
renal in jury may still be present( as in pyelonephritis or renal amyloidosis). Most often an 
underlying cause for the initial renal insult cannot be found yet progressive renal in jury w ith  
loss of function continues. It appears that a critica l mass (threshold or "tr igge r-po in t") of 
nephron loss is necessary before self-perpetuating mechanisms continue to destroy remaining 
viable nephrons. "Super-nephrons" that result from hypertrophy of renal function and
increased glomerular volume in remaining viable nephrons may result in their eventual 
demise.
Figure 2. Compensatory increase in single-nephron GFR following decreased total kidney GFR. 
Following major reduction in total kidney GFR, some remaining nephrons increase their GFR; 
the signal for this increase is not known.
Hemodynamic adaptations cause increased single nephron GFR, glom erular plasma flow, and 
increased transglomerular capillary hydraulic pressure that are in itia lly  adaptive to maintain 
excretory function and increased total kidney GFR. It is possible that this in tra g lo m e ru la r 
hypertension and increased glom erular volume eventually harm glom eruli however, as shown 
in Figure 3. Tubular hypermetabolism, hyperammoniagenesis, renal m ineralization, systemic 
arterial hypertension, intrarenal coagulation, and immune mechanisms may also contribute to 
chronic progressive renal injury.
Figure 3. Compensatory increases (adaptations) in g lom erular hemodynamics and g lom eru la r 
volume may actually be maladaptive in some instances as shown in this figure.
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Acute Decrease in Renal Mass
GFR
"Compensatory" Adaptation
0 %
Weeks to Months
Diabetes Mellitus
Glomerular Hemodynamics
Glomerular Volume
Glomerular Hypertension 
Glomerular Hypertrophy 
P r o t e i n u r i a T u b u l a r  Hypertrophy
^  Mesangial Cells
^  Mesangial Matrix
Dennis J. Chew, DVM, ACVIM; The Ohio State University College of Veterinary Medicine 2000
Urinalysis
About 10 % of clinical cats with CRF retain their ability to concentrate urine to greater 
than 1.025 specific gravity. Isosthenuria(l.007-1.015) is encountered in about 60% of cases, 
while moderate urine concentration from 1.016-1.025 is seen in about 30% o f cases. When urine 
specific gravity is less than 1.035, the presence of renal disease should be suspected in cats, 
especially when dehydrated. 50% of cats with CRF have mild to moderate (+1 to +2) 
proteinuria based on dipstrip reactions. Hyaline and granular cast can be seen in nearly half of 
cats with CRF. It is likely that many cats with CRF will display diagnostically relevant 
microproteinuria as evaluated with the urinary protein to creatinine ratio.
Treatm ent of Cats with C R F
Most treatments for cats with CRF are similar as for dogs with CRF (dietary 
modification, phosphate restriction, H-2 receptor blockers). Dietary protein restriction to about 
2 0  % of calories from protein are presently recommended by our nephrology and nutrition 
service. Since most commercial cat foods are acidifying, these foods should be discontinued and 
either a non-acidifying prescription catfood provided or a homemade diet fed. Cats with 
experimental CRF due to subtotal nephrectomy experienced fewer lesions o f glomerulosclerosis 
in remnant tissue when fed diets restricted in protein and calories, compared to those that were 
not restricted. GFR and degree o f proteinuria were higher in those cats fed the high 
protein/calorie diet, but GFR did not change in either feeding group over a one year study period 
(Adams and Polzin).
Subcutaneous Fluids
Subcutaneous fluids administered at home can be well-tolerated by the cat and owner for 
long times. Fluids such as Lactated Ringer's solution can be given at 100-200 ml daily as needed 
daily, every other day, or only during times of stress.
Hypokalemia
Hypokalemia occurs more commonly in cats than in dogs with CRF and is most likely to 
occur at presentation in those with polyuric renal failure, especially when anorexia is present. 
Hypokalemia is much more common than hyperkalemia in cats with CRF. Hypokalemia may 
also develop after rehydration with potassium-deficient fluids, during periods of spontaneous 
diuresis, and during periods of intensive therapeutic diuresis.
An initial oral doses of 3-8 mEq/day of potassium is given to those cats with mild 
hypokalemia; often the dose is tapered to 2-4 mEq/day for chronic maintenance. Potassium 
supplementation at 10 to 20 mEq/L of can be given in fluids for cats receiving subcutaneous 
fluids at home.
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Metabolic Acidosis
Potassium citrate or potassium gluconate may provide correction o f acidosis as well as 
additional potassium that may be o f benefit. Sodium bicarbonate is generally avoided as an 
alkalinizing agent because of the potential for the sodium component to exacerbate systemic 
arterial hypertension believed to be common in cats with CRF. Uremic acidosis can contribute 
to increased dietary protein needs encountered in CRF.
Human Recombinant Erythropoietin (EPO )
The use of EPO to combat hypo-proliferative anemia o f CRF is more financially 
attractive for use in cats due to their small size in general as compared to dogs. The use of EPO is 
generally restricted to cats with PCV less than 20 % due to the possible development of anti- 
EPO antibodies in as many as 60 to 70% % o f cats exposed to this human product. Clinically 
significant anti-EPO antibody formation usually takes place within 30 to 90 days after starting 
treatment if  it is going to be a problem. Severe anemia and dependence on transfusions may be 
prolonged - anti-EPO antibodies likely cross react with native endogenous EPO.
Renal Transplantation
Renal transplantation has achieved a degree of success in cats with chronic renal failure 
greater than that experienced in dogs. Cyclosporine and prednisolone provide adequate 
immunosuppression to allow allograft survival for extended periods in some cats (Gregory and 
Gourley). A high degree of surgical skill is required for successful anastomoses of small vessels 
and ureteral implantation into the bladder. Vascular thrombosis or stenosis, ureteral stenosis, and 
uroabdomen are all complications related to the degree o f technical difficulty encountered during 
this surgery. Cases most likely to be candidates for successful transplantation are those without 
other systemic diseases, without severe hypertension, without urinary or other organ system 
infections, and those in which uremic lesions throughout the body are not too severe. Successful 
renal transplantation as replacement therapy for CRF in cats requires a unique team of talented 
surgeons and veterinarians specially skilled in immunology.
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Dietary modification and nutritional support are important parts in the overall 
management of patients with CRF. Treatment will depend on the animal's degree of 
compensation toward CRF. Animals that are asymptomatic or have mild signs (minimal weight 
loss, slight decrease in appetite, occasional vomiting, mild anemia, not dehydrated) are treated 
on an outpatient basis. Animals with decompensated CRF have more severe signs/problems 
including vomiting, anorexia, depression, moderate to severe anemia, dehydration, electrolyte, and 
acid-base disorders that may require hospitalization for initial stabilization (see Uremic Crisis).
An ideal diet for dogs and cats with CRF would accommodate decreased renal functional 
reserves, minimize formation of uremic toxins, decrease obligatory urine volume in those with 
polyuria, optimize food intake and nutritional status, avoid diet-related problems, optimize the 
animal's quality of life, and delay or prevent the progression of renal disease. This may be asking 
too much for any one diet to do - this ideal diet has not yet been developed. Indeed, it is likely 
that no one dietary formulation will be able to take care of the needs of all animals with CRF 
depending on individual differences as well as stage of renal disease.
It is important to distinguish between factors that can contribute to the quality of an 
animal's life from those that can prevent progressive loss of renal function. It is possible that 
dietary factors that improve an animal's sense of well-being have nothing to do with preservation 
of renal function. The factors which might contribute to progression of CRF have been under 
intense study for the past 2 0  years (most information has been in dogs with more recent studies 
in cats). Emphasis for study has traditionally been on the role o f dietary protein which recently 
has been supplanted by those emphasizing phosphorus. Despite many studies, it remains 
difficult to separate with certainty just how important individual nutrient formulations contribute 
to the progression o f CRF, though much has been clarified as regards protein and 
phosphorus(further below).
Management of Anorexia
Chronic uremia frequently is associated with poor appetite due to a combination of 
central depression from uremic toxins, GI ulceration, stomatitis and oral ulcers, and/or lingual 
necrosis. An altered sense of smell/taste during uremia may also be contributing to anorexia. 
Foods that are designed for the treatment o f CRF are often restricted in protein, phosphorus, 
and salt which may make them less palatable in general. Aversion to foods that were associated 
with hospitalization or forced feedings can also contribute to anorexia.
Cimetidine, ranitidine, and famotidine (H-2 receptor blockers) can be useful to treat 
gastric ulcers/gastritis when administered to uremic dogs and cats to reduce gastric acid secretion. 
Increased gastrin concentration in serum during CRF (decreased renal degradation^ believed to 
be responsible for stimulation of gastric acid over-secretion and ulcer formation. Some uremic 
dogs and cats dramatically increase their food intake and interest in food after starting one of
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these drugs. Some uremic animals may need this medication for an extended period of time 
(months to the rest of their lives). Much of our experience has either been with cimetidine at an 
initial dose of 10 mg/kg followed by 5 mg/kg PO BID or famotidine (Pepcid®) at 1 mg/kg once 
daily. Omeprazole(proton pump blocker in stomach) is an alternative to the H2-receptor 
blockers for its effect to decrease stomach acid, but we have little experience in its use during 
CRF. It can be considered for use in those in which H-2 receptor blockers were not effective in 
the control o f vomiting.
Metoclopramide (Reglan®) may be useful in uremic animals that vomit or show signs of 
nausea (excessive liplicking, swallowing, drooling). It works partly by depressing the CTZ 
emetic center in the brain and also by enhancing gastric emptying. We usually have used this in 
those patients in which H-2 blockers were ineffective, though some recommend its use as the 
first-line agent o f choice. It can be given orally at 0.2 to 0.4 mg/kg TID to QID and may be most 
effective if given about 30 minutes before a meal. Sucralfate (Carafate®) as the "gastrointestinal 
band-aid" may be useful to coat painful GI ulcers and promote increase food intake. We usually 
administer sucralfate to those that have melena from GI bleeding.
Flavors added to protein-restricted food can enhance their appeal and intake, including 
small amounts o f bacon drippings, hamburger grease, chicken drippings, tuna juice, clam juice, 
or baby food. Some animals will increase their intake of protein-restricted foods if the food is 
prewarmed in the microwave or fried (ala burgers). Offering a variety o f commercially available 
diets designed for the treatment of CRF (Vet's Choice, Hills, Waltham, Vet Kem, , lams, 
Innovative Veterinary Diets) may allow the pet to select one that it will consume to the greatest 
degree. Home-made protein and phosphorus restricted diets may be consumed by the pet with 
CRF when commercial foods will not be eaten. Multiple small volume meals with special diets 
should be attempted in an effort to avoid overdistension o f the stomach and nausea or vomiting 
that might be encountered during CRF.
Figure 1) H ierarchy for Dietary Modification Consideration During C R F
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Water and caloric intake are the first priorities while designing dietary modifications for 
dogs and cats with CRF. Fresh water should be available at all times to encourage maximal 
hydration. Adding water or flavored broths to dry foods may encourage more water intake than 
otherwise. Some animals maintain better hydration when fed canned foods rather than dry 
foods, an effect attributed to the greater amount o f water that is available for intestinal 
absorption. Adding water to dry food in a 1:1 volume ratio may also provide additional water to 
help maintain hydration.
Caloric intake is pivotal toward the ultimate success or failure o f a dietary regimen. 
Adequate caloric intake is essential to turn off the balance of catabolic forces that are so often 
operative in patients with CRF. In the absence o f adequate caloric intake, catabolism is enhanced 
as insulin secretion is diminished at a time that glucagon secretion is enhanced. When dietary 
protein restriction is prescribed, it is imperative to ensure adequate non-protein calories at the 
time of protein intake ; otherwise the protein will be degraded for energy and not utilized by the 
body while generating more nitrogenous waste products for accumulation throughout the body.
Dietary Protein Restriction
Mild to moderate dietary protein restriction with high quality protein at a time of 
generous non-protein caloric intake remains a cornerstone treatment in the management of stable 
CRF (after decompensated CRF has been stabilized if necessary) Since many uremic solutes are 
generated following protein degradation, dietary protein restriction may be beneficial in 
alleviation of uremic signs associated with moderate to severe azotemia. Moderate azotemia is 
defined as a BUN > 70 mg/dl and a serum creatinine > 2.5 mg/dl in the hydrated state. It is 
important to establish post-rehydration BUN and serum creatinine concentrations as the baseline 
for evaluation as to whether protein restriction is likely to "make the animal feel better". It is 
unlikely that protein restriction in patients with lower baseline concentrations of increased BUN 
or serum creatinine will be able to enjoy the salutary effects o f protein restriction, since their 
starting points for uremic waste products is marginal. Protein restriction has the potential to 
result in generation o f less uremic solute, phosphorus, and acid for excretion. Lower protein 
intake can result in generation of less urea for excretion into urine which reduces the magnitude of 
obligatory polyuria and secondary polydipsia, a tremendous benefit to some clients. Obligatory 
polyuria is a function of the level o f renal function and of the solutes requiring renal excretion.
Is it a bad idea to recommend mild dietary protein restriction for those with confirmed 
primary renal disease but that are not yet in obvious excretory failure? Examples o f such cases 
would include those with normal BUN and serum creatinine, submaximal urinary concentration, 
proteinuria on dipstrip, increased urinary protein to creatinine ratio, excessive casts in urinary 
sediment, and abnormal renal imaging. It may be a good idea to get the patient used to the idea of 
certain dietary alterations that will become more necessary if renal function does progressively 
decline in the future. There is no evidence to suggest that dietary modification (protein or 
phosphorus restriction) prevents progression of chronic renal disease in either dogs or cats that 
are not yet azotemic, however.
Dietary protein restriction does reduce GFR, an effect that for BUN is overcome because 
less urea nitrogen is generated at the same time. It is expected that the BUN will decrease if
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adequate calories are taken in at the same time that a high quality and reduced quantity of protein 
is ingested. The goal is for most o f the ingested protein to be used for anabolic processes and not 
to be degraded to urea and other nitrogenous wastes. Serum creatinine should not change very 
much, though it may increase to a small degree due to decreases in GFR. Serum phosphorus 
concentrations should decrease, though not necessarily to the normal range depending on the 
starting point above baseline. Even though serum phosphorus may decline, the degree of 
phosphorus restriction in commercially available protein and phosphorus restricted diets may 
not be sufficient to reverse renal secondary hyperparathyroidism. Dogs and cats in CRF fed 
diets restricted in protein usually show less proteinuria than those fed higher protein diets. This 
could simply be a result o f the damaged glomeruli already there and the effect of hemodynamic 
changes following protein feeding. Alternatively, the greater proteinuria observed during high 
dietary protein feeding could serves as an indicator for further risk o f nephron injury. No studies 
o f experimental dogs or cats with severe reduction in renal mass have convincingly shown that 
dietary protein restriction retarded the progression of CRF. Phosphorus restriction in 
experimental dogs and cats with CRF does protect against progression of CRF.
There is evidence emerging from studies at the University of Minnesota (Jacob F) that the 
time interval to uremic crisis is increased in clinical dogs with CRF (serum creatinine fro 2 to 8  
mg/dl) that are eating diets that are protein, phosphorus, and sodium restricted as well as 
enhanced in lipids. Uremic episodes, and mortality were lower in dogs eating the modified vs 
maintenance diets. Dogs that lived 6  months or longer with their CRF were studied as to the 
progression of their renal failure on these two diets. Dogs on the modified diet significantly 
reduced progression o f their renal failure (1/S creatinine); this effect was also seen in dogs with 
serum creatinine less than or equal to 3.0 mg/dl. Dogs with experimental renal mass reduction as 
the cause o f renal failure experienced more weight loss, a greater decrease in rear leg 
circumference, and more anemia when eating a normal protein diet compared to dogs eating diets 
with moderate protein restriction over 40 weeks[Polzin 1983]. Over half o f the dogs eating the 
normal protein diet died of uremic complications compared to only 1 o f 1 2  dogs consuming diets 
that were moderately or severely restricted in protein [Polzin 1984], Dogs with 75% renal mass 
reduction did not differ in renal function or degree o f histopathology when fed high, moderate, or 
restricted amount of dietary protein for 4 years[Robertson 1986]. All dogs with 11/12 renal mass 
reduction had glomerular and interstitial renal lesions at 2 0  weeks regardless of dietary protein 
intake. Renal lesions were most severe in those in which GFR increased over time on both 
protein replete and restricted diets [Polzin 1988]. Dietary restriction o f phosphorus and calcium 
in dogs with severe renal mass reduction resulted in greater survival and increased GFR compared 
to dogs eating a calcium and phosphorus replete diet (dietary protein not restricted in either 
group)[Finco 1992]. In another study of dogs with renal mass reduction, dietary phosphorus 
restriction increased survival and the period o f time that GFR was stable, effects that were not 
seen with dietary protein reduction [Finco 1992].
There are conflicting reports about the effect o f dietary protein and calories on the 
progression o f renal failure in experimental cats. Cats with 5/6 renal mass reduction that were fed 
a protein and calorie restricted diet had lower BUN and GFR compared to cats fed a high protein 
diet for one year. Cats of this study that were fed the high protein diet ate and weighed more than 
the cats fed the low protein diet and over half developed hypokalemia while eating the high
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protein diet[Adams 1993], Dietary and caloric restriction resulted in less renal morphologic 
injury compared to cats eating the high protein diet[Adams 1994]. Another study using cats with 
experimental renal mass reduction investigated the interactions of high and low dietary protein 
intake as well as high and low caloric intake for one year. Diets replete in protein were not 
associated with the development of renal lesions but calorie replete diets were associated with 
mild non-glomerular lesions [Finco 1998], A veterinary diet designed for the treatment o f renal 
failure in cats that is both protein and phosphorus restricted was effective in decreasing serum 
phosphorus and PTH levels in clinical cats with mild CRF [Barber 1999], In a similar study, 
feeding clinical cats with CRF a protein and phosphorus restricted diet resulted in decreased 
BUN, serum phosphorus, and prevented PTH levels from increasing over time. Serum creatinine 
tended to go down in the restricted diet group o f cats and increased in the non-restricted dietary 
group. Approximately 60% (29/58) of the cats enrolled in this study accepted the diet -  protein 
restricted diets are not palatable to some cats. Cats of this study that were fed the veterinary diet 
survived a median of 633 days compared to 264 days for cats that ate foods replete in protein 
and phosphorus[Elliott 2000], In a third study, clinical cats with CRF that were fed a protein 
and phosphorus restricted diet (n = 25) decreased serum creatinine from 3.1 to 2.6, decreased 
serum phosphorus, and gained weight over 24 weeks, while cats on non-restricted diets (n = 10) 
increased serum creatinine from 3.0 to 3.6, increased serum phosphorus, and lost weight[Harte 
1994],
Too much protein restriction can result in malnutrition manifested as weight loss, muscle 
wasting, lethargy, loss of condition of skin and coat, decreased skin turgor (without dehydration), 
and decreased resistance o f skin to venapuncture. Laboratory evidence for protein malnutrition 
includes anemia, hypercholesterolemia, and hypoalbuminemia. Acidemia can be exacerbated by 
too much protein restriction (diminished renal tubular ability to mobilize glutamine to secrete 
ammonia needed to acidify urine). This combination of clinical and laboratory abnormalities are 
often attributed to the nature o f the advancing renal lesions but should prompt the clinician to ask 
if they could be caused by protein/calorie malnutrition.
It is controversial as to when in the progression of CRF and to what degree protein 
restriction should be instituted. Guidelines for protein restricted diets are made to take advantage 
of their extrarenal benefits. Dietary protein intake can be considered on an absolute basis of 
Gm/kg/day of protein intake or as the % of calories that are derived from protein (both are 
important). Dogs develop negative nitrogen balance when the % of protein calories is less than 
10% and cats do so when calories derived from protein sources are less than 12%. Both dogs and 
cats develop decreases in protein reserves when calories from proteins are less than 20%. When 
the patient does not eat to fulfill its caloric need, the percentage of calories from protein becomes 
more important. In our scheme, mild protein restriction is provided when proteins provide about 
2 0 % of the calories, moderate protein restriction with 15 % of calories from protein, and severe 
protein restriction when 1 0 % of calories are derived from dietary protein.
Commercial dog foods provide greater than 5 grams/kg/day o f protein o f varying quality. 
Normal dogs require a minimum of 1.25 to 1.75 grams/kg/day of high quality protein. The 
protein requirements for CRF dogs are not known, but they are higher than minimal requirements 
for normal dogs. Either no or minimal protein restriction is recommended if the serum creatinine
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during hydration is less than 2.5 mg/dl. Animals with serum creatinine from 2.5 to 5.0 mg/dl 
(moderate renal failure) may be managed with 2.5 to 4.0 grams/kg./day o f high biologic value 
protein. More severe renal failure manifested in animals with hydrated serum creatinine greater 
than 5.0 mg/dl may benefit from 1.5 to 2.5 Gm/kg/day of protein . 2-3 GM/kg/day is provided 
approximately by 13-17% protein as dry matter. Less is known about protein requirements for 
CRF cats, but 3.3 to 3.7 grams/kg/day is recommended as moderate protein restriction. It is 
important that adequate calories are supplied with restricted protein diets, otherwise endogenous 
and exogenous proteins will be catabolized for energy. The protein and caloric intake must be 
individualized for each animal. A balance between uremic signs, nutritional status, and desirable 
serum biochemistry is sought. Protein intake is progressively lowered if severe uremic signs 
persist. In the face of malnutrition (decreasing body condition score, decreasing lean muscle 
mass, decreasing serum albumin), protein intake is gradually increased. In general, we try to 
prescribe the highest level o f protein intake that the patient will tolerate during renal failure in 
order to maintain a good body condition score. A new concept referred to as the “Nitrogen 
Trap®” involves the feeding o f novel fermentable fibers in an attempt to excrete nitrogenous 
waste products through the colon. Increased colonic blood flow can lead to increased numbers of 
bacteria in the colon with a subsequent decrease in nitrogenous waste products from the blood as 
the bacteria use them in their metabolism. This kind o f diet potentially allows animals with CRF 
to eat higher levels of protein without increasing the level o f waste products that are generated 
and maintained.
Phosphorus Restriction
Phosphorus restriction can have beneficial effects on renal histology, renal function, 
and/or mortality in dogs and cats with chronic renal failure. These effects are independent of 
protein restriction (ie protein restriction is not necessary to see benefits achieved with 
phosphorus restriction). It is not precisely known how phosphorus restriction exerts its 
beneficial effects, but it may be through less renal mineralization and blunted degree o f secondary 
hyperparathyroidism. Less renal mineralization may occur due to lowered concentration and 
actions o f PTH and possibly from a direct lowering of the calcium x phosphorus product.
There are no currently available commercial diets that are both replete in protein and 
restricted in phosphorus. It is theoretically possible to do so but this process is difficult in 
commercial formulations. Diets are formulated to be restricted in phosphorus largely by limiting 
the amount o f protein since phosphates are associated with proteins. The dietary source of 
protein also influences the amount o f dietary phsophate . The quantity o f calcium and 
phosphorus supplemental salts as well as the form o f the phosphorus supplement influence the 
degree o f phosphorus intestinal absorption. There is considerable variability by veterinary 
specialty kidney diets in the mg/ 1 0 0  kcal of phosphorus intake that occurs with similar levels of 
dietary protein restriction. Comparison of specialty veterinary foods by % dry matter and on a 
mg/100 kcal basis is available at the Nutrition Support Services Web Site o f The Ohio State 
University College of Veterinary Medicine Veterinary Diet Manual Home Page -  Diet Tables for 
Dogs ; Diet Tables for Cats at http://nss.vet.ohio-state.edu/Diet%20Manual/Introtbl.htm. This 
site was set up and is maintained by Dr. Tony Buffington. Dietary restriction o f protein by 
itself is not sufficient to maintain normal serum phosphorus concentration when GFR is severely 
reduced. Intestinal phosphorus binders (aluminum hydroxide, calcium carbonate, calcium
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acetate) are helpful in these instances. It has been conventional to administer intestinal 
phosphorus binders only when the serum phosphorus is elevated, but there may be reasons to 
administer them to CRF animals before elevation in serum phosphorus occurs. Phosphorus 
intake should be reduced to at least less than 25 % of normal to match the level o f reduction in 
GFR.
Aluminum salts (hydroxide or carbonate) have been used extensively as intestinal 
phosphorus binders. Chronic toxicity from aluminum has been demonstrated in people with 
CRF (who are usually on dialysis) manifested in nervous tissue and bone disease. Whether 
aluminum toxicity is a problem following treatment with aluminum containing compounds in 
dogs and cats remains to be determined. Calcium carbonate is an alternative to aluminum salt 
intestinal phosphorus binders. The dose is usually 100 mg/kg divided twice daily with meals. 
The dose is adjusted after serially evaluating serum phosphorus concentration. Potential 
problems from aluminum toxicity are avoided, but hypercalcemia can occur especially if 
simultaneously supplemented with calcitriol. Calcium acetate has been approved for humans as 
an intestinal phosphorus binder, replacing aluminum salts and calcium carbonate as the 
phosphorus binder of choice. Calcium acetate has excellent phosphorus binding in the intestinal 
lumen and less problems with the development of hypercalcemia than encountered with calcium 
carbonate. Sevelamer HC1 (Renagel®) is a non-calcium, non-aluminum containing intestinal 
phosphate binder that has recently been approved for use in people with renal failure. We have 
used sevelamer successfully in a small number o f dogs and cats as an alternative to aluminum and 
calcium containing compounds; there are no reports of its efficacy or safety in veterinary 
medicine to date. Tertiary iron salts are being used as phosphate binders in people in Europe but 
have yet to be approved for such use in the USA. It should be noted that all intestinal phosphate 
binders work better when given with food or within a few hours of food ingestion.
Metabolic Acidosis
Metabolic acidosis of varying severity often accompanies chronic renal failure. Anorexia, 
nausea, vomiting, and weight loss may in part be caused by this acidosis. Muscle weakness, 
lethargy, hypokalemia, skeletal demineralization, hyperphosphatemia, and hypercalciuria may 
also exacerbated by chronic metabolic acidosis. Accelerated progression o f chronic renal failure 
attributed to tubular hypermetabolism (ammoniagenesis) during chronic metabolic acidosis has 
been suggested. Diet influences the degree o f acid end-products required for excretion. Egg- 
protein has traditionally been assumed to be the most biologically-utilizable protein, but studies 
in dog with chronic renal failure revealed that these diets (high in sulfur-containing amino acids) 
were acidifying compared to vegetable source protein diets. Lower protein diets can result in less 
acid for excretion especially if they contain less animal protein sources. Veterinary foods 
designed for the treatment of renal failure are usually designed to be mildy alkalinizing by the 
addition o f salts that are metabolized to bicarbonate (potassium citrate). Acidifying diets should 
be discontinued -  most grocery store foods in the USA have been formulated to be acidifying in 
both dogs and cats. Acid-base balance should be re-evaluated after dietary modification to see if 
supplemental alkali is needed. Sodium bicarbonate, potassium citrate, calcium carbonate, and 
calcium acetate are sources of alkali.
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8Potassium Supplementation
Hypokalemia can result in chronic renal failure as reported in cats. Correction of 
hypokalemia is essential in these instances. Potassium supplementation to cats with chronic renal 
failure and normal serum potassium concentration is more controversial. A study at OSU failed 
to show a beneficial effect o f potassium gluconate supplementation over that o f sodium gluconate 
in a population o f cats with chronic renal failure and normal serum potassium. Veterinary foods 
designed for renal failure often contain additional potassium supplementation in the form of 
potassium citrate.
Dietary Lipids
Intrarenal vasoconstriction or vasodilatation occurs in response to eicosanoids derived 
from dietary fatty acid intake. It appears to be possible to select specific dietary lipids to 
enhance or decrease vasoconstriction. Recent studies in experimental dogs demonstrated that 
certain dietary lipids exerted a protective effect on renal function and histology whereas other 
dietary lipids exacerbated progression of CRF. I f  such effects are demonstrated in clinical animals 
with CRF, modification o f dietary lipid intake could prove useful to prolong the life o f severely 
damaged kidneys. Dogs with 15/16 renal mass reduction were studied for 20 months while eating 
basal foods supplemented with lipid to achieve a 15% concentration. Dogs treated with omega-3 
PUFA supplementation (menhaden fish oil) developed fewer renal lesions (expansion of 
mesangial matrix, glomerular sclerosis, and interstitial inflammation) compared to those in dogs 
receiving either omega- 6  PUFA (safflower oil) or saturated fatty acids (beef tallow). Lower levels 
o f proteinuria, serum creatinine, cholesterol, and triglycerides were found in dogs that received 
omega-3 supplentation. Global GFR was greater in dogs treated with omega-3 PUFA compared 
to omega- 6  PUFA [Brown 1998], Intraglomerular hypertension and hypertrophy were observed 
in dogs treated with omega-6 PUFA. Clearly, supplementation with omega-3 was renoprotective, 
while supplementation enhanced renal injury under the conditions o f this study. The amount of 
additional dietary lipid provided in this study in order to see these effects was substantial. Dogs 
of this study had very severe reduction in renal mass -  whether similar effects would be seen in 
dogs with less severe loss o f renal mass is unknown. How important is the absolute dose of 
omega- 6  or omega-3 versus the ratio of omega 6  to omega 3 ? Single nephron micropuncture 
studies in dogs show that a ratio o f omega- 6  to omega-3 of 5:1 was “protective” in that 
glomerular capillary pressure increased very little. Much larger increases in glomerular capillary 
pressure are observed at dietary ratios of 25:1 and 50:1.
Sodium Intake
Most diets designed for use in CRF are limited in sodium content on the basis that this 
may help to treat systemic hypertension that may be common in both dogs and cats with chronic 
renal failure. Sodium restriction alone however is not sufficient to treat hypertension associated 
with chronic renal failure in dogs or cats. Gradual conversion to sodium-restricted diets is 
recommended as the CRF kidney has adapted to provide natriuresis per remaining nephron. A 
sudden decrease in dietary sodium intake could result in dehydration as it may take time to 
decrease the natriuretic response.
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CALCITRIO L IN TREATM EN T OF RENAL HYPERPARATHYROIDISM
Dennis J. Chew, DVM and Larry A. Nagode, DVM, PhD 
The Ohio State University College o f Veterinary Medicine, Columbus, Ohio
Pathophysiology - Development of Renal Secondary Hyperparathyroidism
Fig 1a. Calcitriol "Trade-Off" Hypothesis
EA R LY  C H R O N IC  R EN AL FAILUR E
Fig 1b. Calcitriol "Trade-Off" Hypothesis  
L A T E  C H R O N IC  R EN A L FA ILU R E
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Figure la  and lb  emphasize the importance of either relative or absolute calcitriol deficits 
in the evolution o f renal secondary hyperparathyroidism. Increased serum phosphorus decreases 
serum ionized calcium to a substantial degree by mass-law effect only when the increases in 
serum phosphorus are very large. The finding o f a normal calcitriol concentration has often been 
erroneously interpreted to mean that calcitriol deficits do not occur or are not important early in 
chronic renal disease. Normal serum calcitriol and calcium concentrations in these instances, 
however, are established and maintained by the "correcting forces" o f increased levels of 
parathyroid hormone (PTH). In more advanced stages o f renal disease, absolute decreases in 
calcitriol and calcium concentrations do occur. Renal secondary hyperparathyroidism is the result 
of increased secretion o f PTH by each cell as well as increased number o f cells due to 
hyperplasia. Within the parathyroid gland nucleus, adequate concentrations of calcitriol are 
necessary to inhibit genomic transcription for PTH synthesis as well as to exert antiproliferative 
effects to maintain normal cell numbers. Adequate concentration o f intracellular ionized calcium 
is necessary to allow calcitriol to exert its "silencing" effect on PTH transcription.
Clinical Signs Caused by Excess PTH  and/or Deficits of Calcitriol
PTH is a major uremic toxin. The toxic effects of PTH on tissues are best-known on 
bone (fibrous osteodystrophy, "rubber-jaw"), but many tissues are adversely effected by high 
levels of circulating PTH. Initially, increased levels of PTH are adaptive for the control of 
divalent ion metabolism (calcium, phosphorus). It appears that increased PTH levels become 
maladaptive when concentrations increase beyond a threshold o f 3 to 5 times baseline. Above 5 
times baseline for intact PTH, severe bone disease occurs and the thresholds for injury to other 
tissues , although somewhat variable, seem likely to be in this range. The dominant change in 
tissues adversely affected by excess PTH is that o f increased cytosolic calcium concentration to 
toxic levels. Tissues with the highest concentrations of the PTH/PTHrP receptor will be those 
affected earliest and most severely. Some of the toxicity usually attributed to increased PTH 
may in certain instances be directly due to a lack of adequate calcitriol, as there are calcitriol 
receptors in most tissues. PTH levels referred to are those measured by a validated assay which 
measures intact-PTH. In uremic cats, it may be necessary to dilute the serum prior to analysis 
in order to remove interference from carboxy-terminus PTH molecules when using an intact PTH 
immunoradiometric method.
Central nervous system depression and detrimental effects on the peripheral nerves are 
common in chronic renal failure, caused in large part by excess PTH. Part o f the anemia o f CRF 
may be caused by PTH excess. Abnormal lipid and carbohydrate metabolism can also be caused 
by excess PTH and could contribute to the anorexia o f uremia. Weakness from skeletal muscle 
myopathy during uremia may be caused by both excess PTH and lack o f calcitriol receptor 
activity within muscle cells. Some of the reduced physical activity o f uremic dogs and cats may 
be attributed to bone changes o f excess PTH, although this is difficult to separate from the other 
effects of uremia. Obvious bone pain in animals is rare despite the universal presence of 
histologic bone lesions in chronic renal failure - bone is the earliest tissue to exhibit histologic 
evidence o f hyperparathyroidism perhaps due to its high concentration of PTH receptors. 
Increased renal cellular calcium content caused by increased PTH is toxic and has a role in the
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relentless progression of chronic renal disease. Renal tubular cells have high concentrations of the 
PTH receptor and are among the body tissues affected earliest by excess PTH.
Control of Renal Secondary Hyperparathyroidism :
Diet, Intestinal Phosphorus Binders, and Calcitriol
Dietary phosphorus restriction as single modality treatment is capable of lowering PTH 
levels in some dogs and cats with chronic renal disease or early renal failure (Figure 2). Those 
with greater loss of renal function will require addition of a phosphorus binder given with the 
food to enable enough phosphorus restriction proportionate to the loss o f renal mass. Return of 
serum phosphorus to normal does not guarantee that PTH levels will return to normal, as 
phosphorus restriction only works in those that have enough active tubular machinery capable of 
calcitriol synthesis once the inhibitory effects o f excess phosphorus on calcitriol synthesis are 
removed.
Effectiveness of Low Daily Doses of Calcitriol in Reduction of Renal Secondary 
Hyperparathyroidism in Dogs and Cats
Supplementation with calcitriol to dogs and cats with CRF is designed as a daily therapy 
for life. Low daily oral doses of calcitriol effectively return PTH levels to either normal or below 
the toxic threshold. This effect may take months before the full effect is seen when a dose of 2.5 
to 3.5 nanograms/kg once daily is prescribed. Dogs with experimental subtotal nephrectomy 
required 6  nanograms/kg to effectively lower PTH levels at one month, a dose that we 
infrequently prescribe for those with refractory cases of hyperparathyroidism.
Adequate control of serum phosphorus to concentrations less than 6.0 mg/dl is essential 
prior to and during prescription of calcitriol treatments. Phosphorus restriction relieves 
phosphate-mediated inhibition of the renal 1 -hydroxylase system resulting in enhanced 
endogenous synthesis of calcitriol and subsequent inhibition of PTH synthesis (Figure 1). A 
second reason to institute phosphorus restriction is to reduce the likelihood of soft-tissue 
mineralization by reducing the serum calcium-x-phosphorus product. A third reason is to 
increase ionized calcium concentrations that are operative in the parathyroid gland nucleus. 
Calcium with its associated transcription factor must bind to its DNA binding site in the 
parathyroid cell nucleus in order to fully allow the silencing effect o f calcitriol to decrease the 
synthesis of PTH. As serum phosphorus is reduced, calcium ionization increases. Serum 
phosphorus in excess of 7 or 8  mg/dl provides enough mass-law effect to decrease ionized 
calcium about 0.1 mg/dl, enough to increase PTH secretion. It is almost certain that control of 
secondary hyperparathyroidism will fail in patients who maintain serum phosphorus much 
above the normal range. The effectiveness of calcitriol in control o f hyperparathyroidism has 
been noted to increase in patients in whom serum phosphate was lowered.
Hypercalcemia is a very uncommon side-effect o f low-dose oral calcitriol treatment in our 
experience. When noted, it is usually associated with the use of calcium-containing intestinal 
phosphate binders, especially calcium carbonate. Hypercalcemia can be minimized by giving 
calcitriol at nighttime on an empty stomach if necessary. When evaluated in parallel with 
calcitriol, so-called non-calcemic calcitriol analogues were calcemic at effective doses and showed 
no advantage over calcitriol which remains the gold-standard agent. 1 -alpha-
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hydroxycholecalciferol (available in Europe, Leo Pharmaceutical), a calcitriol precursor, is as 
effective as calcitriol in doses about 1.5 times that of calcitriol.
Though PTH levels decline following calcitriol treatments, it is inherently difficult to 
objectively prove the clinical benefits of lowering PTH levels in dogs and cats with renal disease 
or failure. Parathyroidectomized dogs with experimental subtotal nephrectomy had more stable 
levels of renal function during the second year o f study than did dogs without reduction o f PTH. 
Calcitriol therapy appears to exert an overall improvement in brain wave function o f uremic dogs 
in a preliminary study in our hospital. Hundreds o f veterinarians that have been prescribing 
calcitriol as treatment for their uremic dogs and cats responded to a recent survey from one of 
us(LAN). The vast majority either strongly agreed or agreed with the following statements for 
both dogs and cats : 1. Patients seem brighter, and more alert, and interactive with owners. 2. 
Patients seem to have an improvement in appetite. 3. Patients seem to be more physically active 
than previously. 4. Calcitriol treated patients seem to have longer lifespans. Veterinarians of this 
survey were selected on the basis that they have prescribed calcitriol in at least 5 patients in 
order to get their opinion. Results of this subjective survey provide impetus to further study the 
effects of calcitriol in dogs and cats with naturally-occurring renal disease and renal failure.
SIM PLIFIED  SYNOPSIS
PTH levels often decline following oral low-dose calcitriol treatments in dogs and cats 
with renal failure. Does this reduction in PTH level improve survival time, quality o f life, level of 
GFR and/or degree of renal lesions? Double-blind placebo-controlled studies of calcitriol 
treatment in clinical dogs or cats with renal failure have not been performed to enable these 
questions to be adequately answered. Clients and veterinarians often comment that calcitriol 
seems to result in overall improvement of well-being in renal failure animals compared to those of 
similar degree renal failure that do not receive calcitriol.
Increased survival times of calcitriol treated renal failure dogs and cats are suspected, but 
survival times of dogs or cats with untreated or non-calcitriol treated renal failure animals is 
lacking. Clinical cats with CRF and adequate control o f PTH (dietary protein and phosphrous 
restriction) lived about three times longer than cats with uncontrolled hyperparathyroidism 
(Elliott and Barber). Parathyroidectomized dogs with experimental renal failure had more stable 
and higher levels of GFR during the second year of study than did renal failure dogs without 
reduction of PTH. Seven of eight dogs with PTH reduction lived for the second year while only 
3 of eight dogs with sham PTH surgery survived the same time period. Additionally, less severe 
mesangial matrix changes and soft tissue mineralization as well as more preserved bone 
mineralization were noted in the dogs with PTH reduction (Finco AJVR 1997). Calcitriol 
therapy exerted an overall improvement in brain wave function o f uremic dogs in a preliminary 
study in our hospital. A controlled prospective study of dogs with CRF treated with calcitriol is 
underway at the University o f Minnesota (Polzin 2000).
Calcitriol Protocol for Dogs and Cats with Chronic Renal Failure
1. Start standardized dose o f 2.5 ng/kg SID for routine cases -  check calcium at 1 and 3 weeks.
2. A convenient method to provide calcitriol to small animals is to take one 0.5 microgram 
capsule o f calcitriol (Roche Pharmaceuticals) and dilute it in 20 ml light olive oil. Each 0.1 ml
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then contains 2.5 ng calcitriol. Most cats are dosed with 0.3 to 0.4 ml once daily. It is 
important to keep the calcitriol olive oil solution in a dark container to keep light from 
destroying the calcitriol. We support this method for providing calcitriol as long as it is not 
stored for appreciable periods (a month supply at a time is suggested to be stable).
3. Alternatively, compounding pharmacies will provide capsules with a prescribed ng content 
and stabilizing agents. They will also provide various concentrations o f calcitriol in 
pharmaceutical oil. With stabilizing agents, the preparation is stable for many years.
4. 1 -alpha-hydroxy-cholecalciferol (Leo Pharmaceuticals, Denmark) is available as a calcitriol 
precursor converted in the liver by 25-hydroxylation to calcitriol. The doses of 1-alpha- 
hydroxy-cholecalciferol need to be increased compared to calcitriol by about 50% since not all 
precursor is converted to calcitriol.
5. For those with 10 x increase or greater in PTH, consider pulse therapy first. Consider pulse 
therapy for those who fail to adequately suppress PTH on standard low dose calcitriol.
6 . Give 20 ng/kg twice weekly for one month and recheck PTH. Make sure to give the high 
doses of calcitriol at night before the animal’s bedtime on an empty stomach to minimize 
calcium absorption from the intestine.
7. Pulse dosing is an attempt to treat “nodular” hyperplasia of the PTG that occurs from single 
clones of PTG cells with very few calcitriol receptors. The hope is to induce more calcitriol 
receptors so that calcitriol will then be able to exert its negative effect on PTH synthesis.
8 . If PTH still elevated substantially at one month recheck, increase dose to 25 ng/kg twice 
weekly for the next month and recheck PTH levels. Increase dose by 5 ng/kg each month if 
PTH levels do not decline.
9. Check calcium levels at 1 and 2 days after the 3rd dose to make sure that bothersome 
hypercalcemia is not developing. It is conceivable that some hypercalcemia can occur rapidly 
as a result of transcaltachia, a direct cell membrane effect on the intestinal epithelium 
independent o f any genomic effects that calcitriol exerts later.
10. When PTH levels have returned to normal or near normal, start daily low dose calcitriol 
therapy.
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Diet Binders
% Functional Nephrons
Fig. 3) The initial portion of this figure 
illustrates the typical abnormalities of 
untreated progressive chronic renal failure 
(loss of nephron mass). Dietary restriction 
of phosphorus initially results in correction 
or reduction of hyperparathyroidism 
(HPTH), but only temporarily as further 
GFR is lost. The addition of phosphate 
binders to the phosphate restricted diet 
results in reduced PTH concentrations, but 
PTH becomes increased again if sufficient 
nephrons continue to be lost. HPTH 
eventually develops with extensive loss of 
nephron mass even when serum phosphorus 
remains normal with the use of dietary 
restriction and phosphate binders (dashed 
arrow top right).
%  F u n c t io n a l N e p h r o n s
Fig. 4)
A = No calcitriol supplementation.
Calcitriol normalizes only at the expense of 
elevated PTH.
B = Calcitriol treatment is started at time "x" 
late enough in the renal disease when 
calcitriol is decreased and PTH is elevated 
with restoration o f both to normal.
C = Calcitriol treatment is started at an early 
enough stage where calcitriol concentrations 
are still normal as a consequence of the 
increased PTH. Calcitriol supplementation 
remains beneficial to maintain normal 
calcitriol concentrations while decreasing 
PTH.
D = Calcitriol treatment is started very early 
in the course o f progressive nephron loss, 
prior to either PTH increase or calcitriol 
decrease.
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Role of ACE-Inhibition in Renal Disease
Dennis J. Chew, DVM ; Diplomate, ACVIM (Internal Medicine)
The Ohio State University College of Veterinary Medicine, Columbus, Ohio
Angiotensin-II plays a pathophysiologic role in proteinuria and the progression of renal 
disease. It may play a role in the progression of non-proteinuric renal diseases too. Angiontensin- 
II receptors exist within glomeruli and vasculature o f the renal tubules[Yamada 1990]. 
Converting enzyme facilitates the generation o f angiotensin-II from angiotensin-I either locally 
within the kidney via brush border of proximal tubules or via activity o f systemic endothelium. 
Angiotensin-II activity within the kidney causes vasoconstriction of glomerular arterioles with a 
preferential effect exerted at the efferent arteriole compared to the afferent arteriole. 
Vasoconstriction o f the efferent arteriole at a time of no change in the afferent arteriole increases 
intraglomerular capillary pressure. Progression of renal disease in remnant nephrons can be 
attributed in part to the persistence of intraglomerular hypertension, a process that is associated 
with increased trafficking o f marcomolecules into the mesangium with resulting proliferation of 
mesangial cells and increase mesangial matrix (glomerulosclerosis). Angiotensin-II has non- 
hemodynamic effects that are potentially important since it can act as a growth factor and 
stimulate other growth factors that influence renal vascular and tubular growth.
The use o f ACE-I decreases systemic blood pressure as well as the degree of 
intraglomerular hypertension, and may prevent loss o f heparin sulfate that can occur in 
glomerular disease thereby limiting the degree o f proteinuria. ACE-I may limit renal growth in 
chronic renal disease, as well as decrease the size of the endothelial pores within glomeruli again 
limiting the degree o f proteinuria[Grauer 2000], The magnitude of proteinuria has been shown to 
be a good predictor of progression o f CRD in people and rats[Gruaer 2000; Klahr 1999; Ots 
2000]. Excess proteinuria can damage renal tubules which then synthesize excess vasoactive and 
inflammatory substances that favor infiltration o f interstital inflammatory cells and renal 
scarring[Zoja 2000]. D ecreased infiltration o f m acrophages and dow regulation of 
pro inflammatory cytokines are also possible renoprotective effects following ACE-I [Ots 2000].
There is growing evidence that angiotensin-converting enzyme inhibitors (ACE-I) reduce 
systemic blood pressure, reduce proteinuria, and slow the progression of a variety o f renal 
diseases in humans [Maschio 1996; Kshirsagar 2000] and dogs[Grauer 2000]. The best response 
appears to be seen in people with glomerular disease and substantial proteinuria and in the 
prevention o f the progression of diabetic nephropathy. Substantial benefit has also been achieved 
in people with non-diabetic progressive nephropathies. Lisinopril treatment o f dogs with 
experimentally induced diabetes mellitus and reduction in renal mass resulted in reduced 
glomerular transcapillary pressure, hypertrophy of glomerular cells, proteinuria, and mean 
arterial pressure[Brown SA, 1993].
There is one clinical study in dogsfGrauer 2000] regarding the use of ACE inhibition for 
the treatment o f renal disease. Samoyed dogs with x-linked hereditary nephritis undergoing 
treatment with enalapril experienced less proteinuria, increased excretory function, less 
glomerular basement membrane splitting, and greater survival times than control dogs[Grodecki
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1997], Twenty-nine clinical dogs with glomerular disease ( 1 6  membranous GN and 13 
membranoproliferative GN) were treated with either enalapril at 0.5 mg/kg once or twice daily ( 
n = 16) or placebo (n = 14) as a means of ACE inhibition for 6  months in a multi-center 
prospective double-blind study stratified within glomerular disease diagnosis. Doses of enalapril 
or placebo were increased from once to twice daily if  < 50% reduction o f UPCR was achieved 
following one month o f treatment. One dog received both placebo and enalapril. All dogs also 
were concurrently treated with aspirin at 0.5 to 5.0 mg/kg once or twice daily as well as with a 
moderately protein-restricted diet designed for the treatment o f renal failure dogs. Enalapril and 
placebo groups were equally matched at the start with regard to degree o f azotemia, systolic 
blood pressure, and glomerular histologic score but the dogs receiving enalapril had greater 
UPCR (8.7±4.4 vs 4.7±2.3) than control dogs.
There were significant differences between groups after 6  moths o f treatment for UPCR 
(-4.2±1.4 vs 1.9±0.9), and UPCR x serum creatinine(-6.3±10.5 vs 8.3±10.1), systolic blood 
pressure (-16.7±7.0 vs 6 .8 ± 6 . 8  mm Hg), and response scores (1.4 ±0.8 vs 0.3±0.5) for enalapril 
vs control dogs respectively. Response scores were assigned as 0, 1, or 2 based on magnitude of 
change in UPCR and serum creatinine (higher scores were more stable or improving). Serum 
creatinine was 1 .6 ± 0 . 6  initially and 2.7±1.5 at 6  months in the placebo treated dogs compared to 
1,9±0.6 and 1.7±0.7 in the enalapril treated dogs.
In the enalapril group o f dogs, 9 improved, 4 had no progression and 3 showed 
progression; euthanasia due to renal failure occurred in two dogs at 3 and 5 months o f the study. 
Enalapril was given once daily in 7 dogs throughout, twice daily in 6  dogs starting at one month, 
and twice daily in 3 dogs starting at 3 months. Most dogs that showed decreased UPCR (7/9) had 
the most marked decreases by the one-month evaluation with minimal further decreases 
thereafter. No dogs treated with placebo improved, 4 showed no progression, and 10 showed 
progression. Placebo was given once daily in 3 dogs, twice daily in 9 dogs starting at one month 
and twice daily in 2 dogs starting at 3 months. In the one dog in which placebo treatment was 
followed by enalapril, no progression occurred during placebo treatment and then improvement 
occurred while on enalapril. Improvement in this study was defined as greater than or equal to a 
50% decrease in UPCR with stable serum creatinine, no progression was defined as < 50% 
decrease in UPCR with a stable serum creatinine, and progression was defined as > 50% increase 
in UPCR and or serum creatinine.
Enalapril treatm ent o f clinical dogs with idiopathic glom erulonephritis reduces 
proteinuria as well as systolic blood pressure and delays the onset o f azotemia that would 
otherwise occur at least for six months[Grauer 2000]. Similar benefits on proteinuria and delayed 
onset of azotemia were seen in Samoyed dogs with hereditary nephritis treated with enalapril but 
without decreased systolic blood pressure[Grodecki 1997], No correlation between change in 
systolic blood pressure and change in UPCR could be established in either enalapril or placebo 
treated clinical dogs[Grauer 2000].
Questions remaining to be anwered : Will the renoprotective effect o f enalapril treatment 
o f dogs with more severe azotemia than encountered in the Grauer study (serum creatinine < 3.0) 
be effective? Will enalapril have the same effect in dogs with renal disease that do not have 
UPCR > 3 . 0  (those with minimal or absent proteinuria) ? Will the renoprotective effects of
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enalapril in dogs with glomerulonephritis last longer than the 6  month period that has been 
studied so far ? Will enalapril treatment of dogs with renal amyloidosis have any salutary effect ?
Will enalapril exert similar beneficial effects in cats with advancing renal disease ? 
Enalapril has not been studied in cats to date but benazepril has recently undergone extensive 
study as treatment for 201 European cats with CRF due to a variety o f  causes (not just 
proteinuric ones). Cats o f this study either received benazepril (0.5 to 1.0 mg/kg once daily 
[Fortekor®]; mean dose 0.73 mg/kg) or placebo. The BENRIC (Benazepril in Renal 
Insufficiency in Cats) Study Group utilized a number o f practices to enroll cats with CRF. 
Beneficial effects over placebo were seen for quality o f life, improvement in appetite, weight 
gain, and extended life expectancy. Quality of life also increased in the placebo group (restricted 
protein and phosphorus diet). Minor weight gain occurred in the placebo group; more impressive 
weight gain was observed in cats over a 1 2  month period that received benazepril especially 
those cats that had more severe CRF. Average survial o f benazepril treated cats was 501 days vs 
391 days for plaebo treated cats. When cats with severe CRF were considered, survival was 401 
days in benazepril treated cats vs 126 days for control cats.
Should enalapril or other ACE-inhibitors be given to dogs or cats with any renal disease 
likely to progress ? My suspicion is yes. Proof is available only for dogs with the protein-losing 
nephropathy of idiopathic glomerulonephritis. If enalapril or benazepril is chosen for treatment, 
the dog or cat should return to the clinic to repeat serum creatinine measurement in one to two 
weeks. This is to make sure that GFR has not been reduced too much as a consequence of 
efferent arteriolar dilatation during therapy; repeat systemic blood pressure determination should 
also be undertaken at this visit to ensure that systemic hypotension is not developing. Remember 
that “super nephrons” as compensation for CRF become so by increasing single nephron GFR 
mostly by afferent arteriolar dilatation and that efferent arteriolar dilatation from ACE-I may 
dramatically decrease this single nephron GFR. Any detected decrease in GFR and rise in serum 
creatinine is usually transient and reversible following discontinuation o f the drug. It is important 
to note that development o f azotemia is not dependent on the presence of systemic hypotension 
as the effect o f ACE-I can occur earlier within the glomeruli to create intraglomerular 
hypotension. Hopefully, if  systemic hypotension is present and detected early enough, the 
worsening of azotemia will rapidly return to previous baseline levels following IV fluids. 
Uncommonly, the development of systemic hypotension in those with chronic renal failure can 
add an element of “acute-on-chronic” renal failure that will not immediately abate due to 
acquired renal ischemia and tubular necrosis. Repeat analysis o f UPCR is recommended after 
one month of treatment. If the UPCR has not decreased appropriately, the dose of enalapril is 
usually doubled.
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Erythropoietin Therapy for Anemia in Chronic Renal Failure : Risks and Benefits
Dennis J. Chew, DVM ; Diplomate, ACVIM (Internal Medicine)
The Ohio State University College of Veterinary Medicine, Columbus, Ohio
Anemia is common in dogs and cats with CRF; its severity is correlated with the degree of 
azotemia in dogs [King, 1992], Severe anemia is generally encountered in those patients with the 
most advanced renal disease (highest serum creatinine concentration), though exceptions do occur. 
This anemia is usually characterized as a non-regenerative, normocytic and normochromic and 
was described in 12 o f 17 dogs with CRF in one study [King, 1992]. Another description is that 
of hypoproliferative anemia which describes inadequate red cell production by the bone marrow 
secondary to either an absolute or relative deficiency o f erythropoietin needed to stimulate the 
marrow. Erythropoietin is synthesized within normal kidneys by interstitial cells of the renal 
cortex [Randolph, 1999], but diseased kidneys lose their ability to adequately manufacture it. 
Erythropoietin is synthesized in sufficient quantities by normal kidneys to maintain normal red 
blood cell mass but erythropoietin concentrations are either “normal” or low in dogs[King, 1992; 
Pechereau, 1997] and cats[Pechereau, 1997] with chronic renal failure ; normal range values of 
erythropoietin are inappropriately low for an animal with anemia (relative vs absolute deficit). 
The availability of laboratories to measure erythropoietin is limited; it is not customary nor 
necessary to measure erythropoietin levels in patients with obvious CRF as the source of the 
anemia. Though the primary cause o f anemia in CRF is related to deficits of erythropoietin, 
reduced red blood cell life-span (hemolysis), blood loss (GI ulcers, reduced platelet function), and 
suppression o f marrow response by uremic compounds including PTH may contribute at times. 
Iron deficiency and malnutrition can also decrease the erthropoietic response.
The anemia of CRF contributes to anorexia, weight loss, weakness, lethargy, depression, 
and behavioral changes since many o f these signs are ameliorated if the anemia is corrected 
[Cowgill, 1998], Often the clinical signs in CRF are attributed to that o f “uremia” though many of 
them may at least in part be created by anemia. The benefit of correcting even mild anemia is 
apparent subjectively in some animals (the “feel good” factors and improvement in appetite and
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strength). We often underestimate the effects o f mild anemia, though it is known from 
experiences in human medicine that effects of mild anemia can be profound in their patients.
Some increase in hematocrit (PCV %) can occur if the magnitude o f azotemia is reduced 
through adequate dietary protein restriction; too severe a protein restriction may worsen the 
anemia. Anabolic steroids such as oxymetholone and stanozolol may have some beneficial effect 
to stimulate the bone marrow, but the effect appears to be weak ( if it exists at all) and it may 
take many weeks to observe the effect. Deca-Durabolin (nandrolone decanoate) at 1 to 5 mg/kg 
IM once weekly has been recommended by veterinary nephrologists, but convincing reports of 
efficacy are lacking. Blood transfusions may be necessary. If the PCV is less than 20%, 
transfusion is likely to benefit the patient. If red cells are needed now, blood transfusion is 
needed since an effective response to EPO takes weeks. Conventional wisdom considers 
transfusion as unnecessary when the PCV is in excess o f 20 to 25 %. Some uremic animals that 
are minimally anemic achieve a boost following transfusion that allows them to feel better and eat 
more food. Increased serum phosphorus and metabolic acidosis result in increased ability to 
carry and deliver oxygen with lower number o f red blood cells. Transfused red cells do not last as 
long in the uremic plasma as they would otherwise. Multiple transfusions can result in 
transfusion reactions and shortened red blood cell life-span. Hemolysis and hemoglobinuria may 
add further injury to an already chronically injured kidney.
Human recombinant erythropoietin (r-HuEPO; EPO®- Amgen) has successfully been 
used for the treatment of anemia in some uremic dogs and cats, however it is not approved for 
use in either species. Correction of anemia is achieved within one month o f uninterrupted 
treatment with r-HuEPO in uremic dogs and cats [Cowgill, 1998]; reticulocytosis accompanies 
the increase in red cell mass. Unfortunately, many dogs and cats with CRF develop a clinically 
relevant level of antibodies against the human form of erythropoietin following treatment with r- 
HuEPO. There is an 18.7% difference in primary amino acid sequence between r-HuEPO and r- 
CaEPO [MacLeod, 1998] which can render r-HuEPO immunogenic in non-target species. 
Progressive anemia developed during r-HuEPO treatment in 2 of 3 dogs treated more than 90 
days (detected at 51 and 80 days) and in 5 o f 7 cats treated longer than 180 days (detected
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between 37 and 160 days in 4 cats and somewhere between day 150 and 302 in the fifth cat). 
Anti-r-HuEPO antibodies were detected at time of anemia and persisted for longer than 6  months 
in some instances [Cowgill, 1998]. Anti-r-HuEPO antibodies were detected at the time anemia 
developed in 7 of 32 normal dogs give r-HuEPO for twelve weeks[Cowgill, 1994], Six of 6  
normal experimental Beagles that received r-HuEPO by subcutaneous injection in another study 
developed non-regenerative anemia within 16 weeks, with 4 o f 6  doing so by 4 weeks of 
treatment. Recovery from anemia occurred in all dogs over 5 to 11 weeks (7 week 
median) [Randolph, 1999]. Interestingly in another study, anti-r-HuEPO antibodies only 
developed in normal Beagles when treated with r-HuEPO IV at 3,000 U/kg/da; IV doses of 100 
or 500 U/kg/day for 3 months did not result in detectable levels of antibodies [Bader, 1992 #57]. 
Increased red cell mass was maintained in 2 CRF cats treated with 50-100U/kg r-HuEPO IV 
either once weekly or every other week as needed for 25 to 85 weeks without recurrence of 
anemia [Suda, 1993 #46].
Anti-EPO antibodies may cross react with what little endogenous erythropoietin is 
produced within the body as well as that administered exogenously, actually making an anemia 
worse than before treatment with EPO was started. In these instances, r-HuEPO is initially 
effective in maintaining the HCT within the target range, but progressively loses effectiveness 
despite increased EPO dose. Due to the frequency of development o f anti-EPO antibodies and 
their protracted adverse effects on red blood cell production, human recombinant EPO cannot be 
recommended for use in uremic dogs or cats unless they are already transfusion dependent. There 
is no commercially available blood test to measure for the development of anti-EPO antibodies. 
An increase in M/E ratio in bone marrow cytology occurs prior to an obvious decrease in PCV. 
Uncommon adverse effects associated with r-HuEPO treatment included transient and reversible 
polycythemia, pain at the injection site, hypersensitivity-like cutaneous or mucocutaenous 
reactions, systemic hypertension (normal or low PCV), and seizures (in association with 
moderate to severe azotemia) ; vomiting and uveitis were observed sporadically and only in cats. 
Polycythemia in normal dogs treated with r-CaEPO developed more readily than in dogs treated 
with r-HuEPO suggesting a more powerful receptor effect for homologous EPO [Randolph, 
1999] -  lower doses may be effective when using species-specific EPO.
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Treatment with human recombinant EPO can result in a maximal 1 % per day increase in 
HCT over the first month. When indicated (transfusion dependency), the dose is often started at 
100 Units/kg subcutaneously three times per week until the target hematocrit (Dogs = 37-45 % ; 
Cats = 30-40 % ) is reached, usually within 3 to 4 weeks. If the target HCT is not reached by 
this time, increase the EPO dose by 25 to 50 Units/kg for each injection. If  the target HCT is still 
not reached by 8  to 1 2  weeks, look for other problems (iron deficiency, blood loss, hemolytic 
disease, concurrent infections, inflammatory disease, or neoplastic processes). The unusual 
combination of reticulocytosis (large cells) and tendency for overall microcytosis (decreasing 
MCV) has been noted during r-EPO treatment o f CRF dogs and cats by two veterinary 
investigors [Cowgill, 1998; Randolph, 1999]
Three of 6  dogs and 3 o f 7 cats had iron concentrations less than the reference range in one 
study of uremic patients. Despite this, resistance to the effects o f r-HuEPO that could be 
attributed to iron deficency was not observed [Cowgill, 1998], The need for iron increases 
markedly during erythropoiesis so it is recommended to provide supplemental iron during EPO 
treatments to maximize the erythopoietic response. Ferrous sulfate at 10 mg/kg PO once daily or 
every other day has been recommended at the start o f EPO treatments, but this dose may be too 
low based on assessment of iron stores in experimental dogs treated with r-CaEPO [Randolph, 
1999]. Oral iron treatments may not be tolerated well by cats [Cowgill, 1998].
What should you do if  a decision to treat a dog or cat with human recombinant EPO has 
been implemented and you suspect that anti-EPO antibody production has become a problem? 
In these instances an initial salutary response to EPO (increased PCV) occurs but is followed by 
progressive decline in PCV. If no other problem that could interfere with red cell formation or 
cause blood loss is found, stop EPO treatments and support with transfusions as needed until 
the anti-EPO antibodies are cleared. Unfortunately, animals may require intermittent blood 
transfusion for several months until the anti-EPO antibodies have been cleared.
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Erythropoietin that is specific for the dog or cat protein is not presently commercially 
manufactured. Researchers at Cornell University (MacLeod JN) have cloned the gene for canine 
specific erythropoeitin (r-CaEPO) and have reported its safety in normal dogs. A study is 
underway at Cornell to determine the effectiveness of canine recombinant erythropoietin in the 
treatment of the anemia o f chronic renal failure in dogs, including those have failed treatment with 
human recombinant erythropoietin. Studies using recombinant feline EPO are now underway by 
the same group. Perhaps some drug company will take it upon themselves to prepare species- 
specific forms of erythropoietin that will effectively treat the anemia o f chronic renal failure 
without development o f anti-EPO antibodies. In the meantime, is there some way that we could 
modify the way that we use human recombinant EPO so it would be safe and effective? Would 
less frequent exposure to the human recombinant EPO elicit less o f an immune response from the 
uremic dog or cat? Is IV administration less immunogenic than the subcutaneous route? Would 
lower doses result in less activation of the immune system? Can the human recombinant form of 
EPO be given less frequently so as to get a boost of red cell production intermittently without 
increasing the risk for anti-EPO antibody formation? These are all interesting questions posed to 
me by practitioners - answers to which I do not know.
A novel form of gene therapy is under consideration in which the canine or feline gene for 
erythropoietin is inserted into a vector virus and then injected into the animal’s muscle. As the 
genetic material for erythropoietin is taken into the muscle cell DNA, dog or cat specific 
erythropoietin would be synthesized and secreted by the muscle cells. A dose-related increase of 
hematocrit was seen in normal cats following IM injection of adeno-associated vector virus laden 
with the feline EPO gene for the seven weeks of the study [Beall, 2000], Dose related 
erythropoietic effects were seen in the bone marrow and spleen of these EPO-gene treated cats. 
Serum EPO levels increased following EPO gene injection but not always in direct proportion to 
the number of gene particles given. An Fe-EPO gene treatment study o f cats with CRF and 
anemia started in late 1999 at The OSU Veterinary Medical Teaching Hospital. Two of 5 CRF 
cats treated in this study developed polycythemia; one is alive and requires periodic phlebotomy 
and one died shortly after the development of polycythemia (cause and effect could not be 
definitively established). Cats with polycythemia vera do not show obvious clinical signs until
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the PCV is very elevated; the magnitude and rate o f change in PCV from low to above the normal 
range may be greater in CRF cats following gene therapy than that experienced by cats with 
polycythemia vera and consequently they might show clinical signs at a lower PCV. One cat did 
not respond to the therapy -  we suspect that the gene was not delivered properly to the muscle, 
as muscle mass was severely decreased in this cachetic cat. Adjustment o f the dose o f the genetic 
material is under consideration for future studies. Hydroxyurea as used in the treatment of 
polycythemia vera is a chemotherapeutic agent with minimal side-effects in cats that might be 
useful in EPO-gene treated cats that develop persistent polycythemia.
Alternatively, genes with “on/off’ switch technology could be developed. Such a method 
is currently under study at the University o f Florida (Levy J: AC VIM Proceedings 2001) using a 
doxycycline sensitive regulatory element in which low doses o f doxycycline are used to turn on 
EPO expression. Fixed dose expression of EPO was not reliable in control o f hematocrit nor was 
surgical removal of the injection site successful in returning PCV to lower levels in all cases. This 
group used surgical exposure followed by EPO-gene injection o f the superficial gluteal muscle.
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MANAGEMENT OF ARTERIAL HYPERTENSION IN CHRONIC RENAL FAILURE
Dennis J. Chew, DVM
The Ohio State University College o f Veterinary Medicine, Columbus, Ohio
Systemic hypertension occurs commonly in dogs and cats with chronic renal failure when 
determined by methods that indirectly measure blood pressure. There are many artifacts that 
increase blood pressure transiently while the measurement is being taken. The "white-coat" 
effect refers to increased activation o f the sympathetic nervous system as the cause for the 
temporary increase in blood pressure (which can go very high). Hypertension is commonly 
defined when systolic pressure is > 200 mm Hg, diastolic > 110 , and mean pressure > 150  mm 
Hg. Borderline hypertension is suspected at > 180 mm Hg systolic pressure. Severe systemic 
hypertension can create endorgan damage clinically manifested as blindness (retinal 
hemorrhages, retinal detachments), seizures, dyspnea in cats, and epistaxis. Systemic 
hypertension is a major risk factor for the progression o f CRF in people and rats, but this has not 
been established for dogs and cats with CRF. Perfusion pressure in remnant glomeruli during 
CRF is increased and the fear is that increased systemic blood pressure will be transmitted to the 
glomerular vascular beds causing further damage.
It is essential that dogs and cats be in a quiet environment before and during blood 
pressure measurements by either oscillometry or by ultrasonic Doppler. The averaged results of 5 
consecutive and consistent oscillometric values ( < 2 0  % variability) are recommended for dogs 
taken from the coccygeal artery or 3 ultrasonic Doppler values from the tarsal artery. 
Oscillometry in awake cats is very unreliable compared to direct measurement and a reading is 
not recorded in about 1/3. Ultrasonic Doppler method using the median artery is the indirect 
method of choice for cats.
Treatment of hypertension SHOULD NOT BE UNDERTAKEN UNLESS access to 
serial measurement of blood pressure is available. It is justified to aggressively treat 
hypertension as defined above, especially if there are clinical signs related to the hypertension. It 
is less clear if  cases of CRF with less severe increases in blood pressure benefit from 
antihypertensive maneuvers. Single agent therapy using ACE-Inhibitors (enalapril, benazepril), 
calcium channel blockers (amlodipine), beta adrenergic antagonists (atenolol, propranolol), or 
alpha-1 adrenergic antagonist (prazosin) may lower blood pressure. Diuretics and dietary salt 
restriction are not effective treatment for severe hypertension. Side-effects from 
antihypertensives include hypotension and reduced blood flow to kidneys. In some animals, it 
appears that high systemic blood pressure is helping to drive GFR since when systemic 
hypertension is successfully treated, GRF falls and BUN and creatinine increase. In others, GFR 
actually increases as the level of systemic hypertension declines.
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RENAL TRANSPLANTATION IN THE DOG AND CAT -  AN UPDATE
Dennis J.Chew, DVM Dipl ACVIM (Internal Medicine)
College of Veterinary Medicine, Department of Veterinary Clinical Science 
The Ohio State University, Columbus Ohio ; USA
Feasibility of Renal Transplantation
Availability o f better immunosuppressive agents, improved understanding of rejection 
biology, improved microvascular surgical technique, and improved technique for 
ureteroneocystostomy all have led to improved success in renal transplantation for both dogs and 
cats. Greater success has been achieved in the development of transplant programs for cats 
compared to dogs to date. Despite thorough preparation, patient selection, and appropriate 
immunosuppression, some patients will experience graft failure and death. Dogs undergoing renal 
transplantation survived a mean of 18.3 months and a median o f 8  months in a recent report from 
a transplant program using an aggressive regime n of immunuosuppression (KA Mathews 2000). 
Two dogs from this transplant program survived longer than 5 years following renal 
transplantation with 6  dogs surviving at least 12 months. Cats that underwent renal 
transplantation in another program survived a mean of 15 months and a median of 8  months (n = 
28); cats that were still alive at the time of this report survived a mean o f 26 months and a median 
of 22 months (n = 18) (Gregory 1997). The longest survival period o f cats from this transplant 
program was 81 months (n = 2 ).
The concept o f renal transplantation should not be undertaken lightly. Owners of dogs or 
cats considered candidates for renal transplantation should thoroughly understand the emotional, 
financial, and time commitments that are needed from them and that will be expended by the 
transplant team. Time and expense continue with weekly and then monthly recheck evaluations 
for the first year if  the process has been successful. There is an emotional roller coaster during the 
initial transplantation efforts as one tries to balance the level of immunosuppression so as to 
avoid rejection but yet to avoid development o f life-threatening infections. Successful renal 
transplantation requires a dedicated team of veterinarians with surgical and medical expertise; 
special interest in immunology and infectious diseases is very helpful. There are very few 
veterinary referral sites around the world that develop and maintain the expertise needed to offer 
a successful renal transplant program.
Indications for Renal Transplantation
Surgical renal transplantation does not replace failed medical management (Greogry 1998). 
Renal transplantation is not considered a rescue treatment for animals in the advanced stages of 
chronic renal failure (poor body condition scores with appreciable weight loss) as some groups 
consider them poor transplantation candidates. Progressive weight loss not manageable by 
standard conservative medical management is a major indication for renal transplatation in cats for 
the Gregory group at UCDavis irrespective o f specific levels o f renal functional parameters. The 
Mathews group at Guelph considers dogs candidates for renal transplantation when they are no 
longer responsive to either subcutaneous or intravenous fluids, have no systemic or urinary 
infections, no malignancies, and a urinary protein to creatinine ratio of less than 5.0. It is best to 
start thinking about the possibility o f renal transplantation before the animals are very sick in 
order to avoid the “too-little too-late” syndrome.
Relative and Absolute Contraindications for Renal Transplantation -  from the
Recipient’s Perspective
Advanced catabolism of chronic renal failure lessens the likelihood for a successful renal 
transplant. Efforts to improve body condition scores should be attempted prior to renal 
transplantation using tube gastrostomy feeding if needed. Cats with concomitant 
inflammatory/infiltrative bowel disease may be at increase risk for accelerated renal rejection 
(Gregory 1998). Cats or dogs with other major organ dysfunctions or infectious diseases are not 
good candidates to undergo renal transplantation. Cardiac abnormalities in cats may also be a 
poor indicator of long term success following renal transplantation (increased cardiac size on 
echocardiography, gallop rhythmms, abnormal ECG -  but not murmurs). Cats with 
hyperthyroidism should have this corrected prior to transplantation. Animals with hypertension 
should have this medically controlled prior to renal transplantion (especially cats ). Cats with a 
history o f bacterial UTI (confirmed by quantitative urine culture) are not good candidates for 
renal transplantation due to the possibility o f activation of more UTI while on 
immunosuppressives. A history of a previous UTI is a risk factor for recurrent bacteriuria post 
immunosuppression. If  the history o f UTI is not clear, a cyclosporine challenge for two to three 
weeks followed by urine culture has been suggested to ensure that bacteriuria will not be a 
problem in the future (Gregory 1998). Dogs are not accepted into the transplant program at 
Guelph during acute renal failure from ethylene glycol poisoning due to vasculitis encountered in 
that condition that can threaten the transplanted kidney(KAMathews 2000). Recipients that are 
seropositive for toxoplasmosis are at increased risk for activation o f latent toxoplasmosis during 
immunosuppression and should be monitored closely for the development of acute 
toxoplasmosis (Bernsteen 1999).
Pre-Transplanatation Evaluation -  Donor
The best potential donors for renal transplantation are siblings or parents but they still 
may not be compatible. It is not always possible to locate siblings or parents for consideration, 
so donors will usually be unrelated and unmatched random source animals. It is not desirable to 
use kidneys from related donors if the recipient’s kidney disease is familial in origin. Some 
programs maintain a colony known to be free of infectious diseases and o f known blood type 
that are available for donors. Other programs require that the owner provide a suitable donor 
often following adoption from a humane shelter. It is imperative that animals from shelters be 
screened intensively for infectious diseases initially and then again 8  to 1 2  weeks later to ensure 
that no infectious diseases were incubating when the animal was initially procured. It is 
customary to require owners to sign papers stating that they will permanently adopt donors 
procured from animal shelters. Multiple candidates (adoptees) may need to be screened in order 
to find one that will be a suitable donor. Major and minor cross-match is performed in cats 
between potential donor and recipient for blood compatibility. Some transplant programs only 
consider dogs as donors that are DNA-matched or matched by mixed lymphocyte response 
(Gregory); others accept DEA typed and blood cross-matched donor dogs (KA Mathews).
The donor should have two normal kidneys anatomically (ureter and vascular numbers 
and location) and functionally and be in excellent health for all organ systems. Routine serum 
biochemistry, hematology, and urinalysis should be normal. Imaging of the kidney should include 
ultrasound (preferably with doppler flow capability) and intravenous pyelography (IVP -  to
more fully evaluate the anatomy of the ureter). In cats the donor should be as large as possible, or 
at least not 0.5 kg smaller than the recipient. Dog donors should be as large or larger than the 
recipient. Urine culture to ensure the absence of bacterial UTI should be determined. Potential 
donors should be seronegative for toxoplasmosis. Cats should be seronegative for feline leukemia 
virus (FeLV) and for feline immunovirus (FIV). Dogs should be negative for heartworm.
Pre-Transplanatation Preparation -  Recipients
The anemia of chronic renal failure should be corrected so that the PCV is near the normal 
range prior to transplantation. This can be accomplished by treating with injections o f human 
recombinant erythropoietin that usually result in normal range PCV within 3 to 4 weeks or by 
cross-matched blood transfusions. Many dogs and cats develop clinically relevant levels of anti­
human recombinant eruthropoietin antibodies -  whether this impacts the rejection phenomenon 
is unknown. Animals that have very poor body condition scores should undergo tube 
gastrostomy feeding to improve these scores prior to transplantation -  this may take one to three 
months. An IV line is placed and fluids are given at rates and quantities to ensure adequate 
hydration and maintenance of perfusion during anesthesia and surgery. Correction o f major acid- 
base and electrolyte abnormalities prior to transplantation is desirable.
For cats (Gregory protocol) : Cyclosporin-A is started at 5 mg/kg twice daily 24 to 48 
hours prior to transplantation. Another protocol published by this group is cyclosporine at 7.5 
mg/kg 24 hours prior to surgery or microemulsified cyclosporine at 3 mg/kg twice daily 24 to 36 
hours post renal transplantation(JAVMA 1997). Oral cyclosporine is transferred to gelatin 
capsules due to the unpleasant taste and salivation that occur otherwise. Oral prednisone is 
started on the morning of the transplant at 0.25 mg/kg twice daily for the first 30 days and then 
decreased to once daily. A 12 hour trough level of whole blood cyclosporin is measured on the 
morning of the transplant and should be near 500 ng/ml as measured by high pressure liquid 
chromatography (HPLC). Whole blood levels (lysed RBC) of cyclosporine are about twice that 
of serum. After 3 months the cyclosporin level is targeted to approach 350 ng/ml. Tapering of the 
cyclosporin dosage is titrated to the biologic effect seen which may not correlate with the whole 
blood level. A broad-spectrum non-nephrotoxic antibiotic is given IV immediately prior to the 
transplant surgery. Mannitol at 1-2 gm/kg is given to the recipient cat 15 to 20 minutes prior to 
receiving the donor kidney in order to decrease the incidence of acute tubular necrosis (warm 
ischemia in the donor kidney).
For dogs (KA Mathews protocol): A combination of rabbit antidog antithymocyte serum, 
cyclosporin-A, azathiaprine, and prednisone is used for immunosuppression in this protocol for 
dogs. Antithymocyte serum is given in a gradually increasing dose from day -2  through day 6  
with the goal of decreasing the lymphocyte count to 10% of baseline. On day -2  prednisone at 1 
mg/kg daily is given orally and then azathiaprine is started on day - 1  at 1 . 0  mg/kg daily orally. 
Cyclosporin is added on day 2 or 4 at 10 mg/kg once daily orally and the dose manipulated to 
maintain a 12-hour trough level of 500 to 600 ng/ml of cyclosporine when measured by 
monoclonal RIA. At 6  months, the targeted level of cyclosporin is 400 ng/ml, and 300 ng/ml 
during the second year post transplantation. The KA Mathews protocol considers the 
antithymocyte serum portion of the protocol to be the most important for long term success in 
renal transplantation in the dog. Unfortunately, antidog antithymocyte serum is not commercially 
available and must be raised by the local transplant group. The effect o f locally raised
antithymocyte serum may vary by batch and by group due to differences in methods. Aspirin at 
0.5 mg/kg orally twice daily is given to dogs in an attempt to decrease platelet aggregation (KA 
Mathews). Mannitol at 0.75 g/kg is given IV over 10 minutes post renal transplant to dogs while 
maintaining ample IV fluid infusion (30 ml/kg/hr) in minimize post-transplant renal ischemia.
Methods of Renal Transplantation
Two surgical teams operating at the same time are optimal, one working to harvest the 
kidney from the donor and the other to place the donor kidney into the recipient. The donor 
kidney needs to be in place in the recipient by 60 minutes in methods in which cooling and 
perfusion are not used (Gregory UCD). Either the left or right kidney may be harvested; the left 
kidney o f dogs is preferred by some due to its relatively long renal vein (Mathews 2000). The 
Matthews protocol for dogs involves cold flushing of the donor kidney through the renal artery 
with a solution o f 500 ml of saline in which 6  ml of 2% lidocaine without epinephrine and 2,000 
units of heparin have been added. The renal aretery is flushed until the fluid flowing out the renal 
vein is clear. Microvascular surgery methods that achieve 3-10 times magnification are required 
for anastamosis o f vessels in the cat. Magnification is not essential in larger dogs but it still is 
helpful to facilitate the surgery. The donor kidney is placed in the iliac fossa. The vessels o f the 
donor kidney are anastamosed to the iliac artery and vein by a variety o f end to end (renal artery) 
or end to side (renal vein) methods. The arterial end to side technique in cats appears to be the 
superior method for renal transplantation in cats as it required less surgery time, was not 
associated with pelvic limb vascular flow problems, and had good return o f renal function 
(Bernsteen 1999). Vascular clamping methods have improved this process for some groups 
(Degner), though traditional vascular suturing is still successful. Ureteroneocystosomy is then 
performed -  adjustments in technique have dramatically reduced episodes o f obstruction or 
leakage that occurred with earlier techniques in cats (change from drop in technqiue to a mucosal 
appositional technique). Ureteroneocystostomy is considerably easier in dogs than in cats. The 
native kidneys o f cats are usually left in place to provide some level o f support for renal 
function, unless upper urinary tract infections, severe hypertension, or large cysts o f polycystic 
renal disease are creating problems. The native kidneys of most dogs are removed during the 
transplant surgery due to systemic arterial hypertension associated with the diseased kidneys 
(KA Mathews). A gastrostomy tube should be placed at this time if one is not already in place.
Following the Transplant Patient
The donated kidney should become engorged with blood followed by a vigorous flow of 
urine shortly after the vascular anastamoses have occurred. Hypothermia, hypotension, and 
anemia (blood loss) are immediate concerns following completion o f the renal transplantation that 
can adversely affect the newly placed kidney by reducing its perfusion. Good post-operative 
nursing care and fluid therapy are essential to prevent reduced renal perfusion. If the graft is 
functioning properly, the serum creatinine should rapidly decline. Serum creatinine may be within 
the normal range within 24 hours for those with modest pre-transplant increases and by 3 days 
for those with higher levels o f pre-transplant azotemia.
Urinary specific gravity should increase to greater than 1.020 and the serum creatinine 
should decrease to normal levels by 3 days post-transplantation in cats (Gregory). Otherwise 
concerns exist for renal ischemia (vascular, warm ischemia, hypotension resulting in acute tubular 
necrosis), ureteral obstruction, or leakage of urine from the newly implanted ureter.
PCV/TP , serum creatinine, urinalysis, and whole blood cyclosporine levels should be evaluated 
weekly for the first month and then every 3 to 4 weeks if adequate management has occurred by 
this time. Trough whole blood cyclosporine levels are important to follow as there is tremendous 
variability in oral absorption o f cyclosporine; cyclosporine levels may display little correlation to 
dose. The initial levels o f cyclosporin are stable by 14 to 21 days in dogs (KA Mathews). The 
dose of cyclosporine is decreased after the first several months. The blood concentration of 
cyclosporine may not change despite a decrease in dose due to increased bioavailability over time. 
A new microemulsion form of cyclosporine (NeoraKD-Sandimmune) apparently provides more 
consistent intestinal absorption and less variability in blood levels. Remember that comment drug 
therapy can dramatically influence whole blood cyclosporine concentrations. For example, the 
use of phenobarbital results in lower concentrations and the use o f itraconazole or ketaconazole 
increases the level o f cyclosporine through effects on hepatic metabolism.
CBC and serum biochemistry need to be assessed periodically to evaluate the effect of 
azathiaprine on the bone marrow (cytopenia?) and liver (increased liver enzymes and or 
decreased liver function?) for the immunosuppressive protocol in dogs.
The transplanted kidney can be followed by doppler studies during ultrasound, 
quantitative scintigraphy, GFR by exogenous creatinine or iohexol clearance, low dose DTPA or 
MAG3 nuclear medicine clearance, urinary enzyme measurement, or punch biopsy when it is 
unclear how well the graft is doing.
Complications Following Renal Transplantation
Seventy-one percent o f cats (47/66) undergoing renal transplantation were discharged 
from the hospital in one report. The most common causes o f death in cats after release from the 
hospital were renal failure and related complications (32%), immunosuppression related disease ( 
29% ), and cardiac disease (11%). Three o f 15 dogs receiving renal transplants died due to 
surgical complications (20%) and 4 died (27%) due to allograft rejection (1-12 months later).
Seizures, depression, and coma followed by death have affected some cats in the first few 
days following transplantation; seizures occurred in approximately 2 0 % of all transplanted cats 
in one study (Gregory 1997). Consequently it is important to vigorously monitor the neurologic 
status of cats for 24 to 48 hours post transplantation. Mannitol at 0.5 to 1.0 g/kg IV every 30 to 
60 minutes has been suggested as rescue treatment in these instances. More recently, severe 
systemic hypertension was found to be a major complication contributing to post transplant 
seizures in cats (Kyles 1999). Treatment with hydralazine reduced systolic pressure to < 170 
mm Hg within 15 minutes and dramatically reduced the frequency of post transplant neurologic 
complications.
Vascular thrombosis can occur up to 72 hours post-vascular anastamosis. Ureteral 
obstruction can be a problem when older technique for implanting the new ureter is employed, 
especially in cats.
Bacterial urinary tract infections can be acquired; urine culture is recommended weekly for 
the first 4 weeks by the Mathews group. Treatment of UTI in those on cyclosporine requires
special attention to which antibiotics are chosen -  aminoglycosides and potentiated sulfas are to 
be avoided. Lethal systemic bacterial, fungal, and protozoal infections can occur and may be 
associated with too high a trough level o f cyclosporine needed for maintenance o f the graft. All 
dogs on the cyclosporin, azathiaprine, prednisone, and antithymocyte serum protocol for 
immunosuppression developed infections. Cancer presumptively occurred secondary to the 
immunosuppressive protocol in one dog and in 2  cats.
Peracute rejection occurs when preformed antibodies in the recipient react against 
antigens in donor cells especially those in endothelium. This has not been recognized yet in dogs 
or cats. If  it does occur, the graft is destroyed within hours.
Cytotoxic T-lymphocytes are the primary mechanism o f renal destruction during acute 
rejection; mononuclear cell infiltration is typical on renal biopsy in these instances. Acute 
rejection is most likely to occur during the first month post transplantation; clinical signs may or 
may not be apparent. Enlarged painful kidneys may be present in association with an increase in 
the serum creatinine. A sudden increase o f serum creatinine by as little as 0.3 mg/dl is cause for 
concern in a well-hydrated patient. Enlarged hypoechoic kidneys may be discovered during renal 
ultrasonography. Depression, anorexia, vomiting, proteinuria, and hematuria are variable findings. 
Acute rejection is usually associated with cyclosporine levels that are too low. With acute 
rejection in cats and cyclosporine levels less than 150 ng/ml, aggressive rescue treatment is 
indicated with IV cyclosporine (6 - 8  mg/kg IV over 4-6 hours daily) and IV prednisone (10 mg/kg 
twice daily) until the serum creatinine substantially declines. Oral medicines are resumed at 
higher doses that were associated with better immunosuppression. A protocol for rescue from 
acute rejection in dogs suggests treatment with IV methylprednisolone at 10 mg/kg, 7.5 mg/kg, 
and then 5 mg/kg on 3 successive days while the doses o f cyclosporine and azathiaprin are 
returned to the previous higher doses in which rejection was not a problem (KA Mathews).
Nephrotoxicity and hepatotoxicty o f cyclosporine can be seen in humans, but is rarely 
observed in dogs or cats. Cyclosporin induced nephrotoxicity has been suspected in experimental 
dogs which underwent renal transplantation; it was reversible when cyclosporin was 
discontinued (Kelly 1986).
Chronic rejection is suspected when serum creatinine concentration continues to gradually 
increase over months to years in association with reduction in renal mass (serial ultrasound). This 
can occur with or without previous episodes o f acute rejection. Infection o f the transplanted 
kidney can also cause loss o f renal function but the kidney is usually normal size to enlarged. 
Proteinuria and hematuria can be encountered in the chronic rejection process as with acute 
rejection. Renal biopsy can be used to more definitively determine acute from chronic rejection. 
Alternatively, challenge treatment with an acute rejection rescue protocol o f immunosuppression 
can be implemented to see if  improvement in renal function occurs (acute rejection). Chronic 
rejection is often associated with intimal thickening o f arterioles.
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Renal Insufficiency and Hyperthyroidism in Cats
Dennis J.Chew, DVM, Dipl ACVIM (Internal Medicine)
The Ohio State University College of Veterinary Medicine, Columbus, Ohio
Renal insufficiency and hyperthyroidism are relatively common conditions of older cats. 
It can be difficult to accurately diagnose cats with chronic renal failure, hyperthyroidism, or both 
conditions as there are many overlapping clinical signs (weight loss, polydispsia, polyuria, dilute 
urine). It is likely that hyperthyroidism is underdiagnosed in cats with chronic renal failure since 
nearly half o f cats with CRF and hyperthyroidism will have a normal T4 level on a single 
measurement. The relationship between the development of hyperthryoidism as a consequence of 
renal insufficiency has not been explored. The possibility that hyperthyroidism causes chronic 
renal disease in some cats has received little attention. Most attention has focused on the 
simultaneous occurrence of renal insufficiency and hyperthyroidism in a population o f cats under 
consideration for treatment o f hyperthyroidism. It has been observed that a population of 
hyperthyroid cats develop azotemia or display a worsening of azotemia following therapy that 
induces euthyroidism.
Thyroid hormones exert major effects on renal functions. Normal cats undergo increased 
GFR and RBF and decreased BUN and serum creatinine following thyroxine injections for 30 
days (Adams 1997). Groups o f cats with hyperthyroidism often have increased GFR compared to 
normal cats. Plasma iohexol clearance in 12 hyperthyroid cats was 3.83±1.82 ml/min/kg (N = 
13) compared to normal cats at 1.83 ± 0.56 ml/min/kg (n = 10) (Becker 2000). Similar results 
were found when GFR was determined using DTPA clearance nuclear medicine (2.51 ±0.69 
ml/min/kg in 13 hypethyroid cats vs 2.02 ± 0.27 ml/min/kg in 11 normal cats) (Graves 1994) . 
Hyperthyroidism is known to result in dilute urine and polyuria with polydipsia. This effect is 
likely due to increased RBF and medullary solute washout, though a direct effect on the 
collecting tubules and ADH receptor interaction cannot be excluded. Psychogenic mechanisms 
also cannot be excluded. Hyperthyroidism is known to result in hypercalciuria in other species 
due to enhanced bone calcium mobilization; this effect may have some role in the development 
of polyuria as well as a possible role in creating chronic renal damage by excessive exposure of 
renal tissue to calcium. Most cats with hyperthyroidism also have increased systemic blood
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pressure, which could injure renal tissue. Hyperparathyroidism was noted in 77% of 30 cats with 
untreated hyperthyrodism; the magnitude o f increased PTH levels was very large in some 
instances (Barber 1996). The reversibility o f hyperparathyroidism following correction o f 
hyperthyroidism has not been reported. Though serum creatinine (and calcium) was lower in this 
population o f hyperthyroid and hyperparathyroid cats, the possibility o f  renal secondary 
hyperparathyroidism cannot be excluded (renal disease may still exist and not be detected).
Hyperthyroid cats (n = 12) decreased GFR (iohexol clearance) from 3.83±1.82 to 2.02 ±
0.81 4 to 6  weeks following treatment with methimazole (Becker 2000). Two o f these 12 cats 
developed overt azotemia following treatment in this same study though as a group increases in 
BUN or serum creatinine did not achieve statistical significance. Twenty-two hyperthyroid cats 
treated with radioiodine experienced no change in GFR, BUN, or creatinine 6  days following 
treatment (T4 was decreased), but BUN and creatinine were significantly increased at 30 days 
(T4 was also further lowered) (Adams 1997). No cats with a GFR > 2.25 ml/min/kg developed 
post treatment renal failure in this same study. Thirteen of 15 cats with GFR < 2.25 ml/min/kg 
were in renal failure 30 days following radioiodine treatment (2/15 that failed to suppress T4 did 
not develop azotemia); 9 o f these 15 were azotemic prior to treatment; the others had normal 
paramters initially (Adams 1997). GFR (DTPA nuclear clearance) decreased from 2.51 ± 0.69 
ml/min/kg to 1.40 ± 0.41 ml/min/kg 30 days following bilateral thryoidectomy in 13 cats (Graves 
1994) while creatinine increased from 1.26±0.34 to 2.05±0.60 and BUN increased from 
26.62±6.83 to 34.92±8.95.
Azotemia prior to treatment of hyperthyroidism was detected in as many as 41% of cats 
and in 59% of cats 30 days post treatment in one study (Adams 1997). Twenty-three percent 
developed azotemia for the first time following treatment in the same study. Mean serum 
creatinine and BUN increased at 30 and 90 days post-treatment in 58 cats treated by surgery, 
methimazole, or radioiodine; there were no differences in the magnitude o f increase by treatment 
group (Dibartola 1996). Nine o f these 58 cats had increased serum creatinine concentration prior 
to treatment. Two of 12( Becker 2000) and 2 of 13 (Graves 1994) cats developed overt azotemia 
following treatment with methimazole or bilateral thyroidectomy respectively. Based on results 
o f these three studies, it appears that an estimate for the development o f de novo azotemia
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following treatment for hyperthyroidism in cats is from 15-23%. Some increase in serum 
creatinine concentration is expected following the development o f euthyroidism due to increased 
muscle mass (origin o f creatinine), though decreased GFR certainly contributes to increased 
serum creatinine concentration. It is likely that lessening the degree o f hyperthyroidism results 
in decreased RBF and GFR that unmasks azotemia in cats with marginal renal function prior to 
therapy.
Should cats with overt azotemia and hyperthyroidism be treated for hyperthyroidism ? It 
is likely that many of these cats will increase their level o f azotemia following treatments that 
result in euthyroidism. In some cats this increase in creatinine will be mild, while other cats will 
experience large increases in serum creatinine. If clinical signs related to hyperthyroidism are 
severe, at attempt at treatment is warranted. We recommend screening cats with obvious 
azotemia and those suspected o f renal disease with a methimazole challenge. Methimazole 
treatment provides a reversible means of inducing euthyroidism and observing what happens to 
the level o f renal function. An initial dose of 2.5 mg BID is given for 2 weeks and then serum 
biochemistry is repeated to evaluate renal function and T4 levels. If renal function is stable, the 
dose is gradually increased every two weeks as needed until T4 levels have entered the normal 
range if renal function remains stable. The dose can be increased to 2.5 mg TID, then 5 mg BID, 
and 5 mg TID if needed. Methimazole is discontinued if renal function deteriorates during the 
methimazole challenge. If renal function remains stable, then long term methimazole can be 
considered for therapy or more-definitive treatment o f hyperthyroidism provided by 1-131 
treatment or surgery. The definition o f "stable" renal function is arbitrary and in our hospital 
means that the creatinine increased less than 2 . 0  mg/dl in those without initial azotemia and less 
than 1 . 0  mg/dl in those with obvious azotemia.
Supplementation with thyroxine should be considered for those cats with renal disease 
that become hypothyroid following bilateral thyroidectomy or radioiodine treatment. Anecdotal 
evidence suggests that excretory renal function can be supported in some post-treatment 
hypothyroid cats when supplemental thyroxine is supplied. As a compromise, it may be desirable 
to titrate the dose of methimazole in cats with marginal renal function in such a way as to
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partially control the hyperthyroidism without decreasing GFR too much. Other treatments to
control cardiac effects of uncontrolled hyperthyroidism may be warranted (beta blockers).
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IDIOPATHIC AND INTERSTITIAL CYSTITIS in CATS 
Dennis J. Chew and C.A. Tony Buffington 
The Ohio State University Veterinary Hospital, Columbus, Ohio
Idiopathic cystitis was the most-common diagnosis (64%) in our series o f cats with signs of 
lower urinary tract disease, as has been the case in other series over the past 4 decades. 
Urolithiasis of all types comprised approximately 15% of the cases (7% struvite, 6 % oxalate, and 
1 % unknown), anatomic defects (urachal diverticulum, urethral stricture) at 1 1 % and behavioral 
abnormalities at 9% were next in frequency. Diagnosis of urinary tract neoplasia and bacterial 
urinary tract infection was very uncommon. These data were collected from our referral center 
and should be interpreted with caution to predict frequency of diagnosis in a primary care 
practice.
Terminology referring to disorders of the feline lower urinary tract has been confusing. 
Widespread use of the term FUS (feline urologic syndrome) often was used indiscriminately to 
describe cats with signs of irritative voidings regardless of underlying cause. The term FLUTD 
(feline lower urinary tract diseases) was subsequently coined to shift focus to the fact that many 
diagnosable lower urinary tract diseases exist in cats. The term idiopathic lower urinary tract 
disease is appropriate if  no cause o f irritative voiding signs is found following a complete 
exclusionary diagnostic workup that includes urinalysis, urine culture, and urinary imaging with 
some combination o f radiographs, contrast cystography, contrast urethrography, and 
ultrasonography of the bladder. Use of the term feline interstitial cystitis (FIC) as an umbrella 
term for all cats with idiopathic LUTD is not appropriate. The term feline interstitial cystitis is 
reserved for those cats that have frequent recurrences of clinical signs or persistence of clinical 
signs chronically. Idiopathic cystitis can be acute or chronic, but interstitial cystitis by definition 
is a chronic process. Furthermore, the use of this term should be restricted to those in which 
cystoscopic evaluation of the bladder and urethra has been performed following exclusionary 
diagnostic workup. Cats usually are not subjected to extensive diagnostic testing after an initial 
episode of lower urinary tract signs. Consequently, most o f our data on idiopathic or interstitial 
cystitis have been collected from cats with recurrent disease. Data are especially lacking from 
primary care veterinary practices as most epidemiological studies have been conducted at referral 
centers.
Idiopathic cystitis is a disease of irritative voiding signs ( dysuria, pollakiuria, hematuria, 
urination in inappropriate locations), bacteriologically sterile urine, urine that contains epithelial 
cells without cellular atypia (if any epithelial cells at all), and failure to find a more objective 
cause for this clinical picture after appropriate lower urinary tract diagnostic procedures 
including plain and contrast radiography or ultrasonography. The diagnosis o f idiopathic cystitis 
is a diagnosis of exclusion. Idiopathic cystitis is classified as a non-infectious inflammatory 
lower urinary tract disease. Inappropriate urination was the most common owner-reported 
clinical sign in our series o f cats with idiopathic cystitis. Most cats with non-obstructive 
idiopathic cystitis spontaneously resolve their clinical signs within 5 to 7 days regardless of 
treatment, though signs recur in about 50% of cases. A small group o f cats affected with 
idiopathic cystitis continue to display signs of inflammation either continuously or intermittently. 
Urethral obstruction develops in some males secondary to the inflammatory process within the 
bladder and urethra. Whether this is a self-limiting disease or a chronic disorder with acute 
attacks remains to be determined. Some affected cats have a striking increase in severity of 
clinical signs that appear to be associated with stress, while others display waxing/waning of 
clinical signs without known change in stress. A number o f cats with idiopathic cystitis qualify 
for a narrower diagnosis o f interstitial cystitis if  characteristic submucosal hemorrhages 
(“glomerulations”) are observed during cystoscopy following bladder distension to 80-cm water 
pressure in the absence o f other diagnoses. We estimate that 40% of the cats with an initial
diagnosis o f idiopathic cystitis studied with cystoscopy will display such glomerulations; the 
remaining cats display other lesions supportive o f cystitis, including increased vascularity, 
edema, and exaggerated mucosal friability.
Dysuria, stranguria, pollakiuria, macroscopic hematuria, and urinating in places other than the 
litterbox (inappropriate urination) are non-specific signs that, individually or in some 
combination, cause clients to bring their cats to a veterinarian due to apparent non-obstructive 
problems with the lower urinary tract regardless o f the underlying cause. Inappropriate urination 
was the most common owner-reported clinical sign in our series o f cats with idiopathic cystitis, 
occurring in nearly 98% of females and 87% o f males. Episodes o f inappropriate urination 
occurred more than 6  times per week in 70% and 3 to 6  times per week in 13% of both males and 
females. Increased frequency o f urinations was the next most commonly observed clinical sign, 
occurring in nearly 80% of both females and males. Stranguria was noted in 65% of females and 
75% of males. Macroscopic hematuria was reported least frequently, occurring in 58% of 
females and 67% o f males; frequent episodes o f  hem aturia were reported in about 
50%[Buffmgton, 1997 #80]. It is important to recognize that many cats exhibiting inappropriate 
urinations as the sole owner complaint actually have idiopathic cystitis, rather than a behavior 
disorder. When examined with a cystoscope, we found that 16/24 cats with the single owner 
complaint of inappropriate urinations actually had IC rather than a pure behavior disorder.
A specific diagnosis that accounts for lower urinary tract signs requires integration o f findings 
from history, physical examination, urinalysis, urine culture, survey and contrast radiography, 
ultrasonography, urethroscopy, and cystoscopy (see algorithm at end). It is important initially to 
decide if the cat's diagnosis fits into one o f 3 categories: organic/functional bladder disease, 
behavior problem, or polyuric disorders.
PATHOPHYSIOLOGY
Cats with FIC have abnormalities of local bladder factors, sensory (afferent) neurons, the 
central nervous system, and sympathetic (efferent) neurons. Bladder abnormalities include 
decreased urinary glycosaminoglycan (GAG) excretion, histologic changes, increased bladder 
permeability, and neurogenic inflammation. Histologic changes are typically nonspecific, but 
submucosal hemorrhage and increased numbers o f  m ast cells may be present. The 
neurotransmitter substance P, and the density o f the high-affinity substance P receptor are 
increased in the bladder o f cats with FIC, which may increase an inflammatory response. 
Abnormalities o f both the central and peripheral sympathetic nervous system have been 
identified in cats with FIC. For example, significant increases in tyrosine hydroxylase 
immunoreactivity have been identified in the locus coeruleus (LC). Possibly as a consequence of 
increased LC output, cats with FIC have increased stimulus-induced local NE release from the 
bladder and down-regulation o f central and peripheral alpha-2 adrenoceptors (AR). In the 
detrusor, beta-1 AR are downregulated, and beta-3 AR appear to restore some o f the missing 
beta-1 function. In normal cat spine, a -2  agonists inhibit transmission o f  noxious afferent 
signals to the brain. The receptors appear to be located on the central processes o f sensory 
neurons. Although spinal a-2 AR activation can inhibit nociceptive input acutely, these receptors 
seem to become downregulated after chronic stimulation. In contrast to the apparent activation 
o f the sympathoneural system, abnormalities of the hypothalamic-pituitary-adrenal axis have not 
been reported, suggesting the sympathoneural activation is not just the consequence o f a 
generalized stress response. Abnormalities in the central nervous system may explain the limited 
success o f FIC therapies solely directed at the bladder.
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Treatment of Idiopathic and Interstitial Cystitis
Because the underlying cause(s) o f this disorder are unknown, treatment recommendations must 
necessarily be tentative. A combination of recommendations is usually offered that include a 
discussion of litter box management, how to clean soiled areas, and what normal cat behaviors and 
activities might benefit this cat. Changes in diet, increased water intake, provision of pain relief, and 
drug therapy are also considered. Patients with interstitial cystitis are unusually susceptible to 
changes in their environment, one of which may be abrupt diet changes. Increasing water intake to 
dilute urine and increase frequency of urination is an important part o f treatment. One mechanism 
for this benefit may be the dilution of the noxious components o f urine that gain access to the 
bladder wall as a result of increased bladder permeability.
Dietary Treatment
Some diet modifications may reduce the risk of recurrence of lower urinary tract signs in cats 
with idiopathic cystitis. Since struvite crystals do not appear to damage normal urothelium, dietary 
efforts to reduce struvite crystalluria are not warranted in idiopathic or interstitial cystitis. Efforts to 
acidify the urine have no known value in the treatment o f cats suffering from idiopathic cystitis. 
There is experimental evidence that highly acid urine increases sensory nerve fiber transmissions 
that increase pain perception; consequently cats with idiopathic cystitis should not be blindly placed 
on acidifying diets.
Pending future improvements in understanding of the pathophysiology/etiology, dietary
treatment recommendations for cats with idiopathic cystitis include consideration of the constancy, 
the consistency, and the composition o f the diet. Constancy. Our clinical experience suggests that 
diet change can result in recurrence of signs of idiopathic/interstitial cystitis in some patients. 
Moreover, with the advent of many similarly formulated veterinary and commercial foods marketed 
for use in cats with lower urinary tract signs, signs sometimes recur when cats are switched from any 
o f these foods to another one o f them. These observations suggest that diet change may result in 
recurrence o f signs. This hypothesis is strengthened by the observation that some cats with lower 
urinary tract signs appear to be sensitive to a variety of environmental stimuli[Jones, 1997], Pending 
further study to test this hypothesis, limiting the frequency of diet changes in this group of patients 
may be prudent. Consistency Compared with results from US household surveys, cats with 
idiopathic cystitis were significantly more likely to eat dry food exclusively [Buffington, 1997], We 
recently reported that lower urinary tract signs recurred in only 1 1 % of idiopathic cystitis cats during 
a year of feeding the canned formulation of a veterinary food designed to result in production of an 
acidic urine[Markwell, 1999]. Recurrence occurred in 39% of cats fed the dry form o f the food, 
suggesting that both constancy and consistency (increased water intake) may be important, although 
the reasons for this effect remain to be determined. Both diets contained a similar potential renal 
solute load and resulted in a similar degree of urinary acidification. Interestingly, the urine specific 
gravity o f cats fed the dry form was usually greater than 1.050 (mean o f 1.050), whereas that of 
canned fed the canned diet usually was less than 1.040 (mean of 1.030). It appears that the canned 
form protected nearly 90% of cats against recurrence of lower urinary tract signs for up to one year, 
constancy of diet protected about 60%, and 1 0 % were offered no protection from recurrence by the 
diet .Composition In addition to water, diet-related decreases in urine magnesium, and/or increases in 
urine calcium, potassium, and/or hydrogen ion concentrations all could influence activity o f sensory 
nerve fibers in the urothelium[Maggi, 1993]. Unfortunately, most of these effects have been studied 
using in vitro experimental systems. The effects of urine electrolyte content on lower urinary tract 
signs have not been adequately studied, but may be important in treatment of some patients.
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Cats suffering idiopathic cystitis seem to benefit from provision o f a single, canned diet, if 
such a feeding plan is not too stressful to the cat or the owner. The issues surrounding stress, diet 
change and disease currently are controversial, and further investigation o f these relationships is 
needed.
Amitriptyline
In severe recurrent cases, administration o f the tricyclic anti-depressant amitriptyline may be
considered. We recently reported the results o f amitriptyline treatment in 15 cats with severe 
recurrent interstitial cystitis[Chew, 1998 ]. Failure during this study was defined as the recurrence of 
any lower urinary tract sign during the next 12 months. Amitriptyline successfully eliminated 
clinical signs o f interstitial cystitis in 73% o f the cats for the first 6  months, and in 60% of cats 
studied for the entire 12 months. Despite clinical remission, cystoscopic abnormalities persisted in 
all cats at the 6  and 12-month evaluations. Weight gain, somnolence, decreased grooming, and 
transient cystic calculi were observed in some cats.
Should amitrtipytline be used in some cats with idiopathic or interstitial cystitis? In the absence 
of alternative treatment, the answer is a qualified yes. We consider the use o f amitriptyline only for 
treatment o f chronic idiopathic cystitis in which other “standard” therapies have failed (client 
education about feeding and litterbox management, stress, and methods to increase water intake are 
the standard in our hospital). There is not a good argument to use amitriptyline in acute cystitis since 
spontaneous resoluton o f clinical signs often occurs within a few days and complete resolution 
within 5 to 10 days and it may take weeks to months for amitritpyline to exert a maximal effect. 
Further studies o f amitriptyline for safety and efficacy during treatment o f idiopathic lower urinary 
tract disease are needed, though amitriptyline has been used with apparent safety in cats by animal 
behaviorists for many years. CBC and serum biochemical panels in our series remained normal 
throughout one year. Given the success o f our non-placebo controlled study, double-blind placebo 
controlled studies using amitriptyline treatment for cats with chronic idiopathic lower urinary tract 
disease are warranted. Although amitriptytline has its place in the control o f the signs o f chronic 
lower urinary tract disease associated with interstitial cystitis in cats, it is not an ideal drug since the 
lesions o f cystitis are still apparent cystoscopically during treatment and some undesirable side 
effects occurred in some cats. It is conceivable that lower doses o f amitriptyline may be effective 
when given in combination with other drugs.
Amitriptyline was recently studied in cats with acute non-obstructive idiopathic lower urinary 
tract disease (Kruger ACVIM abstracts 2001). Cats received 5 mg per cat once daily for a total of 7 
days. Compared to placebo, cats treated with amitriptyline reduced the duration of pollakiuria but 
clinical signs recurred sooner and with higher frequency as noted at recheck evaluations at 6 , 1 2 , and 
24 months following initial discharge. It is difficult to understand how such a short course o f 
amitriptyline could exert such a long-term effect.
Glycosaminoglycans
Glycosaminoglycan (GAG) replacement therapy has been used in humans with interstitial 
cystitis, with a success rate in about 10-20% of patients. GAG replacement therapy currently is 
being investigated because o f the abnorm alities observed in GAG excretion and bladder 
permeability in affected cats. The assumption for use of this treatment is that administered GAG 
attaches to the defective urothelium, thereby decreasing bladder permeability, although there may be 
differences in the relative efficacy among the various GAG's in producing this effectfNickel, 1998]. 
Glycosaminoglycans also can exert analgesic and anti-inflammatory effects that might prove useful. 
A double-blinded placebo-controlled multicenter study o f a specific GAG treatment (pentosan
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polysulfate) for cats with interstitial cystitis has recently been concluded in the USA -  FDA 
approval is pending.
Based on evidence in humans with IC, and the absence of demonstrated efficacy o f any o f the 
current veterinary GAG preparations, we cannot recommend this as part o f routine therapy for FIC. 
If  this treatment is used, a powder form that can be added to the food should be used to avoid the 
stress of pill administration.
Antibiotics/Antiviral Agents
Most cats with LUT signs do not have bacterial UTI, and there is no evidence that antibiotics are 
useful in the initial management. Bacterial infection frequently is erroneously diagnosed in cats with 
idiopathic cystitis, due to failure to perform quantitative urine cultures, and the tendency to over­
interpret “bacteria” reported on urinalysis. No conclusive evidence has yet emerged from cats with 
idiopathic or interstitial cystitis that viruses play any role in its pathophysiology, so the use of 
antiviral agents is also not recommended.
Miscellaneous
In preliminary studies, oral interferon, antibiotics, glucocorticoids, and intravesical DMSO 
treatments have not been helpful in the alleviation of clinical signs compared to placebo.
It is likely that pain plays an important role in potentiating or perpetuating inflammation of 
the bladder in cats with chronic idiopathic cystitis. Efforts to break the cycle o f pain- 
inflammation-pain may be helpful in treatment o f some cats. One o f amitriptyline's beneficial 
effects is to decrease sensory nerve fiber transmission. Amitriptyline appears to provide 
analgesia for some cats. Butorphanol has been used by the authors for the relief of bladder pain 
with apparent success in a small number of cats with chronic idiopathic cystitis. Longer-term 
studies on the effect of chronic pain relief as therapy for idiopathic cystitis are needed. There is a 
regrettable lack of guidance in the treatment of chronic visceral pain.
Adjunctive Therapy
Our bias is that stress is very important in the development o f flares in cats with chronic 
idiopathic cystitis and may be important in exposing the first episode o f symptomatic idiopathic 
cystitis. It is unlikely that stress by itself in the presence o f an otherwise completely healthy 
lower urinary tract leads to this disease. Unfortunately, stress is difficult to quantitate objectively 
or in the laboratory. Detailed history designed to reveal stress is necessary to expose "stressors" 
in a cat's life. Stress may result in changes in activity, use o f the litter pan, dietary intake, and 
other factors difficult to assess. Stress manifests itself in a variety o f neuroendocrine responses 
that could modulate the degree o f inflammatory response in the bladder (and other tissues as 
well). Regimens to reduce stress may prove essential in the management o f cats with non­
obstructive idiopathic cystitis. See figure on neurogenic inflammation at end o f notes.
Reduction of the cat’s perception of stress is warranted. Potential sources o f stress include the 
physical environment, other animals, and owners. Since many cats with FIC seem to be more 
reactive than usual (increased sympathetic nervous system outflow), providing separate, secluded 
food, water and litter containers for patients in multi-cat households may be appropriate.
Recently, a pheromone that exerts a calming effect on cats has become available to 
veterinarians. This product (Feliway ®) is a synthetic analogue o f a naturally occurring feline 
facial pheromone. Cats release such pheromones during facial rubbing when they feel 
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comfortable in their environment. Although not specifically tested in cats with FIC, treatment 
with this pheromone has been reported to reduce the anxiety experienced by some cats in 
unfamiliar circumstances. It is conceivable that use o f products that reduce anxiety (and 
associated sympathetic nervous system outflow) could be useful in treatment o f interstitial 
cystitis.
6
Behavior Problem
Cats with a true urinary behavior disorder have a history o f inappropriate urinations without 
evidence o f irritative voiding (no pollakiuria, gross hematuria, vocalizing during urinations, dysuria 
or strangruia). Abnormal locations o f urinations may be on either horizontal or vertical 
surfaces[Marder], Urinalysis should not exhibit excess blood or protein and no opaque calculi are 
seen on survey radiographs. Radiographc contrast procedures (i.e., cystography and urethrography) 
are normal as is the ultrasonographic evaluation o f the bladder. Cystoscopic evaluation of the 
bladder also should be normal. Fourteen o f the 70 cats with idiopathic cystitis in this series would 
have been diagnosed as having a behavior disorder if  they had not been examined using contrast 
radiograpy or cystoscopy. Unfortunately, in the absence o f access to cystoscopic evaluation, cats 
with a normal diagnostic workup including constrast radiography will be diagnosed with a behavior 
disorder when in reality nearly half actually have evidence of bladder inflammation when evaluated 
by cystoscopy. When examined with a cystoscope, we found that 16/24 cats with the single owner 
complaint of inappropriate urinations actually had IC rather than a pure behavior disorder. It is 
interesting to note that nearly 40% of cats being treated for a urinary behavior disorder also had a 
previous history o f cystitis[Horwitz]. There appears to be a cross-over between urinary behavior 
and inflammatory disorders o f the lower urinary tract. One common connection is the ability of 
stress to incite or perpetuate either condition.
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Figure 1. Inappropriate urinations may be the sole complaint noticed by the owner o f a cat 
affected with overflow from dilute urine and polyuria (renal failure, hyperthyroidism, diabetes 
mellitus), cystitis/urethritis (idiopathic, mechanical due to stones, bacterial infection), or with a 
behavior disorder. Behavior disorders should further be characterized into those that are related 
to marking or spraying as contrasted to those with normal eliminations that do not occur in the 
litterbox. Stress can activate episodes of marking or spraying as well as idiopathic cystitis.
Inappropriate Urination 
Inappropriate for the Cat or the Owner ?
Inconvenient Urinations
Dennis J. Chew, DVM, ACVIM; The Ohio State University College o f  Veterinary Medicine 2001
9D iagnostic A lg o r ith m  - L U T D  
I Owner-Observed Signs = -Tj
Hematuria Pollakiuria
Stranguria Urinating Outside Box
Specific Gravity
> 1.025 < 1.025
—    — j Rule Out
Urinalysis | Systemic Disease
(+) or (-) Hematuria Kidney, Thyroid, Diabetes
(+) or (-) Proteinuria 
(+) or (-) Heavy Crystalluria 
(+) or (-) Bacteria 
(+) or (-) pH >7.0
Figure 2-A. It is important to rule out dilute urine as a cause for increased urine production as a 
cause for inappropriate urinations. Cats consuming dry food usually have a urinary specific 
gravity in excess of 1.030 while cats eating canned foods may have specific gravity near 1.025. 
Although the presence of hematuria and proteinuria are often present during active states of 
inflammatory lower urinary tract diseases o f cats, the severity of hematuria and proteinuria can 
wax and wane (false negative finding). False positive findings for hematuria and proteinuria can 
occur when urine samples are obtained by cystocentesis or urinary catheter. Heavy crystalluria is 
an uncommon occurrence in urine from cats o f the 1990’s in the United States. It is important to 
make sure that the finding o f crystalluria is not over interpreted since crystals by themselves do 
not create disease. Crystalluria can be an artifact of urine that has cooled and sat for prolonged 
periiods -  this is especially true for refrigerated samples. The finding of “bacteria” should be 
viewed with caution as there are many artifacts in feline urine that resemble bacteria. Bacteria in 
the presence of hematuria and pyuria more likely do reflect bacterial infection, though this is 
very uncommon in young cats with signs o f lower urinary tract disease. Alkaline urine by itself 
is not a disease and is not a common finding in cats fed acidifying diets common in the 1990’s.
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D iagnostic  A lg o r ith m  - L U T D
(-) = No
(-) = No Radiopaque Calculi Calculi
I
M ore Imaging
Figure 2 B
Urine should be submitted for culture if there is evidence for pyuria, there is dilute urine 
(<1.030), the cat has previously undergone urethral catheterization, or if  the cat has had a 
perineal urethrostomy. Plain radiographs have a good chance toshow radiopaque calculi due to 
calcium oxalate or struvite, but good technique and cleansing enemas are needed to allow 
visualization o f small stones/
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Diagnostic Algorithm - LUTD
?
( + )
G lom erulations 
Interstitial ^0. 
Cystitis
R adiolucent Calculi 
D iverticulum  
Stricture 
N eplasm - Focal M ass 
Polyp
W all T hickening  
No C hanges - N orm al
Id io p a th ic
C y s t it is
Figure 2C . Contrast radiography is indicated in cats with recurrent or persistent clincal signs in 
which no abnormalities were seen on plain radiographs. Small stones, anatomical abnormalities 
(urethral stricture in males, urachal diverticulum) and mass-like lesions may be disclosed, 
although neoplasia of the cat bladder is very uncommon. Ultrasonography may show radiolucent 
cystic calculi and is useful for the assessment of bladder wall thickness if  the bladder is at least 
moderately distended with urine. Ultrasonography is not useful for the evaluation o f the urethra 
however. Urethrocystoscopy is useful to exlcude small urinary calculi and to evaluate the bladder 
and urethra for anatomical abnormalities. Additionally, cystoscopy provides the most 
information about mucosal detail -  it is more likely to detect mucosal abnormalties with this 
method than with other imaging modalities. At present, it is necessary to see “glomerulations” 
following bladder distension to 80 cmH20 pressure in order to make the diagnosis of interstitial 
cystitis. Interstitial cystitis is a sub-category of idiopathic cystitis. The question mark between 
idiopathic and interstitial cystitis at the bottom indicates that it is not know how many cats with a 
diagnosis o f idiopathic cystitis would have a diagnosis of interstitial cystitis if  evaluated with a 
cystoscope.
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Figure 3. What do WE Do ? Step-wise approach to treatment of cats with idiopathic lower 
urinary tract signs. More diagnostics should be performed when cats fail to spontaneously clear 
o f their initial lower urinary tract signs and when signs recur to ensure that the diagnosis is really 
idiopathic lower urinary tract disease. Properly controlled clinical trials may provide better 
approaches to treatment in the future, but this is what we do in the interim.
Step 4____________
12
Signs 
Frequently Recur 
or Persist ?
Step 4
Signs
Recur
Step 3
Step 2
+ Amitriptyline (?) 
+ GAG (?)
+ More Stress / 
Behavioral 
Modification 
+ Pain Relief 
Cystoscopy (?) 
Repeat Urinalysis
+ Facial pheromones 
+ More Stress Reduction 
+ More Water IntakeDynamics 
Extended Data Base:
Urine Culture 
Contrast Radiography 
Ultrasonography
Minimum Data Base :
Urinalysis and Abdominal 
Radiograph___________________
+ Consistent Diet (Canned = BEST)
+ Increase Water Intake
+ Stress Reduction
“Watchful” Waiting -  Spontaneous Resolution 
£lient Education -  “From the Cat’s Point o f View’’
Litterbox Management
Unscented litter/ Texture/Depth -  Preferences/A versions 
Location/Ventilation/Access to Box 
Clean at every toilet flush
Clean Up and Eliminate “Accident” Odors
Urinary History
(Vertical vs Horizontal Periuria? Irritative Voidings ?),
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Environment
Epithelium
GAG
*
T H+,K+, Ca++,? 
I  Mg++,?
LUMEN
m
Figure 4. Neurogenic inflammation as it affects the urinary bladder.
Sensory neurons (C-Fiber) seem to play a central role in transmission of action potentials via the 
dorsal root ganglia (DRG). These signals are perceived as painful by the brain. Sensory fibers 
also can propagate a local axon reflex without transmission of an axon potential. The axon reflex 
results in release o f peptide neurotransmitters such ass substance P (SP) by the nerve endings. 
Interaction o f SP with receptors on vessel walls results in vascular leakage, that can be 
augmented by SP-induced release of histamine by mast cells. These actions may give rise to the 
submucosal petechial hemorrhages observed at cystoscopy. Receptors for SP also occur on 
smooth muscle, which when activated stimulate muscle contraction. Also shown are the 
urothelium (epithelium) and the overlying glycosaminoglycan (GAG) layer adjacent to the 
bladder lumen. Damage or malfunction of either or both of these layers may permit constituents 
of the urine, such as protons, potassium ions, or hyperosmolar (>2,000 mOsm/L) fluid to activate 
the sensory fibers. The effects o f stress on sensory fibers may be related to descending efferent 
sympathetic (SNS) signals stimulating the DRG and inducing peripheral release of 
neuropeptides. Local release o f neurotransmitters by bladder sympathetic fibers also could 
stimulate sensory fibers. Another factor probably involved in chronic bladder inflammation, but 
not shown, is local and systemic release o f nerve growth factors, which may promote sensory 
fiber terminal sprouting to increase the size of sensory fiber receptive fields.
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Updates on Feline Lower Urinary Tract Disease
Dennis J. Chew, DVM Dip ACVIM (Int Medicine)
CAT Buffington DVM PhD Dip ACVN 
Jodi Westropp DVM 
College o f Veterinary Medicine 
The Ohio State University 
Columbus, Ohio USA
Animal Shelter Surrender
4 Million Cats per Year 
Estimated
Patronek GJ, et al JAVMA 209:582-588, 1996 
Most = Inappropriate Urinary Elimination
Epidemiology “FUS”
Incidence < 1%
Prevalence Rate 1 %-6%
1.5% Prevalance Rate in 52 Private Practices 
FUS or Cystitis 
15,226 Cats
Lund EM et al: JAVMA 214(9):1336-1341, 1999
Epidemiology FLUTD -  VMDB
Lekcharoensuk et al, JAVMA 218(9)2001 
University Hospital Based 
22,908 Cats with LUTD (1980-1997)
Proportional Morbidity Rate 
= 8/100 Cats (all causes o f LUTD)
2/100 to 13/100 by Institution
Epidemiology FLUTD - VMDB
Lekcharoensuk et al, JAVMA 218(9)2001 
Idiopathic LUTD 63%
Urethral Obstruction 18%
Infections 12%
Urolithiasis or Plugs 10%
Urinary Incontinence 4%
Trauma 2%
Miscellaneous 2%
Congenital 0.7%
Iatrogenic 0.6%
Neoplasia 0.3%
Neurogenic 0.2%
Drugs and Chemicals 0.01%
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Epidemiology Idiopathic FLUTD - VMDB
Lekcharoensuk et al, JAVMA 218(9), 2001 
Increased Risk Male Castrated - OR 3.0 
Decreased Risk Intact Female - OR 0.23
Increased Risk 4 to < 7 Yr - OR 2.6 
Increased Risk 7 to <10 Yr- OR 2.6 
Decreased Risk < 1 Yr- OR 0.12 
No Increased Risk or Protection Detected by Breed
Risk Factors - Inappropriate Urinations
After Buffington 2001 
INTERNAL
Genetic Factors 
Experiential Background 
Temperament
EXTERNAL
Complexity of Environment 
Resource Quality/Availability 
Sources of Threat/Conflict
Indoor Restriction for Cats
Common Veterinary Recommendation
Decreased Risk Infectious Diseases 
Decreased Risk of Vehicular Trauma 
Decreased Risk from Other Animals
Risk Factors - Indoor Restriction
LUT Signs
Odontoclastic Resorptive lesions 
Obesity 
Hyperthyroidism
Risk Factors - FUS
Excessive Body Weight 
Decreased Activity 
Indoor Litter Pans Exclusively 
Living with Other Cats 
Time Spent Indoors
Risk Factors - FUS (Jones New Zealand)
Time Spent Indoors - Dose Effect
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Move to New House 
Winter Months (Rainy Season) 
Outdoor Prey Access = Protective
Environmental Factors
Benign 
Challenging 
Threatening 
Provocative Environment ?
Internal Factors - Response to Environment
Minimal
Moderate
Severe
Sensitive Cat ?
Internal Factors - Response to Environment
Different Breed Susceptibility
Individual Temperament Differences
Magnitude o f Response = Range is Large
Particular Individual + Environment 
= Response Cannot be Predicted
Indoor Housing - Cats
MAY be More Sensitive to Effects 
than Other More Social Animals (Dogs, Humans)
Cats = Relatively Solitary
< 50 / SQ Kilometer Hunting in Wild 
Avoid Each Other During Hunting 
Lieberg O, et al In :The Domestic C a t: the biology o f its behaviour.
Two-Cat Household s 
50% Time = Out o f Each Other’s Sight 
Most Often Within 1-3 Meters o f Each Other 
Barry KJ et al: Applied Animal Behavior Science 64:193-211, 1999
Stressors for Cats ?
Indoor Restriction 
Dry Foods 
Altered Feeding Schedules 
Unfamiliar Care Takers
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Stress and Cats
Unpredictable Environment 
Severe and Persistent
Hypothalamac-Pituitary-Adrenal Axis 
Activation
Pontine Locus Coeruleus-Norepinephrine Activation
Signals from Environment
Pheromonal
Olfactory
Gustatory
Auditory
Cutaneous
Visual
Environmental Factors
Stress Response 
IF
Perception of Control is Reduced
Stressed Cats
Decreased Play Activity
Decreased Exploratory Activity 
More Time Hiding
Environmental Enrichment
Recommended for Cats 
If Indoor Housing Maintained
Chronic House Soiling
Environmental Enrichment
Access to Resources
Interactions with Owners
Reduction in Level o f Conflict 
Environmental Enrichment 
Feeding
Individually/Quiet Location
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Dry vs Canned ? 
Choices
Simulated Predatory Behaviors
Cleaned Feeding Bowel
Environmental Enrichment 
Water
Freshness 
Taste 
Movement 
Container Shape 
Cleaned Water Bowel
Environmental Enrichment 
Litter Box
Number 
Location 
Cleanliness ?
Depth
Size
Hooded
Tented
Mechanical
Environmental Enrichment 
Physical Environment
Climbing
Scratching
Hiding
Resting
Elevations
Environmental Enrichment 
Play Activities
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(N octurnal ?)
Petting 
Grooming 
Lures 
Laser Pointers 
Toys (mimic prey)
Environmental Enrichment 
Increase Access 
to
Outdoors ??
Environmental Enrichment 
Litter
Preference
Aversion
Depth
Slope
Clumping
Scent
Environmental Enrichment 
Little to No Controlled Studies
Preliminary Studies Underway at OSU (Buffington 2001)
Alpha -2 Adrenoceptors
Alpha-2 AR Throughout Brain 
Large Amount in LC 
Most = Inhibitory Receptors
Presynaptic Stimulation 
Inhibits NA Release and Downregulates Outflow
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GAG-Treatment ?
Uricon® - Pentosan Polysulfate 
DVM Pharmaceuticals
Pending FDA Approval 
Uricon® - PPS Treatment o f IC 
Multicenter, Double Blind 
Placebo-Controlled, Prospective
Ohio State 
Michigan State 
Purdue 
Tennessee
Treatment of FIC:GAG Replacers
Elmiron
(Pentosan Polysufonate Sodium)
Cosequin
(Glucosamine, Sodium Chondroitin Sulfate, mixed GAGs, Manganese) 
CYSTAID ® - VetPlus UK
Treatment of Idiopathic Cystitis 
What Do We Do ?
Clean Soiled Areas 
Litterbox Dynamics 
Stress ID and Reduction 
Increase Water Intake 
Pain Relief 
Amitriptyline 
GAG Replacers 
Facial Pheromones
Litterbox Dynamics
Rule o f “ l + 1”
Cleaning Schedule 
No Scented 
Clumping 
Litter Texture 
Depth o f Litter 
No Hoods 
Location 
Access
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Possible Resource for Cleaning Soiled Areas
Urineplanet.com 
Urine Deodorizer/Removal Kit
Idiopathic Cystitis
30 to 50% Recurrence within 12 Months
85% Spontaneously Resolve Episode 
5 to 7 Days (Many Earlier)
Pathophysiology of FIC ?
Noxious Urine 
Leaky Bladder 
Altered GAG Dynamics 
Altered Urothelium 
Neurogenic Inflammation 
Mast Cell Infiltration 
Increased Sensory Nerves 
Increased Sympathetic Outflow
Idiopathic Cystitis and Diet
18 Canned & 28 Dry
0 Recurrence over 1 Year 
16/18 Canned (89%)
17/28 Dry (61%)
10% Recurrence on Canned 
40 % Recurrence on Dry
60% Helped by Constancy of Dry Diet 
30% More Helped by Canned Diet 
10% Not Helped by Diet
Idiopathic Cystitis and Diet
Acid Urine = No Known Benefit 
Harm ?
Crystalluria = No Known Detriment
Mg Restriction = No Known Benefit 
Harm ?
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Diet and LUTD - Cats
Idiopathic Cystitis 
Stone-Formers
IF Possible, Never Eat Food Dry 
Idiopathic Cystitis and Stone-Former Cats 
Identified Themselves as Predisposed 
to these Conditions
Sensitive Cats 
in a Provocative Environment
Increasing Water Intake
Canned Food 
Water to Dry Food 
Fresh Water 
Water Bowl Filling Dynamics 
Bottled Water 
Running Water 
Flavored Water 
Stress Reduction 
More Cat-Like Activities 
Hunting/Climbing 
More Quality Time with Cat 
Decrease Numbers o f Cats in House 
Decrease Stress o f Owners
Some Cats Don’t Belong 
with Some People
Drugs and Idiopathic Cystitis
NOT Before Excellent Workup 
NOT Before Client Education 
Litterbox Dynamics 
Stress Reduction 
Water Dynamics
Recurrent/Persistent Cases Only
Drugs and Chronic/Recurrent Idiopathic Cystitis
Amitriptyline
Other Norepinephrine/Serotonin Reuptake Inhibitors ? 
Analgesics
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Glycosaminoglycans ? 
Feline Facial Pheromones ?
Treatment of FIC:
Stress management
Feliway 
Facial pheromones 
May have a calming effect if  sprayed in the cat’s environment
Treatment of FIC:Pain Management
Butorphanol can be used 
0.1 mg/kg IV 
0.4 mg/kg SQ
Fentanyl patches also can be considered in severe cases
FIC = A “Sensitive” Cat in a “Provocative” Environment
IC -  CNS Changes 
Treatment - Cats
Environment
Ingestion
Elimination
Interaction
Resources for Owners of Indoor Cats
From the Cat’s Point of View 
www .perfectpaws .com
Felinestein
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MANAGEMENT OF MALE CATS WITH URETHRAL OBSTRUCTION
Dennis J. Chew, DVM , Dip ACVIM and C.A. Tony Buffington , DVM PhD, Dip ACVN 
The Ohio State University College of Veterinary Medicine, Columbus, Ohio
Pathophysiology of Urethral Obstruction
Urethral plugs are the most common cause o f obstruction in male cats. In one series (Krueger 
1991), urethral plugs occurred in 60%, no cause was found in 30%, uroliths alone were 
documented in 1 0 % (struvite exclusively) and uroliths with bacterial urinary tract infection were 
observed in 2%. Occasionally stricture and rarely neoplasia are the causes o f obstruction. 
Urethral obstruction due to calcium oxalate urethroliths is a phenomenon of the 1990’s that was 
not encountered in the 1980’s.
Figure 1) UNDERLYING CAUSES AND MECHANISMS OF URETHRAL OBSTRUCTION
Urethral
Stricture
Most plugs cause obstruction within the penile urethra, but obstructions can also occur at 
more proximal sites. The predominant mineral composition in most plugs is magnesium 
ammonium phosphate (struvite). Secondary components can contribute to plug formation 
including inflammatory exudate ( WBC and proteins), red blood cells, cellular debris, sloughed 
tissue (epithelial cells), struvite crystals and combinations. Virus-like particles resembling 
calicivirus and bacteria have also been observed within urethral plugs examined by transmission 
electron microscopy. Primary inflammatory changes ( exudates, blood, and edema) or changes 
within the urethral wall secondary to intraluminal urethral plugs may contribute to the 
obstructive process. These changes may be magnified following instrumentation with catheters 
and back-flushing solutions used in therapeutic endeavors.
Diagnostics and Management
Urethral obstruction is diagnosed by the finding of an enlarged bladder in a male cat with signs 
of urinary urgency, difficulty in manually expressing urine, and by resistance encountered during 
the passage of a urethral catheter. It may not be obvious what is causing the urethral obstruction. 
Diagnostics and management of urethral obstruction are performed simultaneously. The degree 
of uremia, electrocardiographic stability, and the magnitude of bladder distension will dictate how 
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2quickly and in what order treatment must be performed. Those cats with uremic crisis and those 
with very large hard bladders are in need o f prompt attention.
Figure 2). APPROACH TO THE MORIBUND CAT WITH ADVANCED URETHRAL 
OBSTRUCTION
IV Line
I
Therapeutic
Cystocentesis
Dehydration 
Volume Expansion
Radiograph
Abdominal/Perineal
ECG Stat Bloods
Hyperkalemia Rescue ? 
Hypocalcemia Rescue ?
Pass  ►  Collect/Monitor
Urethral Catheter Urine 0utput
Relief of Obstruction Due to Plugs
Cystocentesis to drain the bladder(decompressive or therapeutic cystocentesis) should be 
performed as soon as possible in cats with very large bladders to prevent rupture of the bladder 
and to allow excretory renal function to resume. Relief o f bladder pressure prior to urethral 
catheterization also may facilitate efforts to dislodge urethral plugs, and provides a superior urine 
sample for analysis prior to manipulation o f the urinary tract and contamination with flushing 
solutions. Plain abdominal/perineal radiographs should follow the decompressive cystocentesis 
so mineralized plugs can be documented or that cystic and/or urethral calculi can be identified ( a 
lateral radiograph often suffices).
Chemical restraint/anesthesia (isoflurane, low-dose IV ketamine, propofol) is often advisable 
to atraumatically relieve the obstruction via urethral catheterization. Urethral relaxation while 
under sedation/anesthesia may further increase the likelihood o f plug dislodgment. Little or no 
sedation is indicated for those with severe uremia. Gentle massage o f the penis may dislodge a 
urethral plug located in the penile urethra, especially when near the external urethral orifice. 
Gentle pulsatile bladder palpation following penile massage may cause a plug to be expelled. 
Rectal massage o f the pelvic urethra may on occasion also contribute to plug dislodgment. 
Aseptic and gentle technique should be used while placing a urethral catheter. Urethral irrigation 
with sterile physiologic solutions (Lactated Ringer's solution or 0.9% saline ) may now dilate the 
urethra and flush the obstructing plug distally out the external urethral opening around the 
catheter. Intermittent gentle digital pressure on the bladder following irrigation attempts may 
change the pressure on the urethral plug and force it to be expelled through the external urethral 
orifice. Care must be taken to ensure that excessive trauma or rupture o f the bladder does not 
occur during this maneuver. Hydropulsion (reverse flushing) within the urethra may be
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3attempted at this point if the obstruction is not yet relieved. The urethra is thoroughly flushed 
to make sure that all debris initially within the lumen has been back-flushed into the bladder or 
has been refluxed out the urethra. The urethral catheter can then usually be advanced into the 
bladder. Failure to adequately remove debris from the bladder and urethra is a major cause of 
rapid re-obstruction following catheter removal.
Figure 3). A Potential Decision-Making Algorithm - An Approach to Management of 
Urethral Obstruction in a Male Cat Due to a Urethral Plug
Urethral Plug
I
Cystocentesis
Decompression
Expell Plug Retropulse Plug
Urethral Patency
IrethPass U t ral Catheter
Irrigate and Drain
y  ^
Urine Stream Blood/Debris ?
Quality ?
Poor Good Clear Very Bloody
T
Remove Catheter
T
Leave Urethral Catheter
“Urethral spasm” refers to pathologic neurogenic or myogenic processes that contract the 
circular smooth and/or skeletal muscle of the urethra. The bladder and preprostatic segments of 
the urethra contain primarily smooth muscle, the prostatic and postprostatic segments contain 
both smooth and skeletal muscle, and the musculature of penile segment is predominantly circular 
skeletal muscle. Innervation of the urethra is provided by the sympathetic nervous system via 
the hypogastric nerve and the somatic nervous system via the pudendal nerve. Part of urethral 
tone maintained by the skeletal muscle (rhabdosphincter) is influenced by sympathetic 
innervation.
Stimulation of adrenoreceptors (particularly a-1) within the urethra increases urethral tone in 
normal cats. It is likely that both pain and stress associated with urethral obstruction increases
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sympathetic outflow from the central nervous system, favoring urethral spasm. Urethritis may 
exist prior to plug formation, or may be acquired secondary to trauma from the physical presence 
o f intraluminal plugs or stones. Attempts to relieve obstruction with catheters, and indwelling 
urethral catheters also can result in urethritis. Urethritis may also be secondary to bacterial 
urinary tract infection (UTI) that is commonly acquired following placement of indwelling 
urinary catheters, even when a closed urinary collection system is employed. The use of 
antibacterial treatment does not prevent UTI.
To reduce pain and inflammation associated with intraluminal obstructing material, all material 
must be removed from the urethra. Using gentle technique during urethral catheterization and 
flushing is essential to minimize iatrogenic damage to the urethra (erosion, inflammation, 
perforation). Installation of an indwelling urethral catheter can be an additional source of pain 
and urethritis, which should be avoided if possible. Repeated cystocentesis to empty the bladder 
is an alternative to passage o f another urethral catheter if obstruction recurs following removal of 
the initial catheter. Repeated cystocentesis also provides indirect pain relief by keeping the 
bladder small and painful mucosal surfaces non-distended.
Drugs recommended for the treatment o f urethrospasm include analgesic, anti-inflammatory, 
antibacterial, and spasmolytic agents. Injection of diluted lidocaine solution through the urethral 
catheter at the time o f its removal has been advocated by some to reduce urethral spasms, but 
this has not been critically evaluated. Also, the local effects o f lidocaine on urothelial healing are 
unknown. If  used, lidocaine should be diluted and injected slowly at low pressure -  excessive 
amounts o f systemically absorbed (> 0.5 mg/kg IV) lidocaine can cause seizures. Systemic 
treatment with a fentanyl (patch), low dose morphine (0.05-0.2 mg/kg IM), butorphanol (0.05- 
0.2 mg/kg IM), and/or low dose medetomidine (2-5 micrograms/kg IM ; centrally acting alpha-2 
agonist that decreases sympathetic outflow) for relief o f pain seems reasonable. It is possible that 
relief of pain will decrease urethral and bladder muscle spasms. Opioids increase urethral 
sphincter tone, increase bladder volume, and inhibit voiding initially but tolerance to these effects 
develops quickly. The central analgesic effects o f opioids are most important. Butorphanol is a 
weak opioid that can be considered for use during the initial 12-24 hours. Unfortunately, patients 
develop tolerance to butorphanol rapidly. Butorphanol also has a ceiling effect in which increased 
doses provide no further analgesia. Finally, butorphanol produces agonist effects at kappa 
receptors and antagonist effects at mu receptors. This may decrease the effects o f more potent 
mu opiods (morphine, oxymorphone, fentanyl) when needed. When additional analgesia is 
needed, combinations of drugs that act by different mechanisms should be considered. For 
example, morphine (opioid) and medetomidine (alpha 2 agonist) may be given every 6 to 12
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hours as needed. Ketoprofen, tolfenamic acid, and carprofen are non-steroidal anti-inflammatory 
drugs (NSAID) that have been used in cats, but their effectiveness in decreasing lower urinary 
tract inflammation has not been substantiated. Adding an NSAID to this regimen might provide 
the most complete level o f analgesia.
Oral prednisolone failed to reduce urethral histopathology in cats that underwent indwelling 
urethral catheterization for 3 days (Barsanti 1992). Glucocorticosteroids should not be given to 
cats while an indwelling urethral catheter is in place due to the associated high risks for 
development of bacterial pyelonephritis. Whether this risk is still present if  glucocorticosteroid 
treatment is given at the time of catheter removal is not known.
Spasmolytic therapy may need to be directed against increased tone of both smooth and 
skeletal muscle. Phenoxybenzamine, acepromazine, and prazosin are alpha-adrenergic antagonists 
that decrease smooth muscle urethral tone in healthy cats. Caution must be practiced when 
administering adrenergic antagonists, since the adrenoreceptor profile along the urethra may 
change in disease states compared to normal cats. Additionally, the effects of such agents may 
vary depending on whether the predominant actions are central or peripheral. Flavoxate and 
oxybutynin exert a direct action to reduce smooth muscle tone. Diazepam reduces skeletal muscle 
tone to the urethra through a central mechanism, while dantrolene exerts its effect on skeletal 
muscle directly. Prazosin and dantrolene have been shown to decrease urethral tone in male cats 
following relief of urethral obstruction.
Chronically, treatment is aimed at controlling the underlying inflammatory condition 
(idiopathic cystitis/urethritis). Efforts to decrease stress in the cat’s life and to increase water 
turnover are indicated for those with idiopathic cystitis. Increased water intake to reduce urine 
specific gravity and specific diet changes are indicated for cats with struvite or oxalate 
urolithiasis. Cats that have previously formed a urethral plug containing struvite as the major 
mineral constituent should eat foods that promote a urinary pH from 6.2-6.5 to ensure maximal 
solubility of struvite while avoiding overacidification.
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1Feline Urolithiasis
Dennis J. Chew and C.A. Tony Buffington
The Ohio State University Veterinary Hospital, Columbus, Ohio, USA 43210-1089.
The two most common stone types in cats are struvite and calcium oxalate. Prior to the late 
1980s, sterile struvite was the most common urolith found in cats. The proportion of struvite 
urolithiasis declined in subsequent years following changes in commercial cat food formulations. 
Unfortunately, this decline appears to have come at the expense o f an increase in the proportion of 
calcium oxalate uroliths. The proportion of stones analyzed at the University of Minnesota 
Urolithiasis Center has shifted from approximately 65% struvite and 2% calcium oxalate in 1984 to 
48% struvite and 40% calcium oxalate in 1995.
Cat urinary bladder stones analyzed by the University o f Minnesota Urolith Center between 
1981 and 1994. The solid line represents the total number of stones. The black bars represent the
Y e a r
proportion of total stones that were struvite, while the open bars represent the proportion of 
calcium oxalate stones.
Struvite Urolithiasis
Struvite crystalluria is not synonymous with struvite urolithiaisis; struvite urolithiasis can 
occur with or without struvite crystalluria, and struvite crystalluria can occur in apparently normal 
cats. Unlike dogs, the vast majority of cats form struvite uroltihs in sterile urine. Struvite 
(magnesium ammonium phosphate) urolithiasis and urethral obstruction have been induced 
experimentally in healthy cats by feeding diets containing three to ten times the amount of
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magnesium found in commercial cat foods. These studies led to the conclusion that magnesium was 
a primary cause of naturally occurring struvite urolithiasis in cats. It subsequently was learned that 
struvite stones in the bladder of healthy cats fed large quantities of magnesium dissolved when the 
urine pH was reduced to approximately 6. These results suggested that magnesium’s effect on 
struvite formation depended on the urine pH. This idea was supported when it was found that the 
form of magnesium used in previous studies increased the urine pH. The research implicating 
magnesium as a potential cause o f urinary stone disease in cats seems to have led cat food 
manufacturers to restrict the magnesium contents o f diets, and to add ingredients to promote a more 
acidic urine in an attempt to minimize the struvite-promoting potential o f their products. In 
retrospect, it appears that few client-owned cats formed struvite urolithiasis despite consumption of 
commercial foods that were alkalinizng and magnesium-replete. This suggests that these diets 
unmasked cats intrinsically susceptible to struvite stone formation rather than directly causing stone 
formation.
The presence or absence of struvite crystalluria on a random urinalysis does not predict 
which cat will form a stone for the first time, though the persistence o f struvite crystalluria is a risk 
factor for recurrence of struvite urolithiasis. We have observed the formation of naturally occurring 
struvite urolithiasis in cats consuming dry diets designed to inhibit struvite formation. This 
observation emphasizes the significance o f that most important nutrient, water, in the treatment o f 
cats with all types o f urolithiasis.
Medical dissolution of struvite urolithiasis using dietary methods has been reported. In an 
uncontrolled study, consumption o f a canned, magnesium-restricted, urine acidifying, salt- 
supplemented diet dissolved naturally occurring struvite calculi over several weeks in cats. Although 
magnesium-restricted acidifying diets are commonly employed to prevent recurrence o f sterile 
struvite uroltihiasis in cats, no data exists to prove their effectiveness in doing so. Because so many 
commercial American diets for cats have been modified to restrict the formation o f struvite, clinicians 
should recognize that acidifying agents such as ammonium chloride or d,1-methionine no longer are 
needed to maintain acidic urine in cats consuming these foods. Acidifying agents should not be 
routinely prescribed for cats with struvite urolithiasis because they impose an additional source of 
acid that may contribute to the development of metabolic acidosis.
Calcium Oxalate Urolithiasis
Calcium oxalate crystalluria is not synonymous with calcium oxalate urolithiasis; oxalate 
crystalluria occurs in some apparently normal cats, and oxalate urolithiasis can form with or without 
oxalate crystalluria seen on urinalysis. Only about half the cats o f one report with calcium oxalate 
uroliths had calcium oxalate crystalluria at the time of diagnosis, and 9% had struvite crystalluria.
In contrast to struvite stone formation, experimental diet manipulations that induce calcium 
oxalate stone formation in healthy cats have not been reported. Acidifying diets increase both urine 
concentration and fractional excretion of calcium, and magnesium restriction reduces the urine 
content of magnesium. These circumstances appear to increase the risk o f calcium oxalate formation. 
Previous commercial cat diets that did not restrict magnesium or reduce urine pH may have obscured
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this susceptibility by resulting in formation of urine in which calcium oxalate stones were unlikely to 
form. When cat food manufacturers added acid-forming ingredients and reduced the magnesium 
content of foods to prevent struvite formation, the diets may no longer have protected cats prone to 
calcium oxalate formation. Cats susceptible to calcium oxalate formation were now consuming a 
“provocative” diet. The diet modifications made by cat food manufacturers may not have “caused” 
an increase in calcium oxalate urolithiasis, however, but only have exposed a population of cats 
already genetically predisposed to calcium oxalate formation (diet sensitive rather than diet induced). 
This hypothesis is compelling in cats, because the overall occurrence o f calcium oxalate urolithiasis 
in the United States appears to be no greater in cats than it is in humans, despite the fact that much 
of the cat population consumes similarly formulated diets.
Two studies of epidemiological factors associated with the development of calcium oxalate 
urolithiasis in cats recently have been published. In a study comparing 91 cats with calcium oxalate 
urolithiasis with 258 age and sex matched controls, increased risk was associated with older age 
(bimodal peaks at 5 and 12 years), Persian and Himalayan breed, indoor housing, and consumption 
of urine acidifying diets[Kirk, 1995]. The other study reviewed the records of 3,498 urolith 
accessions between 1982 and 1992[Thumchai, 1996], This study too found increased risk in older 
cats, Persian and Himalayan (and Burmese) breeds, and that stones removed from the kidneys were 
more likely to be calcium oxalate than struvite. Males and females appear to be at equal risk; male 
dogs are at greater risk than females for calcium oxalate urolithiasis. Both studies were based on 
samples o f convenience, however, so these results may not represent the general population of cats.
Hypercalcemia and calcium oxalate stone formation occasionally occurs in cats with primary 
hyperparathyroidism. Veterinary urologists from the University of Minnesota Urolithiasis Center 
recently reported idiopathic hypercalcemia to be present in approximately one-third of cats from 
which calcium oxalate stones had been removed and submitted to them for analysis. Similar findings 
also were reported from the University of Georgia.
No medical regimen has been shown to successfully dissolve calcium oxalate uroliths, so 
surgery or voiding urohydropropulsion is recommended for these patients. To prevent recurrence, 
some stone-specific alterations may be useful in addition to dilution of the urine. Although a 
decreased risk of recurrence of oxalate stones related to diet change has never been documented in 
cats, changing to a diet that is less acidifying and that has not been magnesium-restricted seems 
reasonable, as long as the resulting urine specific gravity is -1.020. Acidifying agents are 
contraindicated in cats with calcium oxalate urolithiasis. Some veterinary food manufacturers offer 
diets designed to reduce the probability of calcium oxalate stone formation. These diets have been 
tested in healthy cats, and it is hoped that they will prove effective in cats with naturally occurring 
stone disease. The frequency of recurrent calcium oxalate stone formation in cats is not known, so 
the safety, efficacy, and cost-effectiveness of these diets cannot yet be determined.
Treatment of Urolithiasis -  General
The frequency of urolithiasis does not appear to be greater in cats than in either dogs or 
human beings, so no modification of the diet is necessary prior to formation of the first stone. 
Treatment of sporadic calcium oxalate or struvite crystalluria is not necessary in cats that have never
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formed a stone previously; neither oxalate or struvite crystalluria (without stone formation) is know 
to damage the urothelium[Cohen, 1991]. Therapy of cats with a stone includes acute treatment to 
remove or dissolve the stone, and chronic therapy to reduce the risk o f recurrence. Stone-specific 
treatment recommendations can be based on quantitative stone analysis when stone material from 
spontaneous voiding, catheter aspiration, voiding urohydroexpulsion or surgery can be obtained for 
analysis. When the stone type is unknown, the choice o f empiric medical or surgical therapy is 
offered to the client after the risks and benefits have been explained.
Post-operative abdominal radiographs should be taken to ensure that all calculi were 
removed, otherwise “pseudo-recurrence” of urolithiasis may occur. Failure to remove all stones at 
the time of cystotomy is common ( 20% of cats in one study [Lulich, 1993] ) and seems to be more 
likely to occur with calcium oxalate uroliths. Flushing of stones from the bladder to the urethra as 
well as dragging stones distally during urinary catheter withdrawal are suspected procedures that 
could account for this.
All cats that have formed a stone are at increased risk for recurrence. Urolithiasis seems to be 
a diet sensitive disease, in which an intrinsic susceptibility in the patient is exposed by provocative 
nutrients. Water may be the most important nutrient to prevent recurrence o f stone formation. 
Increased water intake is the cornerstone o f therapy for urolithiasis in both human and veterinary 
medicine. Increasing water intake to dilute urine and increase frequency o f urination is an important 
part of treatment. Decreasing the concentration o f potential stone-forming minerals in their urine and 
increasing their voiding frequency are primary therapy to reduce the risk o f formation o f a new 
stone. When a urolith is diagnosed, the patient should be switched to a canned diet, or water (one 
cup per cup dry food) should be added to the dry food before presentation to the cat. Additional 
water can be added to the food to reduce the urine specific gravity until food intake declines; the goal 
of a urinary specific gravity near 1.020 is recommended. A food appropriate for the stone type 
should be chosen if possible. Salting the food or water is not recommended for cats with calcium 
oxalates as the extra sodium may increase calciuria.
In those cats with a history of both struvite and calcium oxalate urolithiasis, prevention 
regimens should be biased toward calcium oxalate since we can successfully dissolve the struvite but 
not the oxalate stone with medical dissolution protocols if  needed.
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About-Face from Previous Reccs to 
11 Dietary Calcium Intake
If Dietary Calcium Intake =
1f Calcium Binding with Oxalates 
= If Fecal Calcium Oxalate Excretion
M ild  A lka lin iz ing  D iet
Difficult to Find Off Grocery Shelf 
Most = Acidifying
Canned Foods 
= Less Acidifying in General
Veterinary Diets :
for Renal Failure Patients
Urologic Diets - "O" - Neutral U pH
jj
11 Water Intake 
Add Water to Dry Food 
Change to Canned Food 
MOST IMPORTANT MANUEVER ?
lalcium Oxalate Stones 
Dietary Prophylaxis
Calcium Oxalates - Prevent Recurrences
Promote Water Intake 
Canned Diets 
Water to Dry
Urine pH > 6.5
Add Citrate If Needed
Calcium Oxalate Stones 
- Other Prophylaxis
Potassium Citrate
Thiazide Diuretics 
Recurrent Cases Only
Calcium Oxalate Stones 
- Potassium
Citrate
Renal Excretion
I
Increased Urinary 
C trate
Calcium Citrate 
( 1f Solubility )
'H C O  Generated
I
Mild Alkalinization
■If BolL Calcium 
Resorption
Jf Calciuria
100 to 150 mg/kg per Day
Calcium Citrate =
More Soluble
than Calcium Oxalate
____
